aspirin has been researched along with Colorectal Neoplasms in 694 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although aspirin has been considered a promising agent for prevention of colorectal cancer, recent data suggest a lack of benefit among older individuals." | 9.51 | Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals. ( Bakshi, A; Buchanan, DD; Cao, Y; Carr, PR; Chan, AT; Gibbs, P; Joshi, AD; Lacaze, P; Macrae, F; Manning, AK; McNeil, JJ; Orchard, SG; Umar, A; Winship, IM; Zalcberg, JR, 2022) |
| "The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM)." | 9.41 | Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial. ( Angelsen, JH; Bjørnbeth, BA; Fristrup, CW; Grønbech, JE; Hemmingsson, O; Isaksson, B; Juel, IS; Larsen, PN; Lindell, G; Mortensen, FV; Mortensen, KE; Rizell, M; Sandström, P; Sandvik, OM; Sparrelid, E; Taflin, H; Taskén, K; Yaqub, S, 2021) |
| "This paper introduces a recent paper on colorectal cancer prevention studies using aspirin." | 9.41 | [Aspirin for Chemoprevention of Colorectal Adenoma and Cancer]. ( Ishikawa, H, 2021) |
| " Data from RCTs in which the incidence of colorectal cancer in patients without active colorectal cancer assigned to aspirin versus control were included." | 9.41 | Aspirin chemoprevention in colorectal cancer: network meta-analysis of low, moderate, and high doses. ( Di Re, A; Shah, D; Toh, JWT, 2023) |
| "Although aspirin is recommended for the prevention of colorectal cancer (CRC) among adults aged 50 to 59 years, recent data from a randomized clinical trial suggest a lack of benefit and even possible harm among older adults." | 9.41 | Aspirin Use and Risk of Colorectal Cancer Among Older Adults. ( Cao, Y; Chan, AT; Drew, DA; Giovannucci, EL; Guo, CG; Joshi, AD; Leung, WK; Ma, W; Meyerhardt, JA; Ng, K; Nguyen, LH; Ogino, S; Song, M, 2021) |
| "This trial will test the efficacy of novel methods for implementing national guidelines to support informed decision-making about taking aspirin in 50-70-year-olds to reduce the risk of CRC and other chronic diseases." | 9.41 | An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial. ( Boyd, L; Broun, K; Chondros, P; Emery, J; Fishman, G; Forbes, C; Gutierrez, JM; Jenkins, M; Karnchanachari, N; Macrae, F; Marker, J; McGill, S; McIntosh, J; Milton, S; Novy, K; Saya, S; Shub, M; Taylor, N; Trevena, L; Walter, FM; Whitburn, S, 2021) |
| "Although substantial evidence supports aspirin's efficacy in colorectal cancer chemoprevention, key molecular mechanisms are uncertain." | 9.34 | Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk. ( Baron, JA; Barry, EL; Fedirko, V; Jones, DP; Liu, K; Ma, C; Mott, LA; Passarelli, MN; Peacock, JL; Uppal, K, 2020) |
| "Aspirin is associated with decreased risk of colorectal cancer (CRC), potentially by modulating the gut microbiome." | 9.34 | Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk. ( Church, TR; Demmer, RT; Knights, D; Meyer, KA; Onyeaghala, GC; Prizment, AE; Sadowsky, MJ; Shaukat, A; Staley, C; Straka, RJ; Thyagarajan, B; Vivek, S, 2020) |
| " Several epidemiological studies have shown that regular use of low dose aspirin is associated with a 20 to 30% reduction in the risk of sporadic colonic adenomas and colorectal cancer regardless of family risk." | 9.34 | Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. ( Ait-Omar, A; Benallaoua, M; Benamouzig, R; Boubaya, M; Deutsch, D; Helfen, S; Levy, V; Mary, F; Soualy, A, 2020) |
| "Among adults aged 40 to 80 years not using aspirin or other antithrombotic medications, administration of a single dose of oral aspirin prior to fecal immunochemical testing, compared with placebo, did not significantly increase test sensitivity for detecting advanced colorectal neoplasms at 2 predefined cutoffs of a quantitative fecal immunochemical test." | 9.30 | Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial. ( Block, T; Böck, W; Brenner, H; Calderazzo, S; Czock, D; Dikopoulos, N; Eisenbach, T; Kopp-Schneider, A; Ludwig, L; Mangold, J; Seufferlein, T; Stolz, T; Tikk, K, 2019) |
| "Aspirin dosing strategies accounting for body weight suggested in previous trials of colorectal cancer may not apply to adenomas." | 9.30 | Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial. ( Ahnen, DJ; Baron, JA; Barry, EL; Mott, LA; Passarelli, MN; Rees, JR, 2019) |
| "BCC incidence was evaluated in a randomized, double-blind, placebo-controlled clinical trial of aspirin (81 mg daily or 325 mg daily for ~3 years) and/or folic acid (1 mg daily for ~6 years) for the prevention of colorectal adenomas among 1121 participants with a previous adenoma." | 9.27 | Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas. ( Baron, JA; Barry, EL; Bresalier, RS; Gangar, P; Karagas, MR; McKeown-Eyssen, G; Passarelli, MN; Rees, JR; Zhang, D, 2018) |
| "The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and aspirin both have proof of concept for colorectal cancer chemoprevention, aligned with an excellent safety profile." | 9.27 | Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. ( Clifford, G; Hepburn, T; Hull, MA; Loadman, PM; Logan, RF; Montgomery, AA; Rees, CJ; Shafayat, A; Sprange, K; Tan, W; Whitham, D; Williams, EA, 2018) |
| "Epidemiological studies and cardiovascular prevention trials have shown that low-dose aspirin can reduce colorectal cancer (CRC) incidence and mortality, including inhibition of distant metastases." | 9.27 | The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. ( Bachleitner-Hofmann, T; Briata, IM; Caviglia, S; Clavarezza, M; DeCensi, A; Gnant, M; Haefeli, WE; Mislej, EM; Oppezzi, M; Paleari, L; Petrera, M; Puntoni, M; Roth, W; Scherer, D; Stabuc, B; Ulrich, CM, 2018) |
| "Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined." | 9.24 | ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. ( Backman, V; Carolan, PJ; Chan, AT; Chin, SM; Chung, DC; Colizzo, FP; Drew, DA; Flagg, M; Freedman, M; Gala, M; Garber, JJ; Gilpin, KK; Huttenhower, C; Kedrin, D; Khalili, H; Kwon, DS; Markowitz, SD; Milne, GL; Nishioka, NS; Parziale, M; Pond, E; Rawlings, CA; Richter, JM; Roy, HK; Schuck, MM; Staller, K; Stewart, K; Wang, M, 2017) |
| "Low-dose aspirin was associated with small absolute risk reductions in major cardiovascular disease events and small absolute increases in major bleeding." | 9.22 | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Bean, SI; Evans, CV; Guirguis-Blake, JM; Perdue, LA; Senger, CA, 2022) |
| " Most studies have demonstrated that the NSAID, aspirin, plays a beneficial role in the prevention of CRC and colonic adenomas." | 9.22 | Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies. ( Haydon, A; Orchard, SG; Zalcberg, JR; Zaman, FY, 2022) |
| " There is evidence that patients carrying PIK3CA mutations may benefit from treatment with acetylsalicylic acid, commonly known as aspirin, particularly in the setting of colorectal cancer." | 9.22 | Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited. ( Benndorf, RA; Hall, DCN, 2022) |
| "Aspirin (acetylsalicylic acid, ASA) is inexpensive and is established in preventing cardiovascular disease (CVD) and colorectal adenomas." | 9.22 | Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas. ( Block, RC; Mousa, SA; Wang, IE; Yi, S, 2022) |
| "In a prospective study, the combination of calcitriol, aspirin, and calcium carbonate did not prevent recurrence of colorectal adenomas over a 3-year period." | 9.22 | Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2016) |
| "In a nested case-control study in the Physicians' Health Study, we prospectively investigated the associations of plasma C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor receptor 2 (TNFR-2) with risk of colorectal cancer, and whether aspirin modified these associations among 268 colorectal cancer patients and 446 age- and smoking-matched controls." | 9.22 | Inflammatory biomarkers, aspirin, and risk of colorectal cancer: Findings from the physicians' health study. ( Chan, AT; Kim, C; Ma, J; Rifai, N; Sesso, HD; Stampfer, MJ; Zhang, X, 2016) |
| "Regular aspirin use may decrease cancer risk by reducing chronic inflammation." | 9.20 | Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Chaturvedi, AK; Hildesheim, A; Katki, HA; Kemp, TJ; Lang Kuhs, KA; Loftfield, E; Pinto, LA; Purdue, MP; Safaeian, M; Shiels, MS; Trabert, B; Wentzensen, N, 2015) |
| "Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is abrogated in those taking aspirin." | 9.20 | Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. ( Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, MG; Eccles, D; Evans, DG; Ho, JW; Hodgson, SV; Lindblom, A; Lubinski, J; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Moeslein, G; Morrison, PJ; Movahedi, M; Murday, V; Olschwang, S; Ramesar, RS; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2015) |
| "Aspirin has been shown to protect against colorectal neoplasms; however, the optimal chemopreventive dose and underlying mechanisms are unclear." | 9.20 | Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). ( Ahnen, DJ; Baron, JA; Barry, EL; Bradshaw, PT; Bresalier, RS; Fedirko, V; Figueiredo, JC; Milne, GL; Sandler, RS, 2015) |
| " The safety profile and potential cardiovascular benefits associated with ω-3 PUFAs make EPA a strong candidate for colorectal cancer (CRC) chemoprevention, alone or in combination with aspirin, which itself has recognized anti-CRC activity." | 9.17 | A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized cont ( Clifford, GM; Hull, MA; Loadman, PM; Logan, RF; Montgomery, AA; Rees, CJ; Sandell, AC; Whitham, D, 2013) |
| "We investigated whether CYP2C9 genotype was associated with risk of colorectal adenoma and/or modified associations with aspirin treatment or cigarette smoking in a cohort of 928 participants in a randomized trial of aspirin chemoprevention." | 9.17 | CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Makar, KW; McKeown-Eyssen, GE; Mott, LA; Poole, EM; Sandler, RS; Ulrich, CM, 2013) |
| "272 patients (naive for chronic aspirin use) with colorectal adenomas were randomly assigned to treatment with lysine acetylsalicylate 160 mg/day (n=73) or 300 mg/day (n=67) or placebo (n=132) for 4 years." | 9.16 | Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2012) |
| "Low-dose aspirin reduces colorectal cancer (CRC) incidence and mortality." | 9.16 | Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis. ( Benamouzig, R; Cooper, GS; Hassan, C; Launois, R; Rex, DK; Zullo, A, 2012) |
| "High quality evidence indicates that aspirin is effective in reducing colorectal polyps; and numerous epidemiological studies point towards an ability to prevent colorectal cancer." | 9.15 | The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. ( Ali, R; Chia, WK; Toh, HC, 2011) |
| " The protective effect of 81 mg of aspirin for colorectal adenomas persisted with continued posttreatment NSAID use." | 9.14 | Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Grau, MV; Gui, J; Haile, RW; McKeown-Eyssen, G; Sandler, RS; Summers, RW, 2009) |
| " Aspirin inhibits COX-2 activity and lowers the risk for colorectal adenomas and cancer." | 9.14 | Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. ( Ahnen, DJ; Ali, IU; Baron, JA; Barry, EL; Bresalier, RS; Burke, C; Grau, MV; Gui, J; McKeown-Eyssen, GE; Munroe, DJ; Saibil, F; Sandler, RS; Sansbury, LB; Tsang, S, 2009) |
| "Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas." | 9.14 | Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2010) |
| "Study subjects, about half of whom were recruited after fortification of grain products with folic acid in the United States and Canada, consisted of 871 individuals with a recent history of one or more colorectal adenomas who were randomized to receive either a 1 mg/day folic acid supplement or a placebo within one of three randomly assigned aspirin treatment groups (placebo, 81, or 325 mg/day)." | 9.14 | Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation. ( Baron, JA; Grau, MV; Levine, AJ; Mott, LA; Ueland, PM, 2010) |
| "The Aspirin/Folate Polyp Prevention Study is a randomized clinical trial of folic acid supplementation and incidence of new colorectal adenomas in individuals with a history of adenomas (n = 1,084)." | 9.13 | Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation. ( Ahnen, DJ; Ali, I; Baron, JA; Barry, EL; Figueiredo, JC; Grau, MV; Haile, RW; Levine, AJ; Midttun, O; Munroe, D; Sandler, RS; Tsang, S; Ueland, PM, 2008) |
| "8%) of 434 patients receiving aspirin had a recurrent adenoma compared with 121 (28." | 9.13 | Aspirin and folic acid for the prevention of recurrent colorectal adenomas. ( Armitage, NC; Grainge, MJ; Logan, RF; Muir, KR; Shepherd, VC, 2008) |
| "Exposure of aspirin has been associated with reduced risk of colorectal cancer (CRC) incidence, but aspirin use in relation to CRC patients' mortality remains undetermined." | 9.12 | Timing of Aspirin Use Among Patients With Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis. ( Fan, Y; Xiao, S; Xie, W; Zhou, L, 2021) |
| " The pooled relative risk (RR) with 95% confidence interval (CI) was used to estimate the effect of aspirin on colorectal cancer and/or colorectal adenomas." | 9.12 | Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials. ( Bhan, C; Cao, C; Cheng, C; Guo, Z; Han, T; Ji, Z; Ma, S; Qu, G; Sun, C; Yan, Y; Yang, H; Zhang, H; Zhou, Q, 2021) |
| " Overall, the results indicated that aspirin significantly reduced the risk of developing colorectal adenomas but not advanced lesions at 3 years (risk ratio (RR) = 0." | 9.12 | Influence of aspirin on prevention of colorectal cancer: an updated systematic review and meta-analysis of randomized controlled trials. ( Abdulhamid, AS; Alharbi, FA; Alomari, MS; Aziz, M; Ghaddaf, AA; Mullah, AN; Zaidi, SF, 2021) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 9.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 9.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| "To assess the safety and efficacy of folic acid supplementation for preventing colorectal adenomas." | 9.12 | Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. ( Ahnen, DJ; Allen, JI; Baron, JA; Barry, EL; Beck, GJ; Bond, JH; Bresalier, RS; Burke, CA; Byers, T; Church, TR; Cole, BF; Greenberg, ER; Haile, RW; Mandel, JS; Marcon, N; McKeown-Eyssen, G; Mott, LA; Pearson, LH; Rees, JR; Robertson, DJ; Rothstein, RI; Saibil, F; Sandler, RS; Snover, DC; Summers, RW; Ueland, PM, 2007) |
| "Regular use of aspirin and other nonsteroidal antiinflammatory drugs reduces both the development of colorectal neoplasia and recurrence of colorectal adenoma (CRA)." | 9.12 | Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial. ( Grainge, MJ; Houlston, RS; Hubner, RA; Liu, JF; Logan, RFA; Muir, KR, 2007) |
| "Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers." | 9.10 | A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. ( Baron, JA; Budinger, S; Halabi, S; Karp, DD; Keresztes, R; Loprinzi, CL; Paskett, E; Petrelli, N; Pipas, JM; Sandler, RS; Schilsky, R; Steinbach, G, 2003) |
| "We performed a randomized, double-blind trial of aspirin as a chemopreventive agent against colorectal adenomas." | 9.10 | A randomized trial of aspirin to prevent colorectal adenomas. ( Ahnen, D; Allen, JI; Baron, JA; Beach, M; Beck, GJ; Bond, JH; Bresalier, R; Burke, CA; Byers, T; Church, TR; Cole, BF; Greenberg, ER; Haile, RW; Mandel, JS; Marcon, N; McKeown-Eyssen, G; Mott, LA; Pearson, L; Rothstein, R; Saibil, F; Sandler, RS; Snover, DC; Summers, RW; van Stolk, RU, 2003) |
| "Among the 238 patients who completed the year 1 colonoscopy, at least one adenoma was observed in 38 patients of the 126 (30%) in the aspirin group and in 46 of the 112 (41%) in the placebo group; relative risk was 0." | 9.10 | Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Girard, B; Jullian, E; Little, J; Martin, A; Piednoir, B, 2003) |
| "We tested the hypothesis that aspirin, at a single, once-daily 81-mg dose, will reduce colonic mucosal concentration of prostaglandin estradiol (E2) in individuals at high risk for colorectal cancer development similar to our prior observations in a young normal-risk population." | 9.09 | Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. ( Bailey, J; Boland, CR; Brenner, DE; Burney, K; Krishnan, K; Normolle, D; Peters-Golden, M; Rock, CL; Ruffin, MT; Shureiqi, I, 2001) |
| " A multicentre, double-blind, randomized, controlled trial is underway to determine the efficacy of regular aspirin intake (160 or 300 mg/day) in reducing colorectal adenoma recurrence." | 9.09 | APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Little, J; Martin, A; Yoon, H, 2001) |
| "In contrast to most observational studies, the randomized Physicians' Health Study found no association between aspirin use and colorectal cancer after 5 years." | 9.08 | Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. ( Buring, JE; Glynn, RJ; Hennekens, CH; Lee, IM; Manson, JE; Stürmer, T, 1998) |
| " Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users." | 9.05 | Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis. ( Cao, LL; Chen, QY; Huang, CM; Li, P; Lin, JL; Lin, JX; Lin, M; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2020) |
| "We aimed to evaluate the association between selective COX-2 inhibitors (coxibs) and the risk of colorectal neoplasms and vascular events with and without low-dose aspirin." | 9.01 | Risks of colorectal neoplasms and cardiovascular thromboembolic events after the combined use of selective COX-2 inhibitors and aspirin with 5-year follow-up: a meta-analysis. ( He, P; Xie, H; Yang, C; Ye, G; Zhong, W, 2019) |
| "Regular aspirin use is associated with reduced risk of colorectal cancer (CRC)." | 8.98 | Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations. ( Barrett, JH; Bishop, DT; Burn, J; Casey, G; Elliott, F; Forman, D; Haile, R; Hopper, JL; Jackson, MS; Jenkins, M; Lindor, NM; Marchand, LL; Northwood, E; Potter, JD; Santibanez-Koref, M; Scherer, D; Sheth, H; Smith, G; Thibodeau, SN; Ulrich, CM; Win, AK; Wolf, CR, 2018) |
| "In patients with a previous history of colorectal cancer or adenomas, low-dose aspirin (80-160 mg/day) compared to placebo taken for 2 to 4 years reduces the risk of recurrent colorectal adenomas (relative risk (RR), 0." | 8.95 | Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. ( Chaiyakunapruk, N; Ching, SM; Lim, KG; Phisalprapa, P; Saokaew, S; Veettil, SK, 2017) |
| "Both aspirin use and screening with flexible sigmoidoscopy or guaiac faecal occult blood testing (FOBT) may reduce mortality from colorectal cancer, but comparative effectiveness of these interventions is unknown." | 8.95 | Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. ( Adami, HO; Bretthauer, M; Buring, JE; Cook, NR; Emilsson, L; Gaziano, MJ; Holme, Ø; Kalager, M; Løberg, M; Sesso, HD, 2017) |
| "Regular aspirin use has been associated with inhibition of the whole spectrum of colorectal carcinogenesis, including prevention of metastases and reduced total mortality in colorectal cancer." | 8.93 | PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies. ( Clavarezza, M; Cuzick, J; DeCensi, A; DeCensi, M; Paleari, L; Puntoni, M, 2016) |
| "To determine whether aspirin or non-aspirin non-steroidal anti-inflammatory drugs (NA-NSAIDs) prevent colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD)." | 8.93 | Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease? ( Burr, NE; Hull, MA; Subramanian, V, 2016) |
| "Through search the possible randomized control trials, we make a renewed meta-analysis in order to assess the impact of aspirin in preventing the recurrence of colorectal adenoma." | 8.93 | The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a Renewed Meta-Analysis of Randomized Trials. ( Cheng, DW; Gao, XK; Lu, XJ; Luo, H; Tu, J; Wang, Y; Wang, YJ; Xu, XL; Yan, BC; Zhang, HL; Zhao, TY, 2016) |
| "Considerable interest has emerged over the last decade regarding the role of aspirin in prevention of colorectal cancer." | 8.93 | The role of aspirin in colorectal cancer chemoprevention. ( Singh Ranger, G, 2016) |
| "The objective of this meta-analysis was to systematically assess the survival benefit of aspirin use before or after diagnosis for patients with colorectal cancer (CRC)." | 8.91 | Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. ( Cai, J; Li, P; Shi, Y; Wu, H; Wu, Y; Xia, D; Xu, J; Yang, J; Ye, Y; Zhang, H, 2015) |
| "To examine the association between long-term oral low-dose aspirin and overall survival in colorectal cancer patients after diagnosis." | 8.91 | [Association of long-term oral low-dose aspirin and survival in colorectal cancer: a meta-analysis]. ( Chen, P; Dai, W; Wu, F; Ye, H; Zheng, Q, 2015) |
| "Abundant epidemiologic evidence indicates that regular and long-term use of aspirin is associated with a significant reduction in the incidence of colorectal cancer." | 8.90 | Aspirin and colorectal cancer: back to the future. ( Manthravadi, S; Sha, D; Sinicrope, FA; Tougeron, D, 2014) |
| "Epidemiological evidence suggests that use of aspirin after the diagnosis of colorectal cancer can lengthen survival." | 8.90 | Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. ( He, J; Shi, WT; Wang, J; Ye, XF, 2014) |
| "In previous meta-analyses, aspirin use has been associated with reduced risk of colorectal cancer." | 8.89 | Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. ( Chen, S; Fu, J; Yang, Y; Ye, X, 2013) |
| "In addition to longstanding evidence from observational studies, evidence from randomised trials of the effectiveness of aspirin for chemoprevention of colorectal cancer has increased substantially in recent years." | 8.89 | Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits. ( Rothwell, PM, 2013) |
| "A high-quality body of evidence supports the use of aspirin in reducing sporadic and hereditary adenomatous polyps, and numerous observational studies point to a reduction in colorectal cancer (CRC) risk." | 8.88 | Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. ( Ali, R; Chia, WK; Toh, HC, 2012) |
| "Previous studies have shown that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) lower colorectal cancer (CRC) risk." | 8.86 | Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. ( Barnetson, RA; Campbell, H; Cetnarskyj, R; Din, FV; Dunlop, MG; Farrington, SM; Porteous, ME; Stark, L; Tenesa, A; Theodoratou, E, 2010) |
| "This meta-analysis suggests that aspirin prevents recurrent colorectal adenomas among patients with a history of colorectal adenomas." | 8.85 | The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. ( Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A, 2009) |
| "We combined data from all randomized double-blind placebo-controlled trials that evaluated aspirin for the prevention of colorectal adenomas." | 8.85 | Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. ( Baron, JA; Benamouzig, R; Chaussade, S; Cole, BF; Grainge, MJ; Halabi, S; Logan, RF; Sandler, RS, 2009) |
| "Aspirin for prevention of colorectal cancer is controversial." | 8.84 | The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. ( Barrowman, N; Code, C; Dubé, C; Lewin, G; Moher, D; Rostom, A; Sampson, M; Tsertsvadze, A, 2007) |
| "Randomised trials have shown that aspirin reduces the short-term risk of recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large trials have shown no effect in primary prevention of colorectal cancer during 10 years' follow-up." | 8.84 | Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. ( Flossmann, E; Rothwell, PM, 2007) |
| "To evaluate the cost-effectiveness of aspirin chemoprevention alone and in combination with colonoscopy surveillance in patients with prior adenoma resection." | 8.84 | Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysis. ( Arguedas, MR; DuPont, AW; Wilcox, CM, 2007) |
| "There is combined evidence from three randomized trials that aspirin significantly reduced the recurrence of sporadic adenomatous polyps." | 8.82 | Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. ( Asano, TK; McLeod, RS, 2004) |
| "Observational studies have found a decreased rate of colorectal cancer in people who regularly took aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs)." | 8.81 | Celecoxib as adjunctive therapy for treatment of colorectal cancer. ( North, GL, 2001) |
| "Epidemiologic studies indicate strongly that aspirin use reduces the risk of colorectal cancer and adenoma by approximately 40 to 50%." | 8.80 | The prevention of colorectal cancer by aspirin use. ( Giovannucci, E, 1999) |
| "There is increasing evidence to suggest that aspirin and other non-steroidal anti-inflammatory drugs reduce the risk of colorectal cancer." | 8.80 | Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins. ( Arber, N; Strul, H, 2000) |
| "There is substantial experimental, clinical and epidemiological evidence that regular use of non-steroid anti-inflammatory drugs (NSAIDs), particularly aspirin, is associated with a reduced risk of colorectal cancer." | 8.79 | Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence. ( Forman, D; Weiss, HA, 1996) |
| "Results from previous studies indicate that use of aspirin may improve colorectal cancer (CRC) survival." | 8.31 | Low-dose aspirin use and colorectal cancer survival in 32,195 patients-A national cohort study. ( Ekström Smedby, K; Glimelius, B; Martling, A; Matthiessen, P; Nordenvall, C; Shahrivar, M; Syk, I; Weibull, CE, 2023) |
| "Growing evidence suggests quercetin and aspirin may have anticancer properties, notably in the case of colorectal cancer." | 8.31 | Exploring the potential of quercetin/aspirin-loaded chitosan nanoparticles coated with Eudragit L100 in the treatment of induced-colorectal cancer in rats. ( Abdelgawad, MA; Ahmed, YM; Ali, HM; Alsaidan, OA; El-Say, KM; Elkomy, MH; Elmowafy, M; Gomaa, HAM; Hendawy, OM; Shalaby, K, 2023) |
| " Therefore, we investigated the risk of discontinuing aspirin concerning thrombotic complications in laparoscopic colorectal cancer surgery." | 8.12 | Impact of aspirin discontinuation on thrombotic complications in laparoscopic colorectal cancer surgery. ( Dono, K; Hamabe, A; Harino, T; Noura, S; Ogino, T; Suzuki, Y; Takeyama, H; Tanida, T; Tomita, N, 2022) |
| "Aspirin intake has been shown to lead to significant protection against colorectal cancer, for example with an up to twofold reduction in colorectal adenoma incidence rates at higher doses." | 8.12 | Aspirin's effect on kinetic parameters of cells contributes to its role in reducing incidence of advanced colorectal adenomas, shown by a multiscale computational study. ( Boland, CR; Goel, A; Komarova, NL; Wang, Y; Wodarz, D, 2022) |
| "The US Preventive Services Task Force (USPSTF) is updating its 2016 recommendation on the use of aspirin for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC)." | 8.12 | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. ( Dehmer, SP; Evans, CV; Guirguis-Blake, JM; Maciosek, MV; O'Keefe, LR; Perdue, LA, 2022) |
| " procera dried latex extract prepared in methanol (MeDL) against inflammation and oxidative stress in experimental model of colorectal carcinoma (CRC)." | 8.12 | Anti-inflammatory and antioxidant effect of methanol extract of latex of Calotropis procera in rat model of colorectal cancer. ( Das, P; Kumar, VL; Verma, S, 2022) |
| "Aspirin inhibited carcinogenesis of intestinal mucosal cells in the ulcerative colitis model by inhibiting the interleukin-6/ Janus kinase/signal transducer and activator of transcription 3 signaling pathway and promoted apoptosis, thereby suppressing proliferation." | 8.12 | Aspirin Inhibits Carcinogenesis of Intestinal Mucosal Cells in UC Mice Through Inhibiting IL-6/JAK/STAT3 Signaling Pathway and Modulating Apoptosis and Proliferation. ( Chen, Y; Diao, T; Li, D; Shang, G; Shi, L; Sun, L; Yin, X, 2022) |
| "Further data from the Aspirin in Reducing Events in the Elderly (ASPREE) trial heightens the concern regarding aspirin use for colorectal cancer prevention in elderly subjects." | 8.12 | Aspirin for Colorectal Cancer Prevention: Age Matters. ( Shureiqi, I, 2022) |
| "Aspirin has been shown to prevent the onset of colorectal adenoma and cancer." | 8.12 | Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by Blood Biochemistry and Nutritional Intake. ( Goto, C; Ishikawa, H; Itoh, Y; Matsuda, T; Mutoh, M; Otani, T; Sano, Y; Suzuki, S; Takeuchi, Y; Yoshida, N, 2022) |
| "To evaluate how prediagnosis obesity and postdiagnosis aspirin use may be associated with overall survival in patients with late-stage colorectal cancer." | 8.12 | Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. ( Advani, SM; Chang, S; Chavez, JC; Dasari, A; Davis, JS; Fogelman, D; Henderson, H; Johnson, B; Kee, B; Kok, M; Kopetz, S; Lee, HY; Maru, D; Menter, DG; Meric-Bernstam, F; Morris, V; Overman, MJ; Parseghian, C; Raghav, KP; San Miguel, Y; Shaw, KR; Shen, JP; Shureiqi, I; Vilar, E; Wolff, RA, 2022) |
| "Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk." | 8.02 | Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study. ( Albanes, D; Alwers, E; Amitay, E; Baron, JA; Bermejo, JL; Berndt, SI; Bishop, DT; Brenner, H; Buchanan, DD; Butterworth, A; Campbell, PT; Casey, G; Castellví-Bel, S; Chan, AT; Chang-Claude, J; Drew, DA; Figueiredo, JC; Gallinger, S; Giles, GG; Gruber, SB; Gsur, A; Gunter, MJ; Hampel, H; Harrison, TA; Hoffmeister, M; Hopper, JL; Keku, TO; Kim, HR; Kweon, SS; Li, CI; Li, L; Lin, Y; Lindblom, A; Lindor, NM; Marchand, LL; Moreno, V; Newcomb, PA; Nounu, A; Peters, U; Pharoah, PDP; Platz, EA; Relton, CL; Rennert, G; Richmond, RC; Sakoda, LC; Schafmayer, C; Scherer, D; Schoen, RE; Slattery, ML; Stadler, ZK; Stewart, ID; Surendran, P; Ulrich, CM; van Dujinhoven, FJB; Van Guelpen, B; Vodicka, P; Vodickova, L; Wareham, NJ; Weinstein, SJ; White, E; Williams, AC; Wolk, A; Woods, MO; Wu, AH; Zheng, W, 2021) |
| "Evidence for aspirin's chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood." | 8.02 | A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. ( Albanes, D; Baron, JA; Bermejo, JL; Berndt, SI; Bishop, DT; Brenner, H; Buchanan, DD; Campbell, PT; Casey, G; Castellví-Bel, S; Chan, AT; Chang-Claude, J; Drew, DA; Figueiredo, JC; Gallinger, S; Giles, GG; Greenhough, A; Gruber, SB; Gsur, A; Gunter, MJ; Hampel, H; Harrison, TA; Heesom, KJ; Hoffmeister, M; Hopper, JL; Keku, TO; Kim, HR; Kweon, SS; Le Marchand, L; Li, CI; Li, L; Lin, Y; Lindblom, A; Lindor, NM; Moreno, V; Newcomb, PA; Nounu, A; Peters, U; Pharoah, PDP; Platz, EA; Relton, CL; Rennert, G; Richmond, RC; Sakoda, LC; Schafmayer, C; Scherer, D; Schoen, RE; Slattery, ML; Stadler, ZK; Ulrich, CM; van Duijnhoven, FJB; Van Guelpen, B; Vodicka, P; Vodickova, L; Weinstein, SJ; White, E; Williams, AC; Wolk, A; Woods, MO; Wu, AH; Zheng, J; Zheng, W, 2021) |
| "Aspirin use reduces colorectal cancer (CRC) incidence, but there is limited evidence regarding associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) with CRC-specific survival." | 8.02 | Associations of Aspirin and Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs With Colorectal Cancer Mortality After Diagnosis. ( Campbell, PT; Cance, WG; Figueiredo, JC; Guinter, MA; Jacobs, EJ; Newton, CC, 2021) |
| "Prior epidemiological and intervention studies have not been able to separate independent effects of dose, timing, and duration of aspirin use in colorectal cancer (CRC) chemoprevention." | 8.02 | Timing of Aspirin Use in Colorectal Cancer Chemoprevention: A Prospective Cohort Study. ( Chan, AT; Giovannucci, EL; Meyerhardt, JA; Zhang, Y, 2021) |
| "Aspirin is a chemopreventive agent for colorectal adenoma and cancer (CRC) that, like many drugs inclusive of chemotherapeutics, has been investigated for its effects on bacterial growth and virulence gene expression." | 8.02 | Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum. ( Brennan, CA; Chan, AT; Drew, DA; Gallini Comeau, CA; Garrett, WS; Glickman, JN; Nakatsu, G; Schoen, RE, 2021) |
| "Patients taking low-dose aspirin to prevent cardiovascular disease (CVD) may also benefit from a reduced risk of colorectal cancer (CRC)." | 8.02 | Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis. ( De Caterina, R; Krucien, N; Marsh, K; Seo, J; Soriano Gabarró, M; Tervonen, T; Vora, P; Wissinger, U, 2021) |
| "Genotype-guided aspirin use for colorectal cancer chemoprevention may offer a cost-effective approach for the future management of average-risk individuals." | 8.02 | Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention? ( Au, TH; Biltaji, E; Brixner, DI; Li, CI; Ose, J; Rivers, Z; Stenehjem, DD; Ulrich, CM; Walker, B, 2021) |
| "With 13 years of follow-up, the authors prospectively evaluated the association between aspirin and ibuprofen use and incident distal adenoma (1221 cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial." | 8.02 | Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial. ( Barry, KH; Berndt, SI; Chudy-Onwugaje, K; Huang, WY; Johnson, CC; Katki, HA; Purdue, MP; Su, LJ; Wang, L, 2021) |
| "Several epidemiological and cohort studies suggest that regular low-dose aspirin use independently reduces the long-term incidence and risk of colorectal cancer deaths by approximately 20%." | 8.02 | Development and user-testing of a brief decision aid for aspirin as a preventive approach alongside colorectal cancer screening. ( Brain, K; Dolwani, S; Edwards, A; Lifford, KJ; Seddon, K; Semedo, L; Smits, S, 2021) |
| "Although compelling evidence exists on the ability of aspirin to treat colorectal cancer (CRC), and numerous theories and targets have been proposed, a consensus has not been reached regarding its mechanism of action." | 7.96 | Aspirin metabolites 2,3‑DHBA and 2,5‑DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention. ( Bhat, GJ; Dachineni, R; Kumar, DR; Lick, T; Sankaranarayanan, R; Valiveti, CK, 2020) |
| "Accumulating evidence suggests that aspirin has anti-tumorigenic properties in colorectal cancer (CRC)." | 7.96 | A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer. ( Boland, C; Goel, A; Komarova, NL; Shimura, T; Toden, S; Wodarz, D, 2020) |
| "Aspirin, as a non-steroidal anti-inflammatory drug, can improve the survival rate of patients with colorectal cancer, while aspirin is effective in patients with PIK3CA mutant colorectal cancer (CRC)." | 7.96 | Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway. ( Chen, Z; Dong, H; Gao, F; Wang, C; Wang, X; Zhang, S; Zhang, X, 2020) |
| "Previous studies suggest that the use of low-dose aspirin before a colorectal cancer (CRC) diagnosis may be associated with a decreased risk of CRC progression." | 7.96 | Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer. ( Azoulay, L; Cricelli, C; Giorli, G; Lapi, F; Pollak, M; Rouette, J; Simonetti, M; Yin, H, 2020) |
| "Aspirin may increase the risk of lower gastrointestinal bleeding (LGIB) from precursors of colorectal cancer (CRC)." | 7.96 | Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study. ( Erichsen, R; Farkas, DK; Sørensen, HT; Troelsen, FS, 2020) |
| "Population-based East Asian data have corroborated reports from non-Asian settings on the association between low-dose aspirin and a lower risk of colorectal cancer (CRC)." | 7.96 | Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan. ( Chan, KA; Lin, HD; Soriano-Gabarró, M; Vora, P, 2020) |
| "We investigated the effect of aspirin on colorectal cancer (CRC) risk among subgroups of women with and without risk factors for CRC." | 7.91 | Effects of Colorectal Cancer Risk Factors on the Association Between Aspirin and Colorectal Cancer. ( Bafford, A; Johnson, KC; Kooperberg, C; Peters, U; Seaton, ME; Zubair, N, 2019) |
| "New Australian guidelines recommend that GPs actively consider prescribing low-dose aspirin to patients aged 50-70 years to reduce their risk of developing colorectal cancer (CRC)." | 7.91 | Benefits and harms of aspirin to reduce colorectal cancer risk: a cross-sectional study of methods to communicate risk in primary care. ( Bickerstaffe, A; Cummings, KL; Emery, JD; Maddumarachchi, S; McIntosh, J; Nguyen, P, 2019) |
| "A significant proportion of patients discontinue their aspirin in the time approaching a breast or colorectal cancer-specific death." | 7.91 | End-of-life prescribing of aspirin in patients with breast or colorectal cancer. ( Barron, TI; Bennett, K; Brown, C; Cranfield, F; Murphy, L; Sharp, L; Smith, A; Visvanathan, K, 2019) |
| "Regular use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) for a longer period has been inversely associated with colorectal cancer (CRC) risk." | 7.91 | Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. ( Amitay, EL; Bläker, H; Brenner, H; Carr, PR; Chang-Claude, J; Herpel, E; Hoffmeister, M; Jansen, L; Kloor, M; Roth, W; Walter, V, 2019) |
| "The chemopreventive effect of aspirin in colorectal cancer (CRC) is well studied, but its benefit in patients after CRC diagnosis and surgery is unclear." | 7.91 | Low-dose aspirin can reduce colorectal cancer mortality after surgery: A 10-year follow-up of 13 528 colorectal cancer patients. ( Chan, FCH; Ho, JMW; Sung, JJY; Tsoi, KKF, 2019) |
| "The antiplatelet effect of low-dose aspirin, via inhibition of cyclooxygenase-1, might contribute to its ability to reduce the risk of colorectal cancer (CRC)." | 7.91 | Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer. ( de Abajo, FJ; García-Rodríguez, LA; Gil, M; Montoya, H; Rodríguez-Martín, S; Rodríguez-Miguel, A, 2019) |
| "In a large screening cohort in Norway, regular use of aspirin and particularly DOACs, were associated with lower PPV of FIT for detection of CRCs and advanced adenomas." | 7.91 | Effects of Oral Anticoagulants and Aspirin on Performance of Fecal Immunochemical Tests in Colorectal Cancer Screening. ( Botteri, E; Bretthauer, M; de Lange, T; Frigstad, SO; Hoff, G; Holme, Ø; Randel, KR; Romstad, KMK, 2019) |
| " We hypothesized that blood platelet count would be associated with systemic inflammation, the densities of tumor infiltrating immune cells, and survival in colorectal cancer (CRC), and these relationships could be altered by aspirin use." | 7.91 | Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer. ( Herzig, KH; Karhu, T; Karttunen, TJ; Klintrup, K; Mäkelä, J; Mäkinen, MJ; Minkkinen, I; Sirniö, P; Tuomisto, A; Väyrynen, JP; Väyrynen, SA, 2019) |
| "Aspirin has been proposed as a novel adjuvant agent in colorectal cancer (CRC)." | 7.88 | Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study. ( Cardwell, CR; Coleman, HG; Gray, RT; Hughes, C; Murray, LJ, 2018) |
| "Aspirin, commonly used for prevention of cardiovascular and cerebrovascular diseases, is well known to protect against development of colorectal cancer (CRC) but increases risk of gastrointestinal bleeding (GIB)." | 7.88 | Risk of gastrointestinal bleeding and benefit from colorectal cancer reduction from long-term use of low-dose aspirin: A retrospective study of 612 509 patients. ( Chan, FC; Hirai, HW; Sung, JJ; Tsoi, KK, 2018) |
| "Aspirin use after diagnosis of colorectal cancer was associated with significantly lower mortality rates and this effect remained significant after adjusting for potential confounders." | 7.85 | The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer. ( Bastiaannet, E; Frouws, MA; Lemmens, VE; Liefers, GJ; Portielje, JEA; Rademaker, E; Van de Velde, CJH; van Herk-Sukel, MPP, 2017) |
| "We used a single, integrated, microsimulation model to generate comparable results for 3 services recommended by the US Preventive Services Task Force: aspirin counseling for the primary prevention of CVD and colorectal cancer, screening and treatment for lipid disorders (usually high cholesterol), and screening and treatment for hypertension." | 7.85 | Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV, 2017) |
| " Evidence suggests that aspirin (a widely used nonsteroidal anti-inflammatory drug) not only prolongs colorectal cancer survival, but can also activate T cell-mediated antitumor immunity and synergize with immunotherapy through inhibition of prostaglandin E2 production." | 7.85 | Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. ( Cao, Y; Chan, AT; da Silva, A; Freeman, GJ; Fuchs, CS; Giannakis, M; Giovannucci, EL; Gu, M; Hamada, T; Keum, N; Kosumi, K; Li, W; Liu, L; Masugi, Y; Meyerhardt, JA; Mima, K; Nevo, D; Nishihara, R; Nowak, JA; Ogino, S; Qian, ZR; Rodig, SJ; Shi, Y; Song, M; Wang, M; Wu, K; Yang, J; Zhang, X, 2017) |
| "Purpose Regular use of aspirin is associated with improved survival for patients with colorectal cancer (CRC)." | 7.85 | Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. ( Adams, SV; Ahnen, DJ; Baron, JA; Burnett-Hartman, AN; Cohen, SA; Hardikar, S; Hua, X; Kocarnik, JM; Lindor, NM; Newcomb, PA; Phipps, AI, 2017) |
| "Evidence from clinical trial populations suggests low-dose aspirin reduces the risk of colorectal cancer (CRC)." | 7.85 | New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case-control study in UK general practice. ( Bromley, S; Cea Soriano, L; García Rodríguez, LA; Lanas, A; Soriano-Gabarró, M, 2017) |
| "Aspirin's potential as a drug continues to be evaluated for the prevention of colorectal cancer (CRC)." | 7.85 | Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer. ( Bhat, GJ; Callegari, E; Dachineni, R; Kesharwani, SS; Kumar, DR; Sankaranarayanan, R; Seefeldt, T; Tummala, H, 2017) |
| " Aspirin has been shown to reduce cancer risk and mortality, particularly in colorectal cancer." | 7.85 | Reduction of NANOG Mediates the Inhibitory Effect of Aspirin on Tumor Growth and Stemness in Colorectal Cancer. ( Cheng, W; Cui, B; Dong, L; Fan, W; Gong, Y; Hou, Z; Kamran, M; Kang, Z; Li, J; Li, M; Li, S; Liu, B; Liu, Q; Luo, Y; Ren, Y; Tian, P; Wang, C; Wang, H; Wang, J; Wang, L; Wen, Q; Xu, J; Xu, L; Xue, X; Yang, M, 2017) |
| "We assessed the role of aspirin in patients with metastatic colorectal cancer who failed all previous treatments and were receiving capecitabine as a salvage option before the introduction of regorafenib and TAS-102." | 7.85 | The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. ( Andrikou, K; Berardi, R; Bianconi, M; Bittoni, A; Cabras, F; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Pusceddu, V; Restivo, A; Scartozzi, M; Scintu, F; Zorcolo, L, 2017) |
| "Evidence has accumulated that long-term use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) protects against colorectal cancer." | 7.85 | Exploring Differences in the Aspirin-Colorectal Cancer Association by Sex and Race/Ethnicity: The Multiethnic Cohort Study. ( Haiman, CA; Kolonel, LN; Marchand, LL; Monroe, KR; Park, SY; Wilkens, LR, 2017) |
| "Numerous evidences indicate that aspirin usage causes a significant reduction in colorectal cancer." | 7.85 | Identification of TMEM208 and PQLC2 as reference genes for normalizing mRNA expression in colorectal cancer treated with aspirin. ( He, Y; Jin, X; Jin, Y; Li, X; Li, Z; Liu, Y; Ning, N; Qiao, Y; RajkumarEzakiel Redpath, RJ; Sun, Y; Wang, G; Wang, T; Weng, M; Wu, Y; Yang, C; Yang, W; Zhang, F; Zhang, L; Zhang, Y; Zhu, Y, 2017) |
| " Daily, low-dose aspirin has been identified as a promising means of preventing colorectal cancer, and stakeholders are already calling for research to facilitate dissemination." | 7.83 | Colorectal cancer prevention and intentions to use low-dose aspirin: A survey of 1000 U.S. adults aged 40-65. ( Donovan, E; Holton, AE; Jensen, JD; Krakow, M; Tavtigian, S; Weaver, J, 2016) |
| "Evidence indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages." | 7.83 | Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV; Whitlock, EP, 2016) |
| "The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years." | 7.83 | Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. ( Bibbins-Domingo, K, 2016) |
| "Regular use of aspirin (acetylsalicylic acid) is associated with reduced incidence and mortality of colorectal cancer (CRC)." | 7.83 | Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study. ( Bains, SJ; Bjørnbeth, BA; Brudvik, KW; Dørum, LM; Mahic, M; Myklebust, TÅ; Møller, B; Småstuen, MC; Taskén, K; Yaqub, S, 2016) |
| "We conducted three differently designed nested case-control studies to evaluate whether the protective effect of low-dose aspirin against colorectal cancer (CRC) is explained by selection bias." | 7.83 | The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice. ( Cea Soriano, L; García Rodríguez, LA; Soriano-Gabarró, M, 2016) |
| "Aspirin use reduces colorectal cancer risk." | 7.83 | Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. ( Cao, Y; Chan, AT; Drew, DA; Fuchs, CS; Garrett, WS; Giovannucci, EL; Inamura, K; Lochhead, P; Mima, K; Morikawa, T; Nishihara, R; Nosho, K; Nowak, JA; Ogino, S; Qian, ZR; Song, M; Wang, M; Wu, K; Zhang, X, 2016) |
| "To evaluate whether aspirin can reduce the risk of colorectal cancer in people with diabetes." | 7.81 | Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. ( Lai, MS; Lin, CC; Shau, WY, 2015) |
| "Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring PIK3CA mutations." | 7.81 | Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. ( Day, FL; Desai, J; Faragher, I; Gibbs, P; Jones, I; Jorissen, RN; Kim, R; Kothari, N; Li, S; Lipton, L; Palmieri, M; Sakthinandeswaren, A; Schell, M; Shibata, D; Sieber, OM; Teer, JK; Tie, J; Tran, B; Wong, HL; Yeatman, T, 2015) |
| "Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer." | 7.81 | Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. ( Baron, JA; Berndt, SI; Brenner, H; Butterbach, K; Caan, BJ; Campbell, PT; Carlson, CS; Casey, G; Chan, AT; Chang-Claude, J; Chanock, SJ; Cotterchio, M; Duggan, D; Figueiredo, JC; Fuchs, CS; Gauderman, WJ; Giovannucci, EL; Gong, J; Haile, RW; Harrison, TA; Hayes, RB; Hoffmeister, M; Hopper, JL; Hsu, L; Hudson, TJ; Hutter, CM; Jacobs, EJ; Jenkins, MA; Jiao, S; Le Marchand, L; Lemire, M; Lin, Y; Lindor, NM; Nan, H; Newcomb, PA; Ogino, S; Peters, U; Pflugeisen, BM; Potter, JD; Qu, C; Rosse, SA; Rudolph, A; Schoen, RE; Schumacher, FR; Seminara, D; Slattery, ML; Thibodeau, SN; Thomas, F; Thornquist, M; Ulrich, CM; Warnick, GS; White, E; Zanke, BW, 2015) |
| " Use of aspirin has been shown to be associated with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers." | 7.81 | Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. ( Ahnen, DJ; Ait Ouakrim, D; Baron, JA; Buchanan, DD; Casey, G; Chau, R; Clendenning, M; Dashti, SG; Gallinger, S; Giles, GG; Haile, RW; Hopper, JL; Jenkins, MA; Le Marchand, L; Leggett, B; Lindor, NM; Macrae, FA; Newcomb, PA; Potter, JD; Rosty, C; Thibodeau, SN; Win, AK; Winship, IM; Young, JP, 2015) |
| "To assess associations between the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) and colorectal cancer risk." | 7.81 | Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. ( Baron, JA; Erichsen, R; Friis, S; Riis, AH; Sørensen, HT, 2015) |
| "Individuals who began taking low-dose aspirin before they were diagnosed with colorectal cancer were reported to have longer survival times than patients who did not take this drug." | 7.80 | Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. ( Baron, JA; Cantwell, MM; Cardwell, CR; Hughes, C; Kunzmann, AT; Murray, LJ; Powe, DG, 2014) |
| "Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer." | 7.80 | Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. ( Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL, 2014) |
| "The aim of this study was to evaluate the relationship between long-term aspirin use with pretreatment 18 Fluorodeoxyglucose (FDG) uptake of primary lesions of Colorectal cancer (CRC) and evaluate their clinical significance." | 7.80 | Correlation between long-term aspirin use and F-fluorodeoxyglucose uptake in colorectal cancer measured by PET/CT. ( Su, B; Wan, J; Xu, B, 2014) |
| "Recent observational studies suggest that postoperative aspirin use may improve Colorectal cancer (CRC)-specific survival and overall survival (OS)." | 7.80 | Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. ( Chew, L; Chew, MH; Chia, WK; Fu, WP; Goh, CH; Goh, HH; Leong, WQ; Pan, YS; Tan, IB; Tang, CL; Toh, HC; Tony, LK, 2014) |
| "There is increasing evidence that aspirin, statins and ACE-inhibitors can reduce the incidence of colorectal cancer." | 7.79 | The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme. ( Crighton, EM; Horgan, PG; Mansouri, D; McMillan, DC; Roxburgh, CS, 2013) |
| "Considerable evidence suggests that aspirin has a chemopreventive effect on colorectal cancer (CRC)." | 7.79 | The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. ( Chen, JS; Chiou, MJ; Huang, WK; Kuo, CF; Lin, YC; See, LC; Yang, TS; Yu, KH, 2013) |
| "To examine whether the association of aspirin intake with colorectal cancer risk differs according to status of tumor BRAF oncogene mutation." | 7.79 | Aspirin use and risk of colorectal cancer according to BRAF mutation status. ( Chan, AT; Cho, E; Fuchs, CS; Giovannucci, E; Imamura, Y; Jung, S; Kuchiba, A; Liao, X; Lochhead, P; Morikawa, T; Nishihara, R; Ogino, S; Qian, ZR; Spiegelman, D; Wang, M; Yamauchi, M, 2013) |
| "Regular aspirin use reduces the risk for colorectal cancer (CRC), possibly through inhibition of WNT/cadherin-associated protein β1 (CTNNB1 or β-catenin) signaling." | 7.79 | Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. ( Chan, AT; Freedman, ML; Fuchs, CS; Giovannucci, EL; Hunter, DJ; Imamura, Y; Kraft, P; Kuchiba, A; Morikawa, T; Nan, H; Ogino, S; Suuriniemi, M; Werner, L; Yamauchi, M, 2013) |
| "Aspirin is associated with a reduced risk of developing colorectal cancer." | 7.79 | Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. ( Donnan, PT; McCowan, C; Munro, AJ; Steele, RJ, 2013) |
| "Patients with colorectal cancer with mutated PIK3CA, identified from two large observational cohorts, had increased cancer-specific and overall survival if they used aspirin regularly after diagnosis compared to non-users." | 7.79 | Potential biomarker for aspirin use in colorectal cancer therapy. ( Langley, RE; Rothwell, PM, 2013) |
| "Clinical and cohort studies have shown that low-dose aspirin and calcium are effective low-risk strategies for primary prevention of colorectal cancer (CRC)." | 7.79 | Combination aspirin and/or calcium chemoprevention with colonoscopy in colorectal cancer prevention: cost-effectiveness analyses. ( Belasco, EJ; Lyford, CP; Pence, BC, 2013) |
| "Aspirin reduces the incidence of and mortality from colorectal cancer (CRC) by unknown mechanisms." | 7.78 | Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. ( Alessi, DR; Din, FV; Dunlop, MG; Green, KA; Houde, VP; Sakamoto, K; Valanciute, A; Zibrova, D, 2012) |
| "Aspirin has been widely reported to reduce the incidence of colorectal cancer." | 7.78 | Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. ( Card, TR; Grainge, MJ; Walker, AJ, 2012) |
| "Aspirin is associated with a reduced risk of colorectal cancer (CRC), and it showed inhibited effects on interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway which is thought to play an important role in intestinal inflammation and the tumorigenesis of CRC." | 7.77 | Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. ( Chen, H; Gao, W; Mao, X; Ren, C; Song, T; Tian, Y; Wang, D; Ye, Y, 2011) |
| "To confirm the role of sex-determining region Y-box 7 (Sox7) in aspirin-mediated growth inhibition of COX-independent human colorectal cancer cells." | 7.77 | SOX7 is involved in aspirin-mediated growth inhibition of human colorectal cancer cells. ( Feng, JX; Gao, YY; Huang, BQ; Huang, SY; Lu, J; Zhang, Y; Zhao, L; Zhou, X, 2011) |
| "To investigate the effect of cyclooxygenase-2 (Cox-2) inhibitor aspirin (acetylsalicylic acid, ASA) and proteasome inhibitor bortezomib in the proliferation and apoptosis of colorectal cancer cell lines." | 7.76 | Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. ( Hatzidaki, E; Karagiannaki, A; Papandreou, CN; Patrikidou, A; Stathakis, NE; Tsapakidis, K; Voutsadakis, IA, 2010) |
| "Regular aspirin intake is associated with a reduction in the incidence of colorectal cancer." | 7.76 | Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line. ( Brown, JE; Dibra, HK; Hooley, P; Nicholl, ID, 2010) |
| "High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention." | 7.76 | Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. ( Algra, A; Elwin, CE; Meade, TW; Norrving, B; Rothwell, PM; Warlow, CP; Wilson, M, 2010) |
| "The optimal duration and dose of aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) in the potential prevention of colorectal cancer (CRC) have not been established." | 7.75 | Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. ( Blot, WJ; Friis, S; McLaughlin, JK; Olsen, JH; Overvad, K; Poulsen, AH; Sørensen, HT; Tjønneland, A; Vogel, U, 2009) |
| "To examine the association between aspirin use after colorectal cancer diagnosis on colorectal cancer-specific and overall survival." | 7.75 | Aspirin use and survival after diagnosis of colorectal cancer. ( Chan, AT; Fuchs, CS; Ogino, S, 2009) |
| "The Aspirin/Folate Polyp Prevention Trial found that aspirin, but not folic acid, reduced recurrence of colorectal adenomas." | 7.75 | Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Cushman, M; Ho, GY; McKeown-Eyssen, G; Rohan, TE; Saibil, F; Sandler, RS; Xue, X, 2009) |
| "Blood levels of long-chain n-3 fatty acids were associated with decreased risk of colorectal cancer among men not using aspirin." | 7.74 | Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. ( Campos, H; Hall, MN; Li, H; Ma, J; Sesso, HD; Stampfer, MJ; Willett, WC, 2007) |
| " Preventive Services Task Force (USPSTF) recommendation and supporting scientific evidence on routine use of aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer." | 7.74 | Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. ( , 2007) |
| "Regular use of aspirin appears to reduce the risk of colorectal cancers that overexpress COX-2 but not the risk of colorectal cancers with weak or absent expression of COX-2." | 7.74 | Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. ( Chan, AT; Fuchs, CS; Ogino, S, 2007) |
| "Long-term data on the risk of colorectal cancer according to dose, duration, and consistency of aspirin therapy are limited." | 7.74 | Aspirin dose and duration of use and risk of colorectal cancer in men. ( Chan, AT; Fuchs, CS; Giovannucci, EL; Meyerhardt, JA; Schernhammer, ES; Wu, K, 2008) |
| "We genotyped ODC G316A in 546 individuals in the United Kingdom Colorectal Adenoma Prevention trial of aspirin for CRA recurrence prevention and pooled our findings with data from two other randomized intervention trials." | 7.74 | Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. ( Grainge, MJ; Houlston, RS; Hubner, RA; Liu, JF; Logan, RF; Muir, KR, 2008) |
| "The reduced risk of colorectal cancer associated with cyclooxygenase enzyme inhibitors, such as aspirin and other nonsteroidal anti-inflammatory drugs, strongly suggests that chronic inflammation is a key mediator in the development of colorectal cancer." | 7.73 | The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. ( El-Omar, EM; Hold, GL; Little, J; Macarthur, M; Sharp, L, 2005) |
| "To examine the influence of aspirin and NSAIDs in prevention of colorectal cancer." | 7.73 | Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. ( Chan, AT; Curhan, GC; Fuchs, CS; Giovannucci, EL; Meyerhardt, JA; Schernhammer, ES, 2005) |
| "The purpose of this study was to test the hypothesis that aspirin use is associated with a decreased risk of incident colorectal cancer." | 7.73 | The association between aspirin use and the incidence of colorectal cancer in women. ( Allison, M; Chlebowski, R; Criqui, M; Garland, C; Kuller, L; Langer, R; McTiernan, A; Roy, H; Wu, L, 2006) |
| "We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas." | 7.73 | Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. ( Ahnen, DJ; Baron, JA; Barry, EL; Bhat, S; Burke, CA; Grau, MV; Haile, RW; O'Brien, TG; Sandler, RS, 2006) |
| "2 years of follow-up and 705 incident colorectal cancer cases, long duration of aspirin use (>20 years) was associated with a reduced risk of colorectal cancer (multivariate rate ratio: 0." | 7.73 | Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. ( Giovannucci, E; Larsson, SC; Wolk, A, 2006) |
| "and aims: Aspirin and other non-steroidal anti-inflammatory drugs have been shown to reduce the risk of colorectal cancer (CRC)." | 7.72 | Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. ( Bernheim, J; Buklan, G; Freund, HR; Grankin, M; Klein, E; Neufeld, D; Nissan, A; Shpitz, B, 2003) |
| "Randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk for recurrent colorectal adenoma." | 7.72 | A prospective study of aspirin use and the risk for colorectal adenoma. ( Chan, AT; Colditz, GA; Fuchs, CS; Giovannucci, EL; Hunter, DJ; Schernhammer, ES; Willett, WC, 2004) |
| "Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce risk of colorectal cancer." | 7.72 | Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. ( Hoffman, M; Levin, TR; Ma, KN; Neuhausen, S; Samowitz, W; Slattery, ML, 2004) |
| "Epidemiological, experimental, and clinical observations provide support for a colorectal cancer chemopreventive role for aspirin." | 7.72 | Effects of low dose aspirin (81 mg) on proliferating cell nuclear antigen and Amaranthus caudatus labeling in normal-risk and high-risk human subjects for colorectal cancer. ( Aoki, T; Boland, CR; Brenner, DE; Krishnan, K; Normolle, DP; Ruffin, MT, 2004) |
| "This paper evaluates aspirin in the reduction of colorectal cancer risk against the nine causality criteria suggested by Bradford-Hill in 1965." | 7.72 | Aspirin and colorectal cancer? ( Morgan, G, 2004) |
| "Use of nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with a reduced risk of colorectal cancer, but limited information is available on the effect of individual nonaspirin NSAIDs." | 7.71 | Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. ( García-Rodríguez, LA; Huerta-Alvarez, C, 2001) |
| "Aspirin may decrease colorectal cancer incidence, but its role as an adjunct to or substitute for screening has not been evaluated." | 7.71 | Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. ( Chernew, ME; Chopra, CL; Fendrick, AM; Huang, G; Ladabaum, U; Scheiman, JM, 2001) |
| "The aim of the study is to compare the cost-effectiveness of aspirin and colonoscopy in the prevention of colorectal cancer." | 7.71 | Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. ( Rex, DK; Sonnenberg, A; Suleiman, S, 2002) |
| "Aspirin and nonsteroidal anti-inflammatory drugs have been reported to protect against the development of colorectal cancer." | 7.70 | Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. ( Galanko, JC; Helm, JF; Murray, SC; Sandler, RS; Woosley, JT, 1998) |
| " Epidemiologic and experimental studies suggest that regular use of aspirin may reduce colorectal cancer risk." | 7.70 | Aspirin use and p53 expression in colorectal cancer. ( Asirwatham, JE; Caporaso, NE; Freedman, AN; Marshall, JR; Mettlin, CJ; Michalek, AM; Petrelli, NJ; Weiss, HA; Zhang, ZF, 1998) |
| "The Leisure World Cohort data on aspirin and colorectal cancer was reanalyzed in an attempt to explain why this study is the lone observational study in which aspirin appears not to be protective." | 7.69 | Aspirin and colorectal cancer: the Leisure World cohort revisited. ( Paganini-Hill, A, 1995) |
| "Most data suggest that the regular use of aspirin reduces the risk of colorectal cancer, but some apparently conflicting evidence exists." | 7.69 | Aspirin and the risk of colorectal cancer in women. ( Colditz, GA; Egan, KM; Giovannucci, E; Hunter, DJ; Speizer, FE; Stampfer, MJ; Willett, WC, 1995) |
| "To determine whether regular use of aspirin decreases the risk for colorectal cancer." | 7.69 | Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. ( Ascherio, A; Colditz, GA; Giovannucci, E; Rimm, EB; Stampfer, MJ; Willett, WC, 1994) |
| "Odds of colorectal cancer as a function of aspirin, nonaspirin NSAIDs, and acetaminophen dispensed to the study population in the 4 years prior to incident colorectal cancer diagnosis." | 7.69 | Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. ( Brown, SH; Maibach, HT; Peleg, II; Wilcox, CM, 1994) |
| "Regular aspirin intake may reduce the risk of colorectal cancer by 50%." | 7.69 | Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. ( Elder, DJ; Hague, A; Hicks, DJ; Paraskeva, C, 1996) |
| "The relationship between aspirin use and colorectal cancer risk was examined by a case-control study in Italy." | 7.69 | Aspirin and colorectal cancer. ( Conti, E; Decarli, A; Falcini, A; Franceschi, S; Giacosa, A; La Vecchia, C; Montella, M; Negri, E, 1997) |
| "The incidence and mortality rates of colorectal cancer (CRC) continue to increase worldwide." | 6.94 | The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial. ( Arimoto, J; Ashikari, K; Fuyuki, A; Higurashi, T; Matsuura, T; Misawa, N; Nakajima, A; Ohkubo, H; Takatsu, T; Yoshihara, T, 2020) |
| "However, the prognosis of stage III colorectal cancer is still poor even after curative resection and adjuvant chemotherapy." | 6.90 | Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial). ( Fukuda, H; Hamaguchi, T; Kanemitsu, Y; Katayama, H; Miyamoto, K; Mizusawa, J; Nakamura, K; Sato, Y; Shibata, T; Shida, D; Shimada, Y; Takashima, A, 2019) |
| "Aspirin could reduce the risk of cancer metastasis." | 6.87 | The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. ( Chen, Y; Hu, X; Lv, Y; Lv, Z; Ni, C; Weng, X; Xia, W; Xin, Y; Xu, Q; Yang, L; Yuan, H; Zhang, W, 2018) |
| "Purpose colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide." | 6.82 | Meta-analysis of aspirin-guided therapy of colorectal cancer. ( Kleebusch, L; Mädge, JC; Schlattmann, P; Stallmach, A, 2022) |
| "Cholangiocarcinoma is the second most common primary hepatic cancer, with a rising incidence worldwide." | 6.72 | A potential role for aspirin in the prevention and treatment of cholangiocarcinoma. ( Shen, X, 2021) |
| "Colorectal cancer is one of the commonest malignancies worldwide." | 6.72 | Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review. ( Amare, GG; Belayneh, YM; Meharie, BG, 2021) |
| "Aspirin also plays a role by its anti-inflammatory action and the stimulation of antitumor immunity." | 6.58 | [Aspirin and colorectal cancer]. ( Di Fiore, F; Grancher, A; Michel, P; Sefrioui, D, 2018) |
| "Aspirin has been extensively investigated in the context of the prevention of cardiovascular disease." | 6.52 | Can We Select Patients for Colorectal Cancer Prevention with Aspirin? ( Arber, N; Kraus, S; Sion, D, 2015) |
| " Long-term use of NSAIDs has been associated with lowered risk of colorectal cancer (CRC), but the use is hampered by adverse effects." | 6.50 | Systematic review: interactions between aspirin, and other nonsteroidal anti-inflammatory drugs, and polymorphisms in relation to colorectal cancer. ( Andersen, V; Vogel, U, 2014) |
| "Over 600,000 people worldwide die of colorectal cancer (CRC) annually, highlighting the importance of developing effective prevention strategies." | 6.47 | Aspirin for the prevention of colorectal cancer. ( Chan, AT; Garcia-Albeniz, X, 2011) |
| "Chemoprevention of colorectal cancer involves the long-term use of pharmacologic agents that can prevent neoplasms from developing in the large bowel." | 6.43 | Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer. ( Benamouzig, R; Chaussade, S; Little, J; Uzzan, B, 2005) |
| "Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria." | 6.42 | Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. ( Asano, TK; McLeod, RS, 2004) |
| "Aspirin was introduced into clinical practice more than 100 years ago." | 6.41 | Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer. ( Lawrence, JR; Paterson, JR, 2001) |
| " When used long term, aspirin has significant adverse effects and is poorly tolerated." | 6.40 | Use and safety of aspirin in the chemoprevention of colorectal cancer. ( Singh, AK; Trotman, BW, 1998) |
| "Aspirin is a well-known non-steroid anti-inflammatory drug." | 5.91 | Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner. ( Hu, LP; Huang, S; Huang, WQ; Ji, J; Jiang, SH; Li, DX; Li, J; Sundquist, J; Sundquist, K; Xing, X; Xu, CJ; Yao, LL; Zhang, NQ; Zhang, XL; Zhang, ZG, 2023) |
| "Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent." | 5.91 | In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023) |
| "Aspirin has recently been attracting attention as a cancer preventive drug, and its inhibitory effects on the development of various cancers have been reported in several large prospective studies." | 5.72 | Salicylic acid directly binds to ribosomal protein S3 and suppresses CDK4 expression in colorectal cancer cells. ( Aono, Y; Horinaka, M; Iizumi, Y; Imai, A; Ishikawa, H; Mutoh, M; Nishimoto, E; Ono, H; Sakai, T; Takakura, H; Taniguchi, K; Yasuda, S, 2022) |
| "In laparoscopic surgery for colorectal cancer (CRC) for patients who receive antiplatelet therapy (APT), it remains unclear whether APT should be continued or temporarily withdrawn." | 5.62 | Impact of perioperative aspirin continuation on bleeding complications in laparoscopic colorectal cancer surgery: a propensity score-matched analysis. ( Fujikawa, T; Takahashi, R, 2021) |
| "However, EPA has only modest anti-colorectal cancer (CRC) activity, when used alone." | 5.62 | Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. ( Coletta, PL; Hull, MA; Hutchinson, JM; Ingram, N; Loadman, PM; Marshall, C; Nicolaou, A; Perry, SL; Race, AD; Spencer, J; Volpato, M, 2021) |
| "Aspirin was viewed as a safe and cheap option for cancer prevention." | 5.62 | Clinicians' opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50-70 years: a qualitative study. ( Alphonse, P; Emery, J; Karnchanachari, N; Lau, P; Macrae, F; McIntosh, J; Milton, S; Nguyen, P; Saya, S; Yogaparan, T, 2021) |
| "Chemoprevention against colorectal cancer (CRC) is greatly needed." | 5.62 | Combined Use of Aspirin and Selective Serotonin Reuptake Inhibitors Is Associated With Lower Risk of Colorectal Cancer: A Nested Case-Control Study. ( Ji, J; Sundquist, J; Sundquist, K; Zhang, N; Zhang, ZG, 2021) |
| "Non-aspirin NSAIDs were associated with lower PCCRC risk after a negative baseline colonoscopy." | 5.56 | Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer. ( Chan, EW; Chen, L; Cheung, KS; Leung, WK; Seto, WK; Wong, ICK, 2020) |
| "Distant metastatic colorectal cancer (CRC) is present in approximately 25% of patients at initial diagnosis, and eventually half of CRC patients will develop metastatic disease." | 5.56 | Identification of the Effects of Aspirin and Sulindac Sulfide on the Inhibition of HMGA2-Mediated Oncogenic Capacities in Colorectal Cancer. ( Chang, HY; Chen, HY; Ekanem, TI; Huang, TC; Lee, KH; Lin, YH; Tan, WQ; Tsai, WL, 2020) |
| "Although aspirin has been considered a promising agent for prevention of colorectal cancer, recent data suggest a lack of benefit among older individuals." | 5.51 | Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals. ( Bakshi, A; Buchanan, DD; Cao, Y; Carr, PR; Chan, AT; Gibbs, P; Joshi, AD; Lacaze, P; Macrae, F; Manning, AK; McNeil, JJ; Orchard, SG; Umar, A; Winship, IM; Zalcberg, JR, 2022) |
| "Regular bowel screening and aspirin reduce colorectal cancer among patients with LS but extracolonic cancers are difficult to detect and manage." | 5.51 | Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up. ( Bertario, L; Bishop, DT; Borthwick, GM; Burn, J; Elliott, F; Evans, DG; Gerdes, AM; Ho, JWC; Lindblom, A; Macrae, F; Mathers, JC; McRonald, FE; Mecklin, JP; Morrison, PJ; Möslein, G; Pylvänäinen, K; Ramesar, RS; Rashbass, J; Reed, L; Seppälä, TT; Sheth, HJ; Thomas, HJW, 2022) |
| " The aspirin analogues fumaryldiaspirin (PN517) and the benzoylsalicylates (PN524, PN528 and PN529), were observed to be more toxic against the OC cell lines than aspirin." | 5.51 | The Cytotoxicity and Synergistic Potential of Aspirin and Aspirin Analogues Towards Oesophageal and Colorectal Cancer. ( Bashir, AIJ; Devitt, A; Kilari, RS; Nicholl, ID; Perry, CJ; Safrany, ST, 2019) |
| "Aspirin has been found to inhibit cancer cell viability and promote CRC cell apoptosis." | 5.51 | Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway. ( Du, Y; Duan, X; Li, H; Liu, J; Ma, B; Su, C; Yang, S; Yang, X; Zhang, D; Zhou, Q, 2019) |
| "Aspirin has been associated with reduced incidence and mortality of colorectal and a few other cancers." | 5.48 | Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy. ( Barchielli, A; Manneschi, G; Mantellini, P; Miccinesi, G; Orso, F; Puliti, D; Ventura, L; Zappa, M, 2018) |
| "The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM)." | 5.41 | Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial. ( Angelsen, JH; Bjørnbeth, BA; Fristrup, CW; Grønbech, JE; Hemmingsson, O; Isaksson, B; Juel, IS; Larsen, PN; Lindell, G; Mortensen, FV; Mortensen, KE; Rizell, M; Sandström, P; Sandvik, OM; Sparrelid, E; Taflin, H; Taskén, K; Yaqub, S, 2021) |
| "This paper introduces a recent paper on colorectal cancer prevention studies using aspirin." | 5.41 | [Aspirin for Chemoprevention of Colorectal Adenoma and Cancer]. ( Ishikawa, H, 2021) |
| " We performed a systematic review and network meta-analysis to assess the comparative efficacy and safety of candidate agents (low-dose aspirin [Asp], high-dose Asp, cyclooxygenase-2 inhibitors [coxibs], calcium, vitamin D, folic acid, ursodeoxycholic acid [UDCA], estrogen, and progesterone, alone or in combination) for preventing colorectal adenoma and CRC." | 5.41 | Chemoprevention of colorectal cancer in general population and high-risk population: a systematic review and network meta-analysis. ( Cao, Y; He, X; Li, J; Ma, Y; Wang, J; You, W; Zhang, Y, 2023) |
| " Data from RCTs in which the incidence of colorectal cancer in patients without active colorectal cancer assigned to aspirin versus control were included." | 5.41 | Aspirin chemoprevention in colorectal cancer: network meta-analysis of low, moderate, and high doses. ( Di Re, A; Shah, D; Toh, JWT, 2023) |
| "Although aspirin is recommended for the prevention of colorectal cancer (CRC) among adults aged 50 to 59 years, recent data from a randomized clinical trial suggest a lack of benefit and even possible harm among older adults." | 5.41 | Aspirin Use and Risk of Colorectal Cancer Among Older Adults. ( Cao, Y; Chan, AT; Drew, DA; Giovannucci, EL; Guo, CG; Joshi, AD; Leung, WK; Ma, W; Meyerhardt, JA; Ng, K; Nguyen, LH; Ogino, S; Song, M, 2021) |
| "This trial will test the efficacy of novel methods for implementing national guidelines to support informed decision-making about taking aspirin in 50-70-year-olds to reduce the risk of CRC and other chronic diseases." | 5.41 | An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial. ( Boyd, L; Broun, K; Chondros, P; Emery, J; Fishman, G; Forbes, C; Gutierrez, JM; Jenkins, M; Karnchanachari, N; Macrae, F; Marker, J; McGill, S; McIntosh, J; Milton, S; Novy, K; Saya, S; Shub, M; Taylor, N; Trevena, L; Walter, FM; Whitburn, S, 2021) |
| "Aspirin was added to human colon cancer cells (HT-29 and RKO) or to PBMC incubated separately or jointly." | 5.37 | Inflammation and colorectal cancer: does aspirin affect the interaction between cancer and immune cells? ( Bergman, M; Bessler, H; Djaldetti, M; Salman, H, 2011) |
| "Colorectal cancer is the third most common cancer and is associated with significant morbidity and mortality." | 5.37 | Activity of aspirin analogues and vanillin in a human colorectal cancer cell line. ( Deb, J; Dibra, H; Kankipati, CS; Manneh, J; Nicholl, ID; Perry, CJ; Rajan, S; Shan, S, 2011) |
| "Although substantial evidence supports aspirin's efficacy in colorectal cancer chemoprevention, key molecular mechanisms are uncertain." | 5.34 | Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk. ( Baron, JA; Barry, EL; Fedirko, V; Jones, DP; Liu, K; Ma, C; Mott, LA; Passarelli, MN; Peacock, JL; Uppal, K, 2020) |
| "Aspirin is associated with decreased risk of colorectal cancer (CRC), potentially by modulating the gut microbiome." | 5.34 | Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk. ( Church, TR; Demmer, RT; Knights, D; Meyer, KA; Onyeaghala, GC; Prizment, AE; Sadowsky, MJ; Shaukat, A; Staley, C; Straka, RJ; Thyagarajan, B; Vivek, S, 2020) |
| " Several epidemiological studies have shown that regular use of low dose aspirin is associated with a 20 to 30% reduction in the risk of sporadic colonic adenomas and colorectal cancer regardless of family risk." | 5.34 | Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. ( Ait-Omar, A; Benallaoua, M; Benamouzig, R; Boubaya, M; Deutsch, D; Helfen, S; Levy, V; Mary, F; Soualy, A, 2020) |
| "Preclinical, epidemiological, and randomised data indicate that aspirin might prevent tumour development and metastasis, leading to reduced cancer mortality, particularly for gastro-oesophageal and colorectal cancer." | 5.30 | Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. ( Adams, R; Berkman, L; Bridgewater, J; Cafferty, F; Cameron, D; Crossley, A; Din, F; Falk, S; Gilbert, D; Graham, J; Gupta, K; Henson, V; Hubner, R; Iveson, T; Jankowski, J; Joharatnam-Hogan, N; Khabra, K; Kunene, V; Kynaston, H; Langley, R; Patel, K; Pramesh, CS; Ring, A; Rowley, S; Sothi, S; Swinson, D; Thomas, A; Underwood, T; Warner, N; Wilson, R, 2019) |
| "Among adults aged 40 to 80 years not using aspirin or other antithrombotic medications, administration of a single dose of oral aspirin prior to fecal immunochemical testing, compared with placebo, did not significantly increase test sensitivity for detecting advanced colorectal neoplasms at 2 predefined cutoffs of a quantitative fecal immunochemical test." | 5.30 | Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial. ( Block, T; Böck, W; Brenner, H; Calderazzo, S; Czock, D; Dikopoulos, N; Eisenbach, T; Kopp-Schneider, A; Ludwig, L; Mangold, J; Seufferlein, T; Stolz, T; Tikk, K, 2019) |
| "Aspirin dosing strategies accounting for body weight suggested in previous trials of colorectal cancer may not apply to adenomas." | 5.30 | Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial. ( Ahnen, DJ; Baron, JA; Barry, EL; Mott, LA; Passarelli, MN; Rees, JR, 2019) |
| "BCC incidence was evaluated in a randomized, double-blind, placebo-controlled clinical trial of aspirin (81 mg daily or 325 mg daily for ~3 years) and/or folic acid (1 mg daily for ~6 years) for the prevention of colorectal adenomas among 1121 participants with a previous adenoma." | 5.27 | Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas. ( Baron, JA; Barry, EL; Bresalier, RS; Gangar, P; Karagas, MR; McKeown-Eyssen, G; Passarelli, MN; Rees, JR; Zhang, D, 2018) |
| "The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and aspirin both have proof of concept for colorectal cancer chemoprevention, aligned with an excellent safety profile." | 5.27 | Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. ( Clifford, G; Hepburn, T; Hull, MA; Loadman, PM; Logan, RF; Montgomery, AA; Rees, CJ; Shafayat, A; Sprange, K; Tan, W; Whitham, D; Williams, EA, 2018) |
| "Epidemiological studies and cardiovascular prevention trials have shown that low-dose aspirin can reduce colorectal cancer (CRC) incidence and mortality, including inhibition of distant metastases." | 5.27 | The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. ( Bachleitner-Hofmann, T; Briata, IM; Caviglia, S; Clavarezza, M; DeCensi, A; Gnant, M; Haefeli, WE; Mislej, EM; Oppezzi, M; Paleari, L; Petrera, M; Puntoni, M; Roth, W; Scherer, D; Stabuc, B; Ulrich, CM, 2018) |
| "Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined." | 5.24 | ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. ( Backman, V; Carolan, PJ; Chan, AT; Chin, SM; Chung, DC; Colizzo, FP; Drew, DA; Flagg, M; Freedman, M; Gala, M; Garber, JJ; Gilpin, KK; Huttenhower, C; Kedrin, D; Khalili, H; Kwon, DS; Markowitz, SD; Milne, GL; Nishioka, NS; Parziale, M; Pond, E; Rawlings, CA; Richter, JM; Roy, HK; Schuck, MM; Staller, K; Stewart, K; Wang, M, 2017) |
| " We performed a meta-analysis for the positive predictive value (PPV) of FIT for detecting advanced colorectal neoplasia (ACRN) or colorectal cancer (CRC) according to the administration of antithrombotic agents including aspirin, antiplatelet agents, and oral anticoagulants (OACs)." | 5.22 | Impact of antiplatelet agents and anticoagulants on the performance of fecal immunochemical tests: a systematic review and meta-analysis. ( Im, E; Jung, YS; Park, CH, 2022) |
| "To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the effectiveness of aspirin to reduce the risk of CVD events (myocardial infarction and stroke), cardiovascular mortality, and all-cause mortality in persons without a history of CVD." | 5.22 | Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Chelmow, D; Coker, TR; Davidson, KW; Davis, EM; Donahue, KE; Jaén, CR; Krist, AH; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Ruiz, JM; Stevermer, J; Tseng, CW; Wong, JB, 2022) |
| "Low-dose aspirin was associated with small absolute risk reductions in major cardiovascular disease events and small absolute increases in major bleeding." | 5.22 | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Bean, SI; Evans, CV; Guirguis-Blake, JM; Perdue, LA; Senger, CA, 2022) |
| " Most studies have demonstrated that the NSAID, aspirin, plays a beneficial role in the prevention of CRC and colonic adenomas." | 5.22 | Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies. ( Haydon, A; Orchard, SG; Zalcberg, JR; Zaman, FY, 2022) |
| " There is evidence that patients carrying PIK3CA mutations may benefit from treatment with acetylsalicylic acid, commonly known as aspirin, particularly in the setting of colorectal cancer." | 5.22 | Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited. ( Benndorf, RA; Hall, DCN, 2022) |
| "Aspirin (acetylsalicylic acid, ASA) is inexpensive and is established in preventing cardiovascular disease (CVD) and colorectal adenomas." | 5.22 | Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas. ( Block, RC; Mousa, SA; Wang, IE; Yi, S, 2022) |
| "In a prospective study, the combination of calcitriol, aspirin, and calcium carbonate did not prevent recurrence of colorectal adenomas over a 3-year period." | 5.22 | Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2016) |
| "Aspirin use is an effective strategy for the chemoprevention of colorectal cancer, even at low doses." | 5.22 | Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial. ( Botma, A; Habermann, N; Klika, KD; Lampe, JW; Liesenfeld, DB; Popanda, O; Potter, JD; Toth, R; Ulrich, CM; Weigel, C, 2016) |
| "In a nested case-control study in the Physicians' Health Study, we prospectively investigated the associations of plasma C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor receptor 2 (TNFR-2) with risk of colorectal cancer, and whether aspirin modified these associations among 268 colorectal cancer patients and 446 age- and smoking-matched controls." | 5.22 | Inflammatory biomarkers, aspirin, and risk of colorectal cancer: Findings from the physicians' health study. ( Chan, AT; Kim, C; Ma, J; Rifai, N; Sesso, HD; Stampfer, MJ; Zhang, X, 2016) |
| "Regular aspirin use may decrease cancer risk by reducing chronic inflammation." | 5.20 | Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Chaturvedi, AK; Hildesheim, A; Katki, HA; Kemp, TJ; Lang Kuhs, KA; Loftfield, E; Pinto, LA; Purdue, MP; Safaeian, M; Shiels, MS; Trabert, B; Wentzensen, N, 2015) |
| "Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is abrogated in those taking aspirin." | 5.20 | Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. ( Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, MG; Eccles, D; Evans, DG; Ho, JW; Hodgson, SV; Lindblom, A; Lubinski, J; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Moeslein, G; Morrison, PJ; Movahedi, M; Murday, V; Olschwang, S; Ramesar, RS; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2015) |
| "Aspirin has been shown to protect against colorectal neoplasms; however, the optimal chemopreventive dose and underlying mechanisms are unclear." | 5.20 | Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS). ( Ahnen, DJ; Baron, JA; Barry, EL; Bradshaw, PT; Bresalier, RS; Fedirko, V; Figueiredo, JC; Milne, GL; Sandler, RS, 2015) |
| " The safety profile and potential cardiovascular benefits associated with ω-3 PUFAs make EPA a strong candidate for colorectal cancer (CRC) chemoprevention, alone or in combination with aspirin, which itself has recognized anti-CRC activity." | 5.17 | A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized cont ( Clifford, GM; Hull, MA; Loadman, PM; Logan, RF; Montgomery, AA; Rees, CJ; Sandell, AC; Whitham, D, 2013) |
| "Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer (CRC) and are associated with reduced disease recurrence and improved outcome after primary treatment." | 5.17 | Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. ( Church, DN; Davidson, B; Domingo, E; Johnstone, E; Kerr, DJ; Midgley, R; Ramamoorthy, R; Sieber, O; Tomlinson, IP; Yanagisawa, Y, 2013) |
| "We investigated whether CYP2C9 genotype was associated with risk of colorectal adenoma and/or modified associations with aspirin treatment or cigarette smoking in a cohort of 928 participants in a randomized trial of aspirin chemoprevention." | 5.17 | CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Makar, KW; McKeown-Eyssen, GE; Mott, LA; Poole, EM; Sandler, RS; Ulrich, CM, 2013) |
| "272 patients (naive for chronic aspirin use) with colorectal adenomas were randomly assigned to treatment with lysine acetylsalicylate 160 mg/day (n=73) or 300 mg/day (n=67) or placebo (n=132) for 4 years." | 5.16 | Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2012) |
| "Low-dose aspirin reduces colorectal cancer (CRC) incidence and mortality." | 5.16 | Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis. ( Benamouzig, R; Cooper, GS; Hassan, C; Launois, R; Rex, DK; Zullo, A, 2012) |
| "We recorded grade 3, 4, or 5 ATE events and other data (including age, baseline cardiovascular risk factors, history of ATE, and aspirin use) from 471 patients with metastatic colorectal cancer in the MAX (Mitomycin, Avastin, Xeloda) trial of capecitabine monotherapy versus capecitabine with bevacizumab with or without mitomycin C." | 5.15 | Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. ( Abdi, E; Blum, R; Chantrill, L; Cummins, MM; Goldstein, D; Karapetis, C; Lowenthal, RM; Marx, G; Murphy, F; Nayagam, SS; Price, TJ; Shannon, J; Simes, RJ; Strickland, AH; Tebbutt, NC; Wilson, K; Zannino, D, 2011) |
| "High quality evidence indicates that aspirin is effective in reducing colorectal polyps; and numerous epidemiological studies point towards an ability to prevent colorectal cancer." | 5.15 | The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. ( Ali, R; Chia, WK; Toh, HC, 2011) |
| " The protective effect of 81 mg of aspirin for colorectal adenomas persisted with continued posttreatment NSAID use." | 5.14 | Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Grau, MV; Gui, J; Haile, RW; McKeown-Eyssen, G; Sandler, RS; Summers, RW, 2009) |
| " We studied prostate cancer occurrence in the Aspirin/Folate Polyp Prevention Study, a placebo-controlled randomized trial of aspirin and folic acid supplementation for the chemoprevention of colorectal adenomas conducted between July 6, 1994, and December 31, 2006." | 5.14 | Folic acid and risk of prostate cancer: results from a randomized clinical trial. ( Baron, JA; Bresalier, RS; Burke, CA; Figueiredo, JC; Grau, MV; Haile, RW; McKeown-Eyssen, GE; Sandler, RS; Summers, RW, 2009) |
| "Our data were collected as part of a randomized clinical trial testing the efficacy of aspirin and folic acid for the prevention of colorectal adenomas." | 5.14 | Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. ( Baron, JA; Bresalier, RS; Chen, X; Figueiredo, JC; Grau, MV; Haile, RW; Hamdan, R; Issa, JP; Levine, AJ; McKeown-Eyssen, G; Shen, L; Wallace, K, 2009) |
| " Aspirin inhibits COX-2 activity and lowers the risk for colorectal adenomas and cancer." | 5.14 | Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. ( Ahnen, DJ; Ali, IU; Baron, JA; Barry, EL; Bresalier, RS; Burke, C; Grau, MV; Gui, J; McKeown-Eyssen, GE; Munroe, DJ; Saibil, F; Sandler, RS; Sansbury, LB; Tsang, S, 2009) |
| "Low-dose aspirin reduces the incidence of colorectal cancer and recurrence of adenomas." | 5.14 | Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. ( Benamouzig, R; Chaussade, S; Deyra, J; Girard, B; Little, J; Martin, A; Uzzan, B, 2010) |
| "Study subjects, about half of whom were recruited after fortification of grain products with folic acid in the United States and Canada, consisted of 871 individuals with a recent history of one or more colorectal adenomas who were randomized to receive either a 1 mg/day folic acid supplement or a placebo within one of three randomly assigned aspirin treatment groups (placebo, 81, or 325 mg/day)." | 5.14 | Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation. ( Baron, JA; Grau, MV; Levine, AJ; Mott, LA; Ueland, PM, 2010) |
| "The Aspirin/Folate Polyp Prevention Study is a randomized clinical trial of folic acid supplementation and incidence of new colorectal adenomas in individuals with a history of adenomas (n = 1,084)." | 5.13 | Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation. ( Ahnen, DJ; Ali, I; Baron, JA; Barry, EL; Figueiredo, JC; Grau, MV; Haile, RW; Levine, AJ; Midttun, O; Munroe, D; Sandler, RS; Tsang, S; Ueland, PM, 2008) |
| " We assessed the association between two common MTHFR variants, 677C>T and 1298A>C, and adenoma recurrence in the context of a randomized double- blind clinical trial of aspirin use and folate supplementation." | 5.13 | MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial. ( Ahnen, D; Ali, IU; Baron, JA; Barry, EL; Cole, BF; Haile, RW; Levine, AJ; Munroe, DJ; Saibil, F; Tsang, S; Ueland, P; Wallace, K, 2008) |
| "The Aspirin/Folate Polyp Prevention Study is a randomized, placebo-controlled trial of aspirin use and folic acid supplementation and incidence of colorectal adenomas in individuals with a history of these lesions." | 5.13 | Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels. ( Ahnen, DJ; Baron, JA; Barry, EL; Bond, J; Bresalier, RS; Byers, T; Figueiredo, JC; Grau, MV; Haile, RW; Levine, AJ; McKeown-Eyssen, GE; Sandler, RS; Summers, RW; Ueland, PM, 2008) |
| "In a randomized, placebo-controlled trial, we used a two-by-two design to investigate the effects of aspirin, at a dose of 600 mg per day, and resistant starch (Novelose), at a dose of 30 g per day, in reducing the risk of adenoma and carcinoma among persons with the Lynch syndrome." | 5.13 | Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. ( Barker, G; Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, M; Eccles, D; Elliott, F; Evans, DG; Fodde, R; Ho, JW; Jarvinen, HJ; Jass, JR; Lindblom, A; Lubinski, J; Lynch, HT; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Morrison, PJ; Möslein, G; Olschwang, S; Ramesar, R; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2008) |
| "8%) of 434 patients receiving aspirin had a recurrent adenoma compared with 121 (28." | 5.13 | Aspirin and folic acid for the prevention of recurrent colorectal adenomas. ( Armitage, NC; Grainge, MJ; Logan, RF; Muir, KR; Shepherd, VC, 2008) |
| "Exposure of aspirin has been associated with reduced risk of colorectal cancer (CRC) incidence, but aspirin use in relation to CRC patients' mortality remains undetermined." | 5.12 | Timing of Aspirin Use Among Patients With Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis. ( Fan, Y; Xiao, S; Xie, W; Zhou, L, 2021) |
| "High-quality evidence indicates that regular use of aspirin is effective in reducing the risk for precancerous colorectal neoplasia and colorectal cancer (CRC)." | 5.12 | Aspirin in the Prevention of Colorectal Neoplasia. ( Chan, AT; Drew, DA, 2021) |
| " The pooled relative risk (RR) with 95% confidence interval (CI) was used to estimate the effect of aspirin on colorectal cancer and/or colorectal adenomas." | 5.12 | Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials. ( Bhan, C; Cao, C; Cheng, C; Guo, Z; Han, T; Ji, Z; Ma, S; Qu, G; Sun, C; Yan, Y; Yang, H; Zhang, H; Zhou, Q, 2021) |
| " Overall, the results indicated that aspirin significantly reduced the risk of developing colorectal adenomas but not advanced lesions at 3 years (risk ratio (RR) = 0." | 5.12 | Influence of aspirin on prevention of colorectal cancer: an updated systematic review and meta-analysis of randomized controlled trials. ( Abdulhamid, AS; Alharbi, FA; Alomari, MS; Aziz, M; Ghaddaf, AA; Mullah, AN; Zaidi, SF, 2021) |
| "Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, have been consistently shown to reduce the risk of colorectal cancer (CRC) in non-experimental studies, but little is known of the factors associated with starting and continuing regular NSAID use and their effect on the NSAID and CRC association." | 5.12 | Colorectal cancer after start of nonsteroidal anti-inflammatory drug use. ( Buring, JE; Gaziano, JM; Glynn, RJ; Kurth, T; Lee, IM; Stürmer, T, 2006) |
| "We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily." | 5.12 | Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006) |
| "The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose." | 5.12 | Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006) |
| " Functional polymorphisms of UGT1A6 (T181A and R184S) and CYP2C9 (R144C and I359L) have been reported to modify the protective effect of aspirin on colorectal adenoma risk." | 5.12 | Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence. ( Armitage, N; Grainge, M; Houlston, RS; Hubner, RA; Liu, JF; Logan, RF; Muir, KR; Popat, S; Shepherd, V, 2006) |
| "To assess the safety and efficacy of folic acid supplementation for preventing colorectal adenomas." | 5.12 | Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. ( Ahnen, DJ; Allen, JI; Baron, JA; Barry, EL; Beck, GJ; Bond, JH; Bresalier, RS; Burke, CA; Byers, T; Church, TR; Cole, BF; Greenberg, ER; Haile, RW; Mandel, JS; Marcon, N; McKeown-Eyssen, G; Mott, LA; Pearson, LH; Rees, JR; Robertson, DJ; Rothstein, RI; Saibil, F; Sandler, RS; Snover, DC; Summers, RW; Ueland, PM, 2007) |
| "Regular use of aspirin and other nonsteroidal antiinflammatory drugs reduces both the development of colorectal neoplasia and recurrence of colorectal adenoma (CRA)." | 5.12 | Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial. ( Grainge, MJ; Houlston, RS; Hubner, RA; Liu, JF; Logan, RFA; Muir, KR, 2007) |
| "Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers." | 5.10 | A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. ( Baron, JA; Budinger, S; Halabi, S; Karp, DD; Keresztes, R; Loprinzi, CL; Paskett, E; Petrelli, N; Pipas, JM; Sandler, RS; Schilsky, R; Steinbach, G, 2003) |
| "We performed a randomized, double-blind trial of aspirin as a chemopreventive agent against colorectal adenomas." | 5.10 | A randomized trial of aspirin to prevent colorectal adenomas. ( Ahnen, D; Allen, JI; Baron, JA; Beach, M; Beck, GJ; Bond, JH; Bresalier, R; Burke, CA; Byers, T; Church, TR; Cole, BF; Greenberg, ER; Haile, RW; Mandel, JS; Marcon, N; McKeown-Eyssen, G; Mott, LA; Pearson, L; Rothstein, R; Saibil, F; Sandler, RS; Snover, DC; Summers, RW; van Stolk, RU, 2003) |
| "Among the 238 patients who completed the year 1 colonoscopy, at least one adenoma was observed in 38 patients of the 126 (30%) in the aspirin group and in 46 of the 112 (41%) in the placebo group; relative risk was 0." | 5.10 | Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Girard, B; Jullian, E; Little, J; Martin, A; Piednoir, B, 2003) |
| "Epidemiological and experimental evidence indicates that aspirin can protect against colorectal cancer." | 5.10 | A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. ( Do, KA; Fischer, SM; Inamdar, N; Sample, D; Schwartz, P; Sinicrope, FA; Wang, X; Wargovich, M, 2002) |
| "We tested the hypothesis that aspirin, at a single, once-daily 81-mg dose, will reduce colonic mucosal concentration of prostaglandin estradiol (E2) in individuals at high risk for colorectal cancer development similar to our prior observations in a young normal-risk population." | 5.09 | Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. ( Bailey, J; Boland, CR; Brenner, DE; Burney, K; Krishnan, K; Normolle, D; Peters-Golden, M; Rock, CL; Ruffin, MT; Shureiqi, I, 2001) |
| " A multicentre, double-blind, randomized, controlled trial is underway to determine the efficacy of regular aspirin intake (160 or 300 mg/day) in reducing colorectal adenoma recurrence." | 5.09 | APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. ( Benamouzig, R; Chaussade, S; Coste, T; Couturier, D; Deyra, J; Little, J; Martin, A; Yoon, H, 2001) |
| "A variety of studies have supported the finding that regular intake of aspirin (acetylsalicylic acid) or nonsteroidal anti-inflammatory agents can affect colorectal cancer carcinogenesis." | 5.08 | Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. ( Boland, CR; Brenner, DE; Crowell, J; Kelloff, G; Krishnan, K; Normolle, D; Peters-Golden, M; Rock, CL; Ruffin, MT; Vaerten, MA, 1997) |
| "In contrast to most observational studies, the randomized Physicians' Health Study found no association between aspirin use and colorectal cancer after 5 years." | 5.08 | Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. ( Buring, JE; Glynn, RJ; Hennekens, CH; Lee, IM; Manson, JE; Stürmer, T, 1998) |
| "Laboratory, clinical, and epidemiologic studies have recently suggested that regular use of aspirin can reduce colorectal cancer incidence or mortality." | 5.07 | Low-dose aspirin and incidence of colorectal tumors in a randomized trial. ( Buring, JE; Gann, PH; Glynn, RJ; Hennekens, CH; Manson, JE, 1993) |
| "Aspirin has been associated with a reduced risk of colorectal cancer, and possibly of a few other digestive tract cancers." | 5.05 | Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. ( Bosetti, C; Gallus, S; La Vecchia, C; Martinetti, M; Santucci, C, 2020) |
| " Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users." | 5.05 | Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis. ( Cao, LL; Chen, QY; Huang, CM; Li, P; Lin, JL; Lin, JX; Lin, M; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2020) |
| "We aimed to evaluate the association between selective COX-2 inhibitors (coxibs) and the risk of colorectal neoplasms and vascular events with and without low-dose aspirin." | 5.01 | Risks of colorectal neoplasms and cardiovascular thromboembolic events after the combined use of selective COX-2 inhibitors and aspirin with 5-year follow-up: a meta-analysis. ( He, P; Xie, H; Yang, C; Ye, G; Zhong, W, 2019) |
| "Regular aspirin use is associated with reduced risk of colorectal cancer (CRC)." | 4.98 | Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations. ( Barrett, JH; Bishop, DT; Burn, J; Casey, G; Elliott, F; Forman, D; Haile, R; Hopper, JL; Jackson, MS; Jenkins, M; Lindor, NM; Marchand, LL; Northwood, E; Potter, JD; Santibanez-Koref, M; Scherer, D; Sheth, H; Smith, G; Thibodeau, SN; Ulrich, CM; Win, AK; Wolf, CR, 2018) |
| "Aspirin reduces the risk of nonfatal myocardial infarction and stroke, and the risk of colorectal cancer." | 4.95 | Aspirin for Primary Prevention. ( Owens, DK; Richman, IB, 2017) |
| "In patients with a previous history of colorectal cancer or adenomas, low-dose aspirin (80-160 mg/day) compared to placebo taken for 2 to 4 years reduces the risk of recurrent colorectal adenomas (relative risk (RR), 0." | 4.95 | Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. ( Chaiyakunapruk, N; Ching, SM; Lim, KG; Phisalprapa, P; Saokaew, S; Veettil, SK, 2017) |
| "The strongest evidence is for non-steroidal anti-inflammatory drugs slowing polyp progression, notably Sulindac and aspirin in patients with familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer, respectively." | 4.95 | Chemoprevention of colorectal neoplasia. ( Eglinton, T; Eteuati, J; Frizelle, F; Hollington, P; Keenan, J; Wakeman, C, 2017) |
| "Both aspirin use and screening with flexible sigmoidoscopy or guaiac faecal occult blood testing (FOBT) may reduce mortality from colorectal cancer, but comparative effectiveness of these interventions is unknown." | 4.95 | Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. ( Adami, HO; Bretthauer, M; Buring, JE; Cook, NR; Emilsson, L; Gaziano, MJ; Holme, Ø; Kalager, M; Løberg, M; Sesso, HD, 2017) |
| "Regular aspirin use has been associated with inhibition of the whole spectrum of colorectal carcinogenesis, including prevention of metastases and reduced total mortality in colorectal cancer." | 4.93 | PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies. ( Clavarezza, M; Cuzick, J; DeCensi, A; DeCensi, M; Paleari, L; Puntoni, M, 2016) |
| "The US Preventive Services Task Force recently recommended the use of aspirin to prevent colorectal cancer and cardiovascular disease among many US adults." | 4.93 | Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. ( Cao, Y; Chan, AT; Fuchs, CS; Giovannucci, EL; Nishihara, R; Ogino, S; Spiegelman, D; Wang, M; Willett, WC; Wu, K, 2016) |
| "To determine whether aspirin or non-aspirin non-steroidal anti-inflammatory drugs (NA-NSAIDs) prevent colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD)." | 4.93 | Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease? ( Burr, NE; Hull, MA; Subramanian, V, 2016) |
| "To conduct systematic reviews of aspirin and 1) total cancer mortality and incidence in persons eligible for primary prevention of cardiovascular disease (CVD) and 2) colorectal cancer (CRC) mortality and incidence in persons at average CRC risk." | 4.93 | Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force. ( Anderson, ML; Buist, DS; Burda, BU; Chubak, J; Kamineni, A; Whitlock, EP; Williams, SB, 2016) |
| "Through search the possible randomized control trials, we make a renewed meta-analysis in order to assess the impact of aspirin in preventing the recurrence of colorectal adenoma." | 4.93 | The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a Renewed Meta-Analysis of Randomized Trials. ( Cheng, DW; Gao, XK; Lu, XJ; Luo, H; Tu, J; Wang, Y; Wang, YJ; Xu, XL; Yan, BC; Zhang, HL; Zhao, TY, 2016) |
| "Considerable interest has emerged over the last decade regarding the role of aspirin in prevention of colorectal cancer." | 4.93 | The role of aspirin in colorectal cancer chemoprevention. ( Singh Ranger, G, 2016) |
| "To review advances in the individualized assessment for ASCVD and bleeding risk, and to provide an update of the randomized clinical trial evidence that examined the use of aspirin for primary prevention (primarily for ASCVD, and secondarily for colorectal cancer)." | 4.93 | Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. ( Manson, JE; Mora, S, 2016) |
| "The objective of this meta-analysis was to systematically assess the survival benefit of aspirin use before or after diagnosis for patients with colorectal cancer (CRC)." | 4.91 | Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. ( Cai, J; Li, P; Shi, Y; Wu, H; Wu, Y; Xia, D; Xu, J; Yang, J; Ye, Y; Zhang, H, 2015) |
| "To examine the association between long-term oral low-dose aspirin and overall survival in colorectal cancer patients after diagnosis." | 4.91 | [Association of long-term oral low-dose aspirin and survival in colorectal cancer: a meta-analysis]. ( Chen, P; Dai, W; Wu, F; Ye, H; Zheng, Q, 2015) |
| "The results of clinical studies have shown that the chronic administration of aspirin, even at the lowdoses (75-100 mg daily) recommended for the prevention of cardiovascular disease, is associated with a reduction of cancer incidence and mortality, in particular colorectal cancer (CRC)." | 4.91 | New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia. ( Di Francesco, L; López Contreras, LA; Patrignani, P; Sacco, A, 2015) |
| "Regular use of aspirin reduces incidence and mortality of various cancers, including colorectal cancer." | 4.90 | Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. ( Chan, AT; Fuchs, CS; Giovannucci, E; Lochhead, P; Meyerhardt, JA; Ogino, S, 2014) |
| " Moreover, the results of clinical studies have shown that the antiplatelet drug aspirin reduces the incidence of vascular events and colorectal cancer." | 4.90 | Role of platelets in inflammation and cancer: novel therapeutic strategies. ( Alberti, S; Dovizio, M; Guillem-Llobat, P; Patrignani, P, 2014) |
| "Abundant epidemiologic evidence indicates that regular and long-term use of aspirin is associated with a significant reduction in the incidence of colorectal cancer." | 4.90 | Aspirin and colorectal cancer: back to the future. ( Manthravadi, S; Sha, D; Sinicrope, FA; Tougeron, D, 2014) |
| "Epidemiological evidence suggests that use of aspirin after the diagnosis of colorectal cancer can lengthen survival." | 4.90 | Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. ( He, J; Shi, WT; Wang, J; Ye, XF, 2014) |
| "In previous meta-analyses, aspirin use has been associated with reduced risk of colorectal cancer." | 4.89 | Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. ( Chen, S; Fu, J; Yang, Y; Ye, X, 2013) |
| "Aspirin taken for several years at doses of at least 75 mg daily reduced long-term incidence and mortality due to colorectal cancer." | 4.89 | Mode of action of aspirin as a chemopreventive agent. ( Bruno, A; Dovizio, M; Patrignani, P; Tacconelli, S, 2013) |
| "In addition to longstanding evidence from observational studies, evidence from randomised trials of the effectiveness of aspirin for chemoprevention of colorectal cancer has increased substantially in recent years." | 4.89 | Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits. ( Rothwell, PM, 2013) |
| "Considerable evidence supports the effectiveness of aspirin for chemoprevention of colorectal cancer (CRC) in addition to its well-established benefits in the prevention of vascular disease." | 4.88 | Aspirin in the chemoprevention of colorectal neoplasia: an overview. ( Arber, N; Baron, JA; Burn, J; Chan, AT; Chia, WK; Elwood, P; Hull, MA; Logan, RF; Rothwell, PM; Schrör, K, 2012) |
| "There is evidence that aspirin is effective for the chemoprevention of colorectal cancer." | 4.88 | Non-aspirin non-steroidal anti-inflammatory drugs for the primary chemoprevention of non-gastrointestinal cancer: summary of evidence. ( Galvao, TF; Lopes, LC; Pereira, MG; Silva, MT; Zimmerman, IR, 2012) |
| "A high-quality body of evidence supports the use of aspirin in reducing sporadic and hereditary adenomatous polyps, and numerous observational studies point to a reduction in colorectal cancer (CRC) risk." | 4.88 | Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. ( Ali, R; Chia, WK; Toh, HC, 2012) |
| "Previous studies have shown that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) lower colorectal cancer (CRC) risk." | 4.86 | Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. ( Barnetson, RA; Campbell, H; Cetnarskyj, R; Din, FV; Dunlop, MG; Farrington, SM; Porteous, ME; Stark, L; Tenesa, A; Theodoratou, E, 2010) |
| "This meta-analysis suggests that aspirin prevents recurrent colorectal adenomas among patients with a history of colorectal adenomas." | 4.85 | The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. ( Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A, 2009) |
| "We combined data from all randomized double-blind placebo-controlled trials that evaluated aspirin for the prevention of colorectal adenomas." | 4.85 | Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. ( Baron, JA; Benamouzig, R; Chaussade, S; Cole, BF; Grainge, MJ; Halabi, S; Logan, RF; Sandler, RS, 2009) |
| "Evidence clearly shows a chemopreventive effect for aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer and probably other cancer types; however, data on the risk-benefit profile for cancer prevention are insufficient and no definitive recommendations can be made." | 4.85 | Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. ( Baron, JA; Brown, PH; Burn, J; Cuzick, J; Greenwald, P; Jankowski, J; La Vecchia, C; Meyskens, F; Otto, F; Senn, HJ; Thun, M, 2009) |
| "Aspirin is the best chemoprevention agent for colorectal cancer risk reduction despite the fact that the evidence for a decrease in mortality is weak." | 4.84 | Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. ( Hunt, R; Jankowski, J, 2008) |
| "Aspirin for prevention of colorectal cancer is controversial." | 4.84 | The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. ( Barrowman, N; Code, C; Dubé, C; Lewin, G; Moher, D; Rostom, A; Sampson, M; Tsertsvadze, A, 2007) |
| "Randomised trials have shown that aspirin reduces the short-term risk of recurrent colorectal adenomas in patients with a history of adenomas or cancer, but large trials have shown no effect in primary prevention of colorectal cancer during 10 years' follow-up." | 4.84 | Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. ( Flossmann, E; Rothwell, PM, 2007) |
| "To evaluate the cost-effectiveness of aspirin chemoprevention alone and in combination with colonoscopy surveillance in patients with prior adenoma resection." | 4.84 | Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysis. ( Arguedas, MR; DuPont, AW; Wilcox, CM, 2007) |
| "Observational studies have consistently shown that aspirin and non-steroidal anti-inflammatory drug (NSAID) use is associated with a close to 50% reduced risk of colorectal cancer." | 4.82 | Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. ( García Rodríguez, LA; González-Pérez, A; López-Ridaura, R, 2003) |
| "There is combined evidence from three randomized trials that aspirin significantly reduced the recurrence of sporadic adenomatous polyps." | 4.82 | Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. ( Asano, TK; McLeod, RS, 2004) |
| "Prolonged use of aspirin and/or non-steroidal anti-inflammatory drugs induces a partial regression of either sporadic adenomas or adenomas in adenomatous polyposis coli (APC), but also their emergence and colonic cancer development in sporadic adenomas." | 4.82 | [Cyclooxygenase 2 inhibitors and adenomatous polyposis coli]. ( Florent, C; Meary, N, 2004) |
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| "Observational studies have found a decreased rate of colorectal cancer in people who regularly took aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs)." | 4.81 | Celecoxib as adjunctive therapy for treatment of colorectal cancer. ( North, GL, 2001) |
| "Epidemiologic studies indicate strongly that aspirin use reduces the risk of colorectal cancer and adenoma by approximately 40 to 50%." | 4.80 | The prevention of colorectal cancer by aspirin use. ( Giovannucci, E, 1999) |
| "Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced risk of colorectal cancer." | 4.80 | Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer. ( Patrignani, P, 2000) |
| "Only case-control studies and most of the prospective cohort studies showed a reduction of colorectal cancer incidence in regular aspirin users." | 4.80 | [Aspirin against cancer]. ( de Gramont, A; Mabro, M, 2000) |
| "There is increasing evidence to suggest that aspirin and other non-steroidal anti-inflammatory drugs reduce the risk of colorectal cancer." | 4.80 | Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins. ( Arber, N; Strul, H, 2000) |
| "Aspirin and other NSAIDs are showing promise in the chemoprevention of colorectal cancer." | 4.80 | Non-steroidal anti-inflammatory drugs and chemoprevention of cancer. ( Morgan, G; Vainio, H, 2000) |
| "There is substantial experimental, clinical and epidemiological evidence that regular use of non-steroid anti-inflammatory drugs (NSAIDs), particularly aspirin, is associated with a reduced risk of colorectal cancer." | 4.79 | Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence. ( Forman, D; Weiss, HA, 1996) |
| "In rodents, nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin inhibit chemically induced adenomas and early carcinomas of the colon." | 4.79 | Aspirin and gastrointestinal cancer. ( Thun, MJ, 1997) |
| "Results from previous studies indicate that use of aspirin may improve colorectal cancer (CRC) survival." | 4.31 | Low-dose aspirin use and colorectal cancer survival in 32,195 patients-A national cohort study. ( Ekström Smedby, K; Glimelius, B; Martling, A; Matthiessen, P; Nordenvall, C; Shahrivar, M; Syk, I; Weibull, CE, 2023) |
| " Outcomes included 6 clinical quality measures of being up to date for colorectal cancer screening, cervical cancer screening, tobacco screening and cessation counseling, BMI screening and follow-up, depression screening and follow-up, and aspirin use for ischemic vascular disease." | 4.31 | The First Year of the COVID-19 Pandemic: Changes in Preventive Services in Community Health Centers. ( Bandi, P; Han, X; Jemal, A; Makaroff, LA; Minihan, AK; Star, J, 2023) |
| "The possible protective effect of aspirin on risk of colorectal cancer (CRC) is still highly debated." | 4.31 | Association between use of low-dose aspirin and detection of colorectal polyps and cancer in a screening setting. ( Botteri, E; Hoff, G; Holme, Ø; Nafisi, S; Randel, KR; Schult, AL; Støer, NC; Veierød, MB, 2023) |
| "Growing evidence suggests quercetin and aspirin may have anticancer properties, notably in the case of colorectal cancer." | 4.31 | Exploring the potential of quercetin/aspirin-loaded chitosan nanoparticles coated with Eudragit L100 in the treatment of induced-colorectal cancer in rats. ( Abdelgawad, MA; Ahmed, YM; Ali, HM; Alsaidan, OA; El-Say, KM; Elkomy, MH; Elmowafy, M; Gomaa, HAM; Hendawy, OM; Shalaby, K, 2023) |
| "We describe our experience running the investigator-initiated phase III randomized, fully accrued, Aspirin for Dukes C and high-risk Dukes B Colorectal cancer trial (ASCOLT, ClinicalTrials." | 4.31 | Operational Challenges of an Asia-Pacific Academic Oncology Clinical Trial. ( Ali, R; Chia, JWK; Day, D; Foo, EMJ; Segelov, E; Simes, J; Toh, HC, 2023) |
| "Aspirin and its active metabolite salicylate have emerged as promising agents for the chemoprevention of colorectal cancer (CRC)." | 4.31 | Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis. ( Hermeking, H; Huang, Z; Liu, C; Rokavec, M, 2023) |
| " Therefore, we investigated the risk of discontinuing aspirin concerning thrombotic complications in laparoscopic colorectal cancer surgery." | 4.12 | Impact of aspirin discontinuation on thrombotic complications in laparoscopic colorectal cancer surgery. ( Dono, K; Hamabe, A; Harino, T; Noura, S; Ogino, T; Suzuki, Y; Takeyama, H; Tanida, T; Tomita, N, 2022) |
| "Aspirin intake has been shown to lead to significant protection against colorectal cancer, for example with an up to twofold reduction in colorectal adenoma incidence rates at higher doses." | 4.12 | Aspirin's effect on kinetic parameters of cells contributes to its role in reducing incidence of advanced colorectal adenomas, shown by a multiscale computational study. ( Boland, CR; Goel, A; Komarova, NL; Wang, Y; Wodarz, D, 2022) |
| "The US Preventive Services Task Force (USPSTF) is updating its 2016 recommendation on the use of aspirin for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC)." | 4.12 | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. ( Dehmer, SP; Evans, CV; Guirguis-Blake, JM; Maciosek, MV; O'Keefe, LR; Perdue, LA, 2022) |
| "Low-dose aspirin and clopidogrel have demonstrated potential chemoprevention for colorectal cancer (CRC)." | 4.12 | Anticoagulant drugs with or without proton pump inhibitor and colorectal cancer risk: a population-based, case-control study. ( Chen, CW; Chen, HM; Ho, PH; Hsiao, HC; Kuo, CJ; Lim, SN; Lin, WR; Yeh, CT, 2022) |
| " procera dried latex extract prepared in methanol (MeDL) against inflammation and oxidative stress in experimental model of colorectal carcinoma (CRC)." | 4.12 | Anti-inflammatory and antioxidant effect of methanol extract of latex of Calotropis procera in rat model of colorectal cancer. ( Das, P; Kumar, VL; Verma, S, 2022) |
| "Aspirin inhibited carcinogenesis of intestinal mucosal cells in the ulcerative colitis model by inhibiting the interleukin-6/ Janus kinase/signal transducer and activator of transcription 3 signaling pathway and promoted apoptosis, thereby suppressing proliferation." | 4.12 | Aspirin Inhibits Carcinogenesis of Intestinal Mucosal Cells in UC Mice Through Inhibiting IL-6/JAK/STAT3 Signaling Pathway and Modulating Apoptosis and Proliferation. ( Chen, Y; Diao, T; Li, D; Shang, G; Shi, L; Sun, L; Yin, X, 2022) |
| "Further data from the Aspirin in Reducing Events in the Elderly (ASPREE) trial heightens the concern regarding aspirin use for colorectal cancer prevention in elderly subjects." | 4.12 | Aspirin for Colorectal Cancer Prevention: Age Matters. ( Shureiqi, I, 2022) |
| "Aspirin has been shown to prevent the onset of colorectal adenoma and cancer." | 4.12 | Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by Blood Biochemistry and Nutritional Intake. ( Goto, C; Ishikawa, H; Itoh, Y; Matsuda, T; Mutoh, M; Otani, T; Sano, Y; Suzuki, S; Takeuchi, Y; Yoshida, N, 2022) |
| "To evaluate how prediagnosis obesity and postdiagnosis aspirin use may be associated with overall survival in patients with late-stage colorectal cancer." | 4.12 | Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. ( Advani, SM; Chang, S; Chavez, JC; Dasari, A; Davis, JS; Fogelman, D; Henderson, H; Johnson, B; Kee, B; Kok, M; Kopetz, S; Lee, HY; Maru, D; Menter, DG; Meric-Bernstam, F; Morris, V; Overman, MJ; Parseghian, C; Raghav, KP; San Miguel, Y; Shaw, KR; Shen, JP; Shureiqi, I; Vilar, E; Wolff, RA, 2022) |
| "Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk." | 4.02 | Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study. ( Albanes, D; Alwers, E; Amitay, E; Baron, JA; Bermejo, JL; Berndt, SI; Bishop, DT; Brenner, H; Buchanan, DD; Butterworth, A; Campbell, PT; Casey, G; Castellví-Bel, S; Chan, AT; Chang-Claude, J; Drew, DA; Figueiredo, JC; Gallinger, S; Giles, GG; Gruber, SB; Gsur, A; Gunter, MJ; Hampel, H; Harrison, TA; Hoffmeister, M; Hopper, JL; Keku, TO; Kim, HR; Kweon, SS; Li, CI; Li, L; Lin, Y; Lindblom, A; Lindor, NM; Marchand, LL; Moreno, V; Newcomb, PA; Nounu, A; Peters, U; Pharoah, PDP; Platz, EA; Relton, CL; Rennert, G; Richmond, RC; Sakoda, LC; Schafmayer, C; Scherer, D; Schoen, RE; Slattery, ML; Stadler, ZK; Stewart, ID; Surendran, P; Ulrich, CM; van Dujinhoven, FJB; Van Guelpen, B; Vodicka, P; Vodickova, L; Wareham, NJ; Weinstein, SJ; White, E; Williams, AC; Wolk, A; Woods, MO; Wu, AH; Zheng, W, 2021) |
| "Evidence for aspirin's chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood." | 4.02 | A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. ( Albanes, D; Baron, JA; Bermejo, JL; Berndt, SI; Bishop, DT; Brenner, H; Buchanan, DD; Campbell, PT; Casey, G; Castellví-Bel, S; Chan, AT; Chang-Claude, J; Drew, DA; Figueiredo, JC; Gallinger, S; Giles, GG; Greenhough, A; Gruber, SB; Gsur, A; Gunter, MJ; Hampel, H; Harrison, TA; Heesom, KJ; Hoffmeister, M; Hopper, JL; Keku, TO; Kim, HR; Kweon, SS; Le Marchand, L; Li, CI; Li, L; Lin, Y; Lindblom, A; Lindor, NM; Moreno, V; Newcomb, PA; Nounu, A; Peters, U; Pharoah, PDP; Platz, EA; Relton, CL; Rennert, G; Richmond, RC; Sakoda, LC; Schafmayer, C; Scherer, D; Schoen, RE; Slattery, ML; Stadler, ZK; Ulrich, CM; van Duijnhoven, FJB; Van Guelpen, B; Vodicka, P; Vodickova, L; Weinstein, SJ; White, E; Williams, AC; Wolk, A; Woods, MO; Wu, AH; Zheng, J; Zheng, W, 2021) |
| " Case presentation A 66-year-old Japanese male patient received regorafenib for metastatic colorectal carcinoma and apixaban for deep vein thrombosis." | 4.02 | Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report. ( Matoba, S; Ookura, T; Shoji, K; Yanishi, K; Zen, K, 2021) |
| "Aspirin use reduces colorectal cancer (CRC) incidence, but there is limited evidence regarding associations of aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) with CRC-specific survival." | 4.02 | Associations of Aspirin and Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs With Colorectal Cancer Mortality After Diagnosis. ( Campbell, PT; Cance, WG; Figueiredo, JC; Guinter, MA; Jacobs, EJ; Newton, CC, 2021) |
| "Prior epidemiological and intervention studies have not been able to separate independent effects of dose, timing, and duration of aspirin use in colorectal cancer (CRC) chemoprevention." | 4.02 | Timing of Aspirin Use in Colorectal Cancer Chemoprevention: A Prospective Cohort Study. ( Chan, AT; Giovannucci, EL; Meyerhardt, JA; Zhang, Y, 2021) |
| "Aspirin reduces the incidence of conventional adenomas driven by APC mutation and thus colorectal cancer." | 4.02 | Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia. ( Bond, CE; Fennell, LJ; Kane, AM; Leggett, BA; Liu, C; McKeone, DM; Pollock, PM; Whitehall, VLJ; Young, G, 2021) |
| "Aspirin is a chemopreventive agent for colorectal adenoma and cancer (CRC) that, like many drugs inclusive of chemotherapeutics, has been investigated for its effects on bacterial growth and virulence gene expression." | 4.02 | Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum. ( Brennan, CA; Chan, AT; Drew, DA; Gallini Comeau, CA; Garrett, WS; Glickman, JN; Nakatsu, G; Schoen, RE, 2021) |
| "Patients taking low-dose aspirin to prevent cardiovascular disease (CVD) may also benefit from a reduced risk of colorectal cancer (CRC)." | 4.02 | Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis. ( De Caterina, R; Krucien, N; Marsh, K; Seo, J; Soriano Gabarró, M; Tervonen, T; Vora, P; Wissinger, U, 2021) |
| "Genotype-guided aspirin use for colorectal cancer chemoprevention may offer a cost-effective approach for the future management of average-risk individuals." | 4.02 | Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention? ( Au, TH; Biltaji, E; Brixner, DI; Li, CI; Ose, J; Rivers, Z; Stenehjem, DD; Ulrich, CM; Walker, B, 2021) |
| "With 13 years of follow-up, the authors prospectively evaluated the association between aspirin and ibuprofen use and incident distal adenoma (1221 cases), recurrent adenoma (862 cases), and incident colorectal cancer (CRC; 2826 cases) among men and women in the population-based Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial." | 4.02 | Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial. ( Barry, KH; Berndt, SI; Chudy-Onwugaje, K; Huang, WY; Johnson, CC; Katki, HA; Purdue, MP; Su, LJ; Wang, L, 2021) |
| "Several epidemiological and cohort studies suggest that regular low-dose aspirin use independently reduces the long-term incidence and risk of colorectal cancer deaths by approximately 20%." | 4.02 | Development and user-testing of a brief decision aid for aspirin as a preventive approach alongside colorectal cancer screening. ( Brain, K; Dolwani, S; Edwards, A; Lifford, KJ; Seddon, K; Semedo, L; Smits, S, 2021) |
| "Although compelling evidence exists on the ability of aspirin to treat colorectal cancer (CRC), and numerous theories and targets have been proposed, a consensus has not been reached regarding its mechanism of action." | 3.96 | Aspirin metabolites 2,3‑DHBA and 2,5‑DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention. ( Bhat, GJ; Dachineni, R; Kumar, DR; Lick, T; Sankaranarayanan, R; Valiveti, CK, 2020) |
| "Accumulating evidence suggests that aspirin has anti-tumorigenic properties in colorectal cancer (CRC)." | 3.96 | A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer. ( Boland, C; Goel, A; Komarova, NL; Shimura, T; Toden, S; Wodarz, D, 2020) |
| "Aspirin, as a non-steroidal anti-inflammatory drug, can improve the survival rate of patients with colorectal cancer, while aspirin is effective in patients with PIK3CA mutant colorectal cancer (CRC)." | 3.96 | Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway. ( Chen, Z; Dong, H; Gao, F; Wang, C; Wang, X; Zhang, S; Zhang, X, 2020) |
| "Previous studies suggest that the use of low-dose aspirin before a colorectal cancer (CRC) diagnosis may be associated with a decreased risk of CRC progression." | 3.96 | Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer. ( Azoulay, L; Cricelli, C; Giorli, G; Lapi, F; Pollak, M; Rouette, J; Simonetti, M; Yin, H, 2020) |
| "Aspirin may increase the risk of lower gastrointestinal bleeding (LGIB) from precursors of colorectal cancer (CRC)." | 3.96 | Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study. ( Erichsen, R; Farkas, DK; Sørensen, HT; Troelsen, FS, 2020) |
| "Population-based East Asian data have corroborated reports from non-Asian settings on the association between low-dose aspirin and a lower risk of colorectal cancer (CRC)." | 3.96 | Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan. ( Chan, KA; Lin, HD; Soriano-Gabarró, M; Vora, P, 2020) |
| " Recently, several impactful studies targeted the association between initiation of aspirin and survival following colorectal cancer (CRC) diagnosis." | 3.96 | A novel calibration framework for survival analysis when a binary covariate is measured at sparse time points. ( Hamada, T; Nevo, D; Ogino, S; Wang, M, 2020) |
| "We investigated the effect of aspirin on colorectal cancer (CRC) risk among subgroups of women with and without risk factors for CRC." | 3.91 | Effects of Colorectal Cancer Risk Factors on the Association Between Aspirin and Colorectal Cancer. ( Bafford, A; Johnson, KC; Kooperberg, C; Peters, U; Seaton, ME; Zubair, N, 2019) |
| "New Australian guidelines recommend that GPs actively consider prescribing low-dose aspirin to patients aged 50-70 years to reduce their risk of developing colorectal cancer (CRC)." | 3.91 | Benefits and harms of aspirin to reduce colorectal cancer risk: a cross-sectional study of methods to communicate risk in primary care. ( Bickerstaffe, A; Cummings, KL; Emery, JD; Maddumarachchi, S; McIntosh, J; Nguyen, P, 2019) |
| "To investigate the association of aspirin use with risk of all-cause, any cancer, gastrointestinal (GI) cancer, and colorectal cancer (CRC) mortality among older adults and to perform an exploratory analysis of the association of aspirin use with mortality stratified by BMI." | 3.91 | Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. ( Cao, Y; Chan, AT; Loomans-Kropp, HA; Pinsky, P; Umar, A, 2019) |
| "A significant proportion of patients discontinue their aspirin in the time approaching a breast or colorectal cancer-specific death." | 3.91 | End-of-life prescribing of aspirin in patients with breast or colorectal cancer. ( Barron, TI; Bennett, K; Brown, C; Cranfield, F; Murphy, L; Sharp, L; Smith, A; Visvanathan, K, 2019) |
| "Regular use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) for a longer period has been inversely associated with colorectal cancer (CRC) risk." | 3.91 | Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. ( Amitay, EL; Bläker, H; Brenner, H; Carr, PR; Chang-Claude, J; Herpel, E; Hoffmeister, M; Jansen, L; Kloor, M; Roth, W; Walter, V, 2019) |
| "The chemopreventive effect of aspirin in colorectal cancer (CRC) is well studied, but its benefit in patients after CRC diagnosis and surgery is unclear." | 3.91 | Low-dose aspirin can reduce colorectal cancer mortality after surgery: A 10-year follow-up of 13 528 colorectal cancer patients. ( Chan, FCH; Ho, JMW; Sung, JJY; Tsoi, KKF, 2019) |
| "The antiplatelet effect of low-dose aspirin, via inhibition of cyclooxygenase-1, might contribute to its ability to reduce the risk of colorectal cancer (CRC)." | 3.91 | Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer. ( de Abajo, FJ; García-Rodríguez, LA; Gil, M; Montoya, H; Rodríguez-Martín, S; Rodríguez-Miguel, A, 2019) |
| "In a large screening cohort in Norway, regular use of aspirin and particularly DOACs, were associated with lower PPV of FIT for detection of CRCs and advanced adenomas." | 3.91 | Effects of Oral Anticoagulants and Aspirin on Performance of Fecal Immunochemical Tests in Colorectal Cancer Screening. ( Botteri, E; Bretthauer, M; de Lange, T; Frigstad, SO; Hoff, G; Holme, Ø; Randel, KR; Romstad, KMK, 2019) |
| "Epidemiological studies indicate that long‑term aspirin usage reduces the incidence of colorectal cancer (CRC) and may protect against other non‑CRC associated adenocarcinomas, including oesophageal cancer." | 3.91 | A novel mechanism for the anticancer activity of aspirin and salicylates. ( Bashir, AIJ; Jones, S; Kankipati, CS; Newman, RM; Nicholl, ID; Perry, CJ; Safrany, ST, 2019) |
| " We hypothesized that blood platelet count would be associated with systemic inflammation, the densities of tumor infiltrating immune cells, and survival in colorectal cancer (CRC), and these relationships could be altered by aspirin use." | 3.91 | Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer. ( Herzig, KH; Karhu, T; Karttunen, TJ; Klintrup, K; Mäkelä, J; Mäkinen, MJ; Minkkinen, I; Sirniö, P; Tuomisto, A; Väyrynen, JP; Väyrynen, SA, 2019) |
| "Aspirin has been proposed as a novel adjuvant agent in colorectal cancer (CRC)." | 3.88 | Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study. ( Cardwell, CR; Coleman, HG; Gray, RT; Hughes, C; Murray, LJ, 2018) |
| "Aspirin, commonly used for prevention of cardiovascular and cerebrovascular diseases, is well known to protect against development of colorectal cancer (CRC) but increases risk of gastrointestinal bleeding (GIB)." | 3.88 | Risk of gastrointestinal bleeding and benefit from colorectal cancer reduction from long-term use of low-dose aspirin: A retrospective study of 612 509 patients. ( Chan, FC; Hirai, HW; Sung, JJ; Tsoi, KK, 2018) |
| "Aspirin use after diagnosis of colorectal cancer was associated with significantly lower mortality rates and this effect remained significant after adjusting for potential confounders." | 3.85 | The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer. ( Bastiaannet, E; Frouws, MA; Lemmens, VE; Liefers, GJ; Portielje, JEA; Rademaker, E; Van de Velde, CJH; van Herk-Sukel, MPP, 2017) |
| "We used a single, integrated, microsimulation model to generate comparable results for 3 services recommended by the US Preventive Services Task Force: aspirin counseling for the primary prevention of CVD and colorectal cancer, screening and treatment for lipid disorders (usually high cholesterol), and screening and treatment for hypertension." | 3.85 | Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV, 2017) |
| " Evidence suggests that aspirin (a widely used nonsteroidal anti-inflammatory drug) not only prolongs colorectal cancer survival, but can also activate T cell-mediated antitumor immunity and synergize with immunotherapy through inhibition of prostaglandin E2 production." | 3.85 | Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. ( Cao, Y; Chan, AT; da Silva, A; Freeman, GJ; Fuchs, CS; Giannakis, M; Giovannucci, EL; Gu, M; Hamada, T; Keum, N; Kosumi, K; Li, W; Liu, L; Masugi, Y; Meyerhardt, JA; Mima, K; Nevo, D; Nishihara, R; Nowak, JA; Ogino, S; Qian, ZR; Rodig, SJ; Shi, Y; Song, M; Wang, M; Wu, K; Yang, J; Zhang, X, 2017) |
| "Purpose Regular use of aspirin is associated with improved survival for patients with colorectal cancer (CRC)." | 3.85 | Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. ( Adams, SV; Ahnen, DJ; Baron, JA; Burnett-Hartman, AN; Cohen, SA; Hardikar, S; Hua, X; Kocarnik, JM; Lindor, NM; Newcomb, PA; Phipps, AI, 2017) |
| "Aspirin is known to reduce the risk of colorectal cancer (CRC) incidence, but the underlying mechanisms are not fully understood." | 3.85 | Effect of aspirin on tumour cell colony formation and evolution. ( Boland, CR; Goel, A; Komarova, NL; Wodarz, D, 2017) |
| "Evidence from clinical trial populations suggests low-dose aspirin reduces the risk of colorectal cancer (CRC)." | 3.85 | New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case-control study in UK general practice. ( Bromley, S; Cea Soriano, L; García Rodríguez, LA; Lanas, A; Soriano-Gabarró, M, 2017) |
| "Aspirin's potential as a drug continues to be evaluated for the prevention of colorectal cancer (CRC)." | 3.85 | Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer. ( Bhat, GJ; Callegari, E; Dachineni, R; Kesharwani, SS; Kumar, DR; Sankaranarayanan, R; Seefeldt, T; Tummala, H, 2017) |
| " Aspirin has been shown to reduce cancer risk and mortality, particularly in colorectal cancer." | 3.85 | Reduction of NANOG Mediates the Inhibitory Effect of Aspirin on Tumor Growth and Stemness in Colorectal Cancer. ( Cheng, W; Cui, B; Dong, L; Fan, W; Gong, Y; Hou, Z; Kamran, M; Kang, Z; Li, J; Li, M; Li, S; Liu, B; Liu, Q; Luo, Y; Ren, Y; Tian, P; Wang, C; Wang, H; Wang, J; Wang, L; Wen, Q; Xu, J; Xu, L; Xue, X; Yang, M, 2017) |
| "Aspirin use is reportedly not to be associated with fecal immunochemical occult blood test (FIT) false-positive results for the detection of colorectal cancer." | 3.85 | Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy? ( Arimoto, J; Endo, H; Hata, Y; Higurashi, T; Inamori, M; Kato, T; Kawamura, H; Nagase, H; Nakajima, A; Nonaka, T; Ohkubo, H; Sakaguchi, T; Sakai, E; Taguri, M; Taniguchi, L; Yamanaka, T, 2017) |
| "We assessed the role of aspirin in patients with metastatic colorectal cancer who failed all previous treatments and were receiving capecitabine as a salvage option before the introduction of regorafenib and TAS-102." | 3.85 | The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. ( Andrikou, K; Berardi, R; Bianconi, M; Bittoni, A; Cabras, F; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Maccaroni, E; Pusceddu, V; Restivo, A; Scartozzi, M; Scintu, F; Zorcolo, L, 2017) |
| "Evidence has accumulated that long-term use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) protects against colorectal cancer." | 3.85 | Exploring Differences in the Aspirin-Colorectal Cancer Association by Sex and Race/Ethnicity: The Multiethnic Cohort Study. ( Haiman, CA; Kolonel, LN; Marchand, LL; Monroe, KR; Park, SY; Wilkens, LR, 2017) |
| "Numerous evidences indicate that aspirin usage causes a significant reduction in colorectal cancer." | 3.85 | Identification of TMEM208 and PQLC2 as reference genes for normalizing mRNA expression in colorectal cancer treated with aspirin. ( He, Y; Jin, X; Jin, Y; Li, X; Li, Z; Liu, Y; Ning, N; Qiao, Y; RajkumarEzakiel Redpath, RJ; Sun, Y; Wang, G; Wang, T; Weng, M; Wu, Y; Yang, C; Yang, W; Zhang, F; Zhang, L; Zhang, Y; Zhu, Y, 2017) |
| "2%) was positively associated with age, male gender, smoking and alcohol drinking, and inversely associated with physical activity, fruit and vegetables consumption and long-term use of aspirin." | 3.83 | Predictors of advanced colorectal neoplasia at initial and surveillance colonoscopy after positive screening immunochemical faecal occult blood test. ( Bagnardi, V; Botteri, E; Crosta, C; de Leone, A; De Roberto, G; Lowenfels, A; Maisonneuve, P; Sonzogni, AM; Tamayo, D, 2016) |
| " Daily, low-dose aspirin has been identified as a promising means of preventing colorectal cancer, and stakeholders are already calling for research to facilitate dissemination." | 3.83 | Colorectal cancer prevention and intentions to use low-dose aspirin: A survey of 1000 U.S. adults aged 40-65. ( Donovan, E; Holton, AE; Jensen, JD; Krakow, M; Tavtigian, S; Weaver, J, 2016) |
| "We identify an aspirin-induced upregulated lncRNA, OLA1P2, in human colorectal cancer." | 3.83 | The aspirin-induced long non-coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation. ( Ben, Q; Chen, W; Guo, H; Li, M; Liu, J; Qu, Y; Wang, Y; Zhang, J, 2016) |
| "Evidence indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages." | 3.83 | Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV; Whitlock, EP, 2016) |
| "The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years." | 3.83 | Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. ( Bibbins-Domingo, K, 2016) |
| " As an illustration, we apply the methods to data from the Aspirin/Folate Polyp Prevention Study, a clinical trial evaluating the effect of oral aspirin, folic acid, or both as a chemoprevention agent against colorectal adenomas." | 3.83 | Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes. ( Barcella, W; Bonetti, M; Cole, BF; Gelber, RD; Lazar, A; Wang, XV; Yip, WK, 2016) |
| "Regular use of aspirin (acetylsalicylic acid) is associated with reduced incidence and mortality of colorectal cancer (CRC)." | 3.83 | Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study. ( Bains, SJ; Bjørnbeth, BA; Brudvik, KW; Dørum, LM; Mahic, M; Myklebust, TÅ; Møller, B; Småstuen, MC; Taskén, K; Yaqub, S, 2016) |
| "We conducted three differently designed nested case-control studies to evaluate whether the protective effect of low-dose aspirin against colorectal cancer (CRC) is explained by selection bias." | 3.83 | The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice. ( Cea Soriano, L; García Rodríguez, LA; Soriano-Gabarró, M, 2016) |
| "Aspirin use reduces colorectal cancer risk." | 3.83 | Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. ( Cao, Y; Chan, AT; Drew, DA; Fuchs, CS; Garrett, WS; Giovannucci, EL; Inamura, K; Lochhead, P; Mima, K; Morikawa, T; Nishihara, R; Nosho, K; Nowak, JA; Ogino, S; Qian, ZR; Song, M; Wang, M; Wu, K; Zhang, X, 2016) |
| "To evaluate whether aspirin can reduce the risk of colorectal cancer in people with diabetes." | 3.81 | Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. ( Lai, MS; Lin, CC; Shau, WY, 2015) |
| "Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring PIK3CA mutations." | 3.81 | Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. ( Day, FL; Desai, J; Faragher, I; Gibbs, P; Jones, I; Jorissen, RN; Kim, R; Kothari, N; Li, S; Lipton, L; Palmieri, M; Sakthinandeswaren, A; Schell, M; Shibata, D; Sieber, OM; Teer, JK; Tie, J; Tran, B; Wong, HL; Yeatman, T, 2015) |
| "Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with lower risk of colorectal cancer." | 3.81 | Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. ( Baron, JA; Berndt, SI; Brenner, H; Butterbach, K; Caan, BJ; Campbell, PT; Carlson, CS; Casey, G; Chan, AT; Chang-Claude, J; Chanock, SJ; Cotterchio, M; Duggan, D; Figueiredo, JC; Fuchs, CS; Gauderman, WJ; Giovannucci, EL; Gong, J; Haile, RW; Harrison, TA; Hayes, RB; Hoffmeister, M; Hopper, JL; Hsu, L; Hudson, TJ; Hutter, CM; Jacobs, EJ; Jenkins, MA; Jiao, S; Le Marchand, L; Lemire, M; Lin, Y; Lindor, NM; Nan, H; Newcomb, PA; Ogino, S; Peters, U; Pflugeisen, BM; Potter, JD; Qu, C; Rosse, SA; Rudolph, A; Schoen, RE; Schumacher, FR; Seminara, D; Slattery, ML; Thibodeau, SN; Thomas, F; Thornquist, M; Ulrich, CM; Warnick, GS; White, E; Zanke, BW, 2015) |
| " Use of aspirin has been shown to be associated with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers." | 3.81 | Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. ( Ahnen, DJ; Ait Ouakrim, D; Baron, JA; Buchanan, DD; Casey, G; Chau, R; Clendenning, M; Dashti, SG; Gallinger, S; Giles, GG; Haile, RW; Hopper, JL; Jenkins, MA; Le Marchand, L; Leggett, B; Lindor, NM; Macrae, FA; Newcomb, PA; Potter, JD; Rosty, C; Thibodeau, SN; Win, AK; Winship, IM; Young, JP, 2015) |
| " Special attention has been paid to the potential chemopreventive effect of aspirin against human colorectal cancer." | 3.81 | Aspirin Targets SIRT1 and AMPK to Induce Senescence of Colorectal Carcinoma Cells. ( Choi, HJ; Jung, YR; Kim, EJ; Kim, HS; Lee, M; Lee, YJ; Park, JJ; Park, MJ, 2015) |
| "To assess associations between the use of low-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) and colorectal cancer risk." | 3.81 | Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study. ( Baron, JA; Erichsen, R; Friis, S; Riis, AH; Sørensen, HT, 2015) |
| "An estimated 335 colorectal cancers, 22 oesophageal adenocarcinomas and 29 oesophageal squamous cell carcinomas (SCC) were potentially prevented due to daily aspirin use." | 3.81 | Cancers prevented in Australia in 2010 through the consumption of aspirin. ( Bain, CJ; Green, AC; Jordan, SJ; Kendall, BJ; Nagle, CM; Neale, RE; Whiteman, DC; Wilson, LF, 2015) |
| "Individuals who began taking low-dose aspirin before they were diagnosed with colorectal cancer were reported to have longer survival times than patients who did not take this drug." | 3.80 | Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. ( Baron, JA; Cantwell, MM; Cardwell, CR; Hughes, C; Kunzmann, AT; Murray, LJ; Powe, DG, 2014) |
| "According to findings of a study in the Journal of the National Cancer Institute, people with a single-nucleotide polymorphism on chromosome 8q24 who regularly use aspirin can cut their risk of colorectal cancer by about half." | 3.80 | Protective effect of aspirin associated with SNP. ( , 2014) |
| "Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer." | 3.80 | Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. ( Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL, 2014) |
| "The aim of this study was to evaluate the relationship between long-term aspirin use with pretreatment 18 Fluorodeoxyglucose (FDG) uptake of primary lesions of Colorectal cancer (CRC) and evaluate their clinical significance." | 3.80 | Correlation between long-term aspirin use and F-fluorodeoxyglucose uptake in colorectal cancer measured by PET/CT. ( Su, B; Wan, J; Xu, B, 2014) |
| "Recent observational studies suggest that postoperative aspirin use may improve Colorectal cancer (CRC)-specific survival and overall survival (OS)." | 3.80 | Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. ( Chew, L; Chew, MH; Chia, WK; Fu, WP; Goh, CH; Goh, HH; Leong, WQ; Pan, YS; Tan, IB; Tang, CL; Toh, HC; Tony, LK, 2014) |
| "There is increasing evidence that aspirin, statins and ACE-inhibitors can reduce the incidence of colorectal cancer." | 3.79 | The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme. ( Crighton, EM; Horgan, PG; Mansouri, D; McMillan, DC; Roxburgh, CS, 2013) |
| "Considerable evidence suggests that aspirin has a chemopreventive effect on colorectal cancer (CRC)." | 3.79 | The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study. ( Chen, JS; Chiou, MJ; Huang, WK; Kuo, CF; Lin, YC; See, LC; Yang, TS; Yu, KH, 2013) |
| "To examine whether the association of aspirin intake with colorectal cancer risk differs according to status of tumor BRAF oncogene mutation." | 3.79 | Aspirin use and risk of colorectal cancer according to BRAF mutation status. ( Chan, AT; Cho, E; Fuchs, CS; Giovannucci, E; Imamura, Y; Jung, S; Kuchiba, A; Liao, X; Lochhead, P; Morikawa, T; Nishihara, R; Ogino, S; Qian, ZR; Spiegelman, D; Wang, M; Yamauchi, M, 2013) |
| "Recent evidence suggests that daily aspirin use decreases cancer risk, particularly for colorectal cancer, but evidence for alternate-day use is scant." | 3.79 | Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. ( Buring, JE; Cook, NR; Lee, IM; Moorthy, MV; Zhang, SM, 2013) |
| "From the Swedish Cancer Register, we identified patients diagnosed with colorectal, lung, prostate and breast cancers between 2006 and 2009 and matched them to the Swedish Prescribed Drug Register to obtain information on low-dose aspirin use prior to diagnosis." | 3.79 | Low-dose aspirin use and cancer characteristics: a population-based cohort study. ( Czene, K; Jonsson, F; Lundholm, C; Pawitan, Y; Smedby, KE; Yin, L, 2013) |
| "Regular aspirin use reduces the risk for colorectal cancer (CRC), possibly through inhibition of WNT/cadherin-associated protein β1 (CTNNB1 or β-catenin) signaling." | 3.79 | Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. ( Chan, AT; Freedman, ML; Fuchs, CS; Giovannucci, EL; Hunter, DJ; Imamura, Y; Kraft, P; Kuchiba, A; Morikawa, T; Nan, H; Ogino, S; Suuriniemi, M; Werner, L; Yamauchi, M, 2013) |
| "Aspirin is associated with a reduced risk of developing colorectal cancer." | 3.79 | Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. ( Donnan, PT; McCowan, C; Munro, AJ; Steele, RJ, 2013) |
| "Patients with colorectal cancer with mutated PIK3CA, identified from two large observational cohorts, had increased cancer-specific and overall survival if they used aspirin regularly after diagnosis compared to non-users." | 3.79 | Potential biomarker for aspirin use in colorectal cancer therapy. ( Langley, RE; Rothwell, PM, 2013) |
| "Clinical and cohort studies have shown that low-dose aspirin and calcium are effective low-risk strategies for primary prevention of colorectal cancer (CRC)." | 3.79 | Combination aspirin and/or calcium chemoprevention with colonoscopy in colorectal cancer prevention: cost-effectiveness analyses. ( Belasco, EJ; Lyford, CP; Pence, BC, 2013) |
| "Aspirin reduces the incidence of and mortality from colorectal cancer (CRC) by unknown mechanisms." | 3.78 | Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. ( Alessi, DR; Din, FV; Dunlop, MG; Green, KA; Houde, VP; Sakamoto, K; Valanciute, A; Zibrova, D, 2012) |
| "Aspirin has been widely reported to reduce the incidence of colorectal cancer." | 3.78 | Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. ( Card, TR; Grainge, MJ; Walker, AJ, 2012) |
| "Among patients with mutated-PIK3CA colorectal cancers, regular use of aspirin after diagnosis was associated with superior colorectal cancer-specific survival (multivariate hazard ratio for cancer-related death, 0." | 3.78 | Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. ( Baba, Y; Chan, AT; Fuchs, CS; Giovannucci, E; Imamura, Y; Kuchiba, A; Liao, X; Lochhead, P; Meyerhardt, JA; Morikawa, T; Nishihara, R; Nosho, K; Ogino, S; Qian, ZR; Shima, K; Sun, R; Yamauchi, M, 2012) |
| "Aspirin is associated with a reduced risk of colorectal cancer (CRC), and it showed inhibited effects on interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway which is thought to play an important role in intestinal inflammation and the tumorigenesis of CRC." | 3.77 | Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. ( Chen, H; Gao, W; Mao, X; Ren, C; Song, T; Tian, Y; Wang, D; Ye, Y, 2011) |
| "Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) lower the risk of colorectal cancer (CRC)." | 3.77 | Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. ( Chan, AT; Fuchs, CS; Giovannucci, EL; Ogino, S, 2011) |
| "Both aspirin and non-aspirin NSAID use reduced colorectal cancer risk (HR for users compared with non-users=0." | 3.77 | Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. ( Cross, AJ; Graubard, BI; Hollenbeck, AR; Laiyemo, AO; Ruder, EH; Schatzkin, A, 2011) |
| "Long-term aspirin or related non-steroidal anti-inflammatory drugs (NSAIDs) ingestion can protect against colorectal cancer (CRC)." | 3.77 | c-Src dependency of NSAID-induced effects on NF-κB-mediated apoptosis in colorectal cancer cells. ( Brady, RR; Dunlop, MG; Loveridge, CJ; Stark, LA, 2011) |
| "To confirm the role of sex-determining region Y-box 7 (Sox7) in aspirin-mediated growth inhibition of COX-independent human colorectal cancer cells." | 3.77 | SOX7 is involved in aspirin-mediated growth inhibition of human colorectal cancer cells. ( Feng, JX; Gao, YY; Huang, BQ; Huang, SY; Lu, J; Zhang, Y; Zhao, L; Zhou, X, 2011) |
| " The protective effects of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) for colorectal cancers in experimental and clinical studies are also demonstrated in this review." | 3.77 | [Oncogenesis humoral mechanisms regulation and NSAIDs ability in prevention of tumors]. ( Drozdov, VN; Kim, VA; Lazebnik, LV, 2011) |
| "To investigate the effect of cyclooxygenase-2 (Cox-2) inhibitor aspirin (acetylsalicylic acid, ASA) and proteasome inhibitor bortezomib in the proliferation and apoptosis of colorectal cancer cell lines." | 3.76 | Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. ( Hatzidaki, E; Karagiannaki, A; Papandreou, CN; Patrikidou, A; Stathakis, NE; Tsapakidis, K; Voutsadakis, IA, 2010) |
| "Regular aspirin intake is associated with a reduction in the incidence of colorectal cancer." | 3.76 | Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line. ( Brown, JE; Dibra, HK; Hooley, P; Nicholl, ID, 2010) |
| "High-dose aspirin (≥500 mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention." | 3.76 | Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. ( Algra, A; Elwin, CE; Meade, TW; Norrving, B; Rothwell, PM; Warlow, CP; Wilson, M, 2010) |
| "To assess the association of low-dose aspirin use with the performance of 2 quantitative iFOBTs in a large sample of patients undergoing colorectal cancer screening." | 3.76 | Low-dose aspirin use and performance of immunochemical fecal occult blood tests. ( Brenner, H; Haug, U; Tao, S, 2010) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of colorectal cancer (CRC), these drugs can also cause harmful side effects." | 3.75 | Patient preferences for the chemoprevention of colorectal cancer. ( Broughton, DE; Gazelle, GS; Hur, C; Kong, CY; Ozanne, EM; Richards, EB; Truong, T, 2009) |
| "The optimal duration and dose of aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) in the potential prevention of colorectal cancer (CRC) have not been established." | 3.75 | Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. ( Blot, WJ; Friis, S; McLaughlin, JK; Olsen, JH; Overvad, K; Poulsen, AH; Sørensen, HT; Tjønneland, A; Vogel, U, 2009) |
| "To examine the association between aspirin use after colorectal cancer diagnosis on colorectal cancer-specific and overall survival." | 3.75 | Aspirin use and survival after diagnosis of colorectal cancer. ( Chan, AT; Fuchs, CS; Ogino, S, 2009) |
| "The Aspirin/Folate Polyp Prevention Trial found that aspirin, but not folic acid, reduced recurrence of colorectal adenomas." | 3.75 | Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Cushman, M; Ho, GY; McKeown-Eyssen, G; Rohan, TE; Saibil, F; Sandler, RS; Xue, X, 2009) |
| " The Task Force has: 1) dropped the age for routine screening for Chlamydia in sexually active women from 25 years and younger to 24 and younger; 2) added a recommendation against the use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent colorectal cancer (CRC); 3) changed its recommendation on screening for carotid artery stenosis." | 3.74 | Should you screen--or not? The latest recommendations. ( Campos-Outcalt, D, 2008) |
| "Blood levels of long-chain n-3 fatty acids were associated with decreased risk of colorectal cancer among men not using aspirin." | 3.74 | Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. ( Campos, H; Hall, MN; Li, H; Ma, J; Sesso, HD; Stampfer, MJ; Willett, WC, 2007) |
| " Preventive Services Task Force (USPSTF) recommendation and supporting scientific evidence on routine use of aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer." | 3.74 | Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. ( , 2007) |
| "Regular use of aspirin appears to reduce the risk of colorectal cancers that overexpress COX-2 but not the risk of colorectal cancers with weak or absent expression of COX-2." | 3.74 | Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. ( Chan, AT; Fuchs, CS; Ogino, S, 2007) |
| "Long-term data on the risk of colorectal cancer according to dose, duration, and consistency of aspirin therapy are limited." | 3.74 | Aspirin dose and duration of use and risk of colorectal cancer in men. ( Chan, AT; Fuchs, CS; Giovannucci, EL; Meyerhardt, JA; Schernhammer, ES; Wu, K, 2008) |
| "We genotyped ODC G316A in 546 individuals in the United Kingdom Colorectal Adenoma Prevention trial of aspirin for CRA recurrence prevention and pooled our findings with data from two other randomized intervention trials." | 3.74 | Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. ( Grainge, MJ; Houlston, RS; Hubner, RA; Liu, JF; Logan, RF; Muir, KR, 2008) |
| "The reduced risk of colorectal cancer associated with cyclooxygenase enzyme inhibitors, such as aspirin and other nonsteroidal anti-inflammatory drugs, strongly suggests that chronic inflammation is a key mediator in the development of colorectal cancer." | 3.73 | The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. ( El-Omar, EM; Hold, GL; Little, J; Macarthur, M; Sharp, L, 2005) |
| "To examine the influence of aspirin and NSAIDs in prevention of colorectal cancer." | 3.73 | Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. ( Chan, AT; Curhan, GC; Fuchs, CS; Giovannucci, EL; Meyerhardt, JA; Schernhammer, ES, 2005) |
| "To explore the separate and joint effects of calcium and aspirin/nonsteroidal anti-inflammatory drugs (NSAID), we used data from two large randomized clinical trials among patients with a recent history of colorectal adenomas." | 3.73 | Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. ( Baron, JA; Barry, EL; Cole, BF; Grau, MV; Haile, RW; Mandel, JS; Sandler, RS, 2005) |
| "The purpose of this study was to test the hypothesis that aspirin use is associated with a decreased risk of incident colorectal cancer." | 3.73 | The association between aspirin use and the incidence of colorectal cancer in women. ( Allison, M; Chlebowski, R; Criqui, M; Garland, C; Kuller, L; Langer, R; McTiernan, A; Roy, H; Wu, L, 2006) |
| "We tested these hypotheses among participants in the Aspirin/Folate Polyp Prevention Study who were randomly assigned to placebo or to aspirin treatment (81 or 325 mg daily) and followed for 3 years for the occurrence of new adenomas." | 3.73 | Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. ( Ahnen, DJ; Baron, JA; Barry, EL; Bhat, S; Burke, CA; Grau, MV; Haile, RW; O'Brien, TG; Sandler, RS, 2006) |
| "2 years of follow-up and 705 incident colorectal cancer cases, long duration of aspirin use (>20 years) was associated with a reduced risk of colorectal cancer (multivariate rate ratio: 0." | 3.73 | Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. ( Giovannucci, E; Larsson, SC; Wolk, A, 2006) |
| "and aims: Aspirin and other non-steroidal anti-inflammatory drugs have been shown to reduce the risk of colorectal cancer (CRC)." | 3.72 | Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. ( Bernheim, J; Buklan, G; Freund, HR; Grankin, M; Klein, E; Neufeld, D; Nissan, A; Shpitz, B, 2003) |
| "Randomized, double-blind, placebo-controlled trials have established that regular aspirin use reduces the risk for recurrent colorectal adenoma." | 3.72 | A prospective study of aspirin use and the risk for colorectal adenoma. ( Chan, AT; Colditz, GA; Fuchs, CS; Giovannucci, EL; Hunter, DJ; Schernhammer, ES; Willett, WC, 2004) |
| "Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce risk of colorectal cancer." | 3.72 | Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. ( Hoffman, M; Levin, TR; Ma, KN; Neuhausen, S; Samowitz, W; Slattery, ML, 2004) |
| "Epidemiological, experimental, and clinical observations provide support for a colorectal cancer chemopreventive role for aspirin." | 3.72 | Effects of low dose aspirin (81 mg) on proliferating cell nuclear antigen and Amaranthus caudatus labeling in normal-risk and high-risk human subjects for colorectal cancer. ( Aoki, T; Boland, CR; Brenner, DE; Krishnan, K; Normolle, DP; Ruffin, MT, 2004) |
| "This paper evaluates aspirin in the reduction of colorectal cancer risk against the nine causality criteria suggested by Bradford-Hill in 1965." | 3.72 | Aspirin and colorectal cancer? ( Morgan, G, 2004) |
| "Regular aspirin use is associated with a reduced risk for colorectal adenoma, whereas smoking increases risk." | 3.72 | A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. ( Chan, AT; Fuchs, CS; Giovannucci, EL; Hunter, DJ; Tranah, GJ, 2004) |
| "The aim of this study is to assess the role of high fibre diet and aspirin on dimethylhydrazine (DMH)-induced colorectal cancer in rats." | 3.72 | The effect of aspirin and high fibre diet on colorectal carcinoma: a comparative experimental study. ( Kiskinis, D; Miliaras, D; Miliaras, S; Vrettou, E; Zavitsanakis, A, 2004) |
| "Use of nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with a reduced risk of colorectal cancer, but limited information is available on the effect of individual nonaspirin NSAIDs." | 3.71 | Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. ( García-Rodríguez, LA; Huerta-Alvarez, C, 2001) |
| "Aspirin may decrease colorectal cancer incidence, but its role as an adjunct to or substitute for screening has not been evaluated." | 3.71 | Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. ( Chernew, ME; Chopra, CL; Fendrick, AM; Huang, G; Ladabaum, U; Scheiman, JM, 2001) |
| "The aim of the study is to compare the cost-effectiveness of aspirin and colonoscopy in the prevention of colorectal cancer." | 3.71 | Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. ( Rex, DK; Sonnenberg, A; Suleiman, S, 2002) |
| "Aspirin and nonsteroidal anti-inflammatory drugs have been reported to protect against the development of colorectal cancer." | 3.70 | Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. ( Galanko, JC; Helm, JF; Murray, SC; Sandler, RS; Woosley, JT, 1998) |
| " Epidemiologic and experimental studies suggest that regular use of aspirin may reduce colorectal cancer risk." | 3.70 | Aspirin use and p53 expression in colorectal cancer. ( Asirwatham, JE; Caporaso, NE; Freedman, AN; Marshall, JR; Mettlin, CJ; Michalek, AM; Petrelli, NJ; Weiss, HA; Zhang, ZF, 1998) |
| " Six colorectal cancer cell lines all but one deficient for human mismatch repair (MMR) genes were examined for microsatellite instability (MSI) prior and after treatment with Aspirin or Sulindac." | 3.70 | [Aspirin suppresses microsatellite instability]. ( Beyser, K; Bocker, T; Dietmaier, W; Fishel, R; Hofstädter, F; Rüschoff, J; Wallinger, S, 1999) |
| "The Leisure World Cohort data on aspirin and colorectal cancer was reanalyzed in an attempt to explain why this study is the lone observational study in which aspirin appears not to be protective." | 3.69 | Aspirin and colorectal cancer: the Leisure World cohort revisited. ( Paganini-Hill, A, 1995) |
| "Most data suggest that the regular use of aspirin reduces the risk of colorectal cancer, but some apparently conflicting evidence exists." | 3.69 | Aspirin and the risk of colorectal cancer in women. ( Colditz, GA; Egan, KM; Giovannucci, E; Hunter, DJ; Speizer, FE; Stampfer, MJ; Willett, WC, 1995) |
| "To determine whether regular use of aspirin decreases the risk for colorectal cancer." | 3.69 | Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. ( Ascherio, A; Colditz, GA; Giovannucci, E; Rimm, EB; Stampfer, MJ; Willett, WC, 1994) |
| "Odds of colorectal cancer as a function of aspirin, nonaspirin NSAIDs, and acetaminophen dispensed to the study population in the 4 years prior to incident colorectal cancer diagnosis." | 3.69 | Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. ( Brown, SH; Maibach, HT; Peleg, II; Wilcox, CM, 1994) |
| "Regular aspirin intake may reduce the risk of colorectal cancer by 50%." | 3.69 | Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. ( Elder, DJ; Hague, A; Hicks, DJ; Paraskeva, C, 1996) |
| "Our objective was to study the relationship between dispensed aspirin, nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs), steroidal antiinflammatory drugs (SAIDs), acetaminophen, calcium, psyllium, and multivitamin preparations and the risk for subsequent colorectal adenoma and adenocarcinoma." | 3.69 | Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. ( Clark, WS; Cotsonis, GA; Lubin, MF; Peleg, II; Wilcox, CM, 1996) |
| "The relationship between aspirin use and colorectal cancer risk was examined by a case-control study in Italy." | 3.69 | Aspirin and colorectal cancer. ( Conti, E; Decarli, A; Falcini, A; Franceschi, S; Giacosa, A; La Vecchia, C; Montella, M; Negri, E, 1997) |
| "Aspirin treatment was associated with a 20% reduction in colorectal polyp number at BCSP surveillance colonoscopy 12 months later." | 3.30 | Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use. ( Brown, LC; Downing, A; Fenton, H; Hull, MA; Loadman, PM; Morris, EJA; Nickerson, C; Rees, CJ; Williams, EA, 2023) |
| "The incidence and mortality rates of colorectal cancer (CRC) continue to increase worldwide." | 2.94 | The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial. ( Arimoto, J; Ashikari, K; Fuyuki, A; Higurashi, T; Matsuura, T; Misawa, N; Nakajima, A; Ohkubo, H; Takatsu, T; Yoshihara, T, 2020) |
| "However, the prognosis of stage III colorectal cancer is still poor even after curative resection and adjuvant chemotherapy." | 2.90 | Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial). ( Fukuda, H; Hamaguchi, T; Kanemitsu, Y; Katayama, H; Miyamoto, K; Mizusawa, J; Nakamura, K; Sato, Y; Shibata, T; Shida, D; Shimada, Y; Takashima, A, 2019) |
| "Aspirin could reduce the risk of cancer metastasis." | 2.87 | The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. ( Chen, Y; Hu, X; Lv, Y; Lv, Z; Ni, C; Weng, X; Xia, W; Xin, Y; Xu, Q; Yang, L; Yuan, H; Zhang, W, 2018) |
| "Purpose colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide." | 2.82 | Meta-analysis of aspirin-guided therapy of colorectal cancer. ( Kleebusch, L; Mädge, JC; Schlattmann, P; Stallmach, A, 2022) |
| "Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four parallel cohorts." | 2.82 | ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. ( Berkman, L; Cafferty, FH; Cameron, D; Coyle, C; Gilbert, D; Gupta, S; Kynaston, H; Langley, RE; MacKenzie, M; Pramesh, CS; Ring, A; Rowley, S; Wilson, RH, 2016) |
| "Aspirin use was not independently associated with recurrent adenoma (RR, 0." | 2.77 | The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Hsu, M; Zauber, AG, 2012) |
| "Cholangiocarcinoma is the second most common primary hepatic cancer, with a rising incidence worldwide." | 2.72 | A potential role for aspirin in the prevention and treatment of cholangiocarcinoma. ( Shen, X, 2021) |
| "Colorectal cancer is one of the commonest malignancies worldwide." | 2.72 | Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review. ( Amare, GG; Belayneh, YM; Meharie, BG, 2021) |
| "Invasive colorectal cancer incidence." | 2.72 | Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. ( Anderson, GL; Assaf, AR; Bassford, T; Beresford, SA; Black, HR; Bowen, D; Brunner, RL; Brzyski, RG; Caan, B; Chlebowski, RT; Gass, M; Harrigan, RC; Hays, J; Heber, D; Heiss, G; Hendrix, SL; Howard, BV; Hsia, J; Hubbell, FA; Jackson, RD; Johnson, KC; Kotchen, JM; Kuller, LH; LaCroix, AZ; Lane, DS; Langer, RD; Lasser, NL; Lewis, CE; Manson, JE; Margolis, KL; Mossavar-Rahmani, Y; Ockene, JK; Parker, LM; Perri, MG; Phillips, L; Prentice, RL; Ritenbaugh, C; Robbins, J; Rossouw, JE; Sarto, GE; Snetselaar, LG; Stefanick, ML; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Whitlock, E, 2006) |
| "Side effects, such as arrhythmia, angina pectoris, and nervous headache, were observed in the celecoxib 400 mg/d group." | 2.72 | [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis]. ( Geng, HG; Li, SR; Sheng, JQ; Su, H; Yan, W; Yang, XY; Yu, DL; Zhang, YH, 2006) |
| "In 10 patients with colorectal cancer, the urinary excretion of 11-dehydro-TXB(2) was significantly higher than in 10 controls, matched for sex, age and cardiovascular risk factors [1001(205-5571) versus 409(113-984) pg/mg creatinine, respectively, median (range), P<0." | 2.71 | Platelet activation in patients with colorectal cancer. ( Capone, ML; Carnevale, V; Filabozzi, P; Grana, M; Padovano, R; Patrignani, P; Ricciotti, E; Sciulli, MG; Tacconelli, S, 2005) |
| "Odds ratios (ORs) for adenoma recurrence were calculated using the lowest quartile of fiber intake as the reference." | 2.70 | Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial. ( Alberts, DS; Giuliano, AR; Guillén-Rodríguez, JM; Jacobs, ET; Martínez, ME; Roe, DJ, 2002) |
| " The adherence rates for all dosing errors between self-report and Medication Event Monitoring System were significantly different (P = ." | 2.68 | Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring. ( Brenner, DE; Burney, KD; Krishnan, K; Ruffin, MT; Zhang, D, 1996) |
| "Globally, colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second leading cause of cancer death." | 2.61 | Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. ( Giovannucci, E; Keum, N, 2019) |
| "The cause of colorectal cancer (CRC) is multifactorial, involving both genetic variants and environmental risk factors." | 2.61 | Gene-environment interactions and colorectal cancer risk: An umbrella review of systematic reviews and meta-analyses of observational studies. ( Campbell, H; Dunlop, MG; Farrington, SM; Ioannidis, JPA; Li, X; Little, J; Montazeri, Z; Theodoratou, E; Timofeeva, M; Yang, T, 2019) |
| "Aspirin also plays a role by its anti-inflammatory action and the stimulation of antitumor immunity." | 2.58 | [Aspirin and colorectal cancer]. ( Di Fiore, F; Grancher, A; Michel, P; Sefrioui, D, 2018) |
| "This syndrome results in early onset colorectal cancer, leukemia and lymphoma, brain tumors and other malignancies." | 2.58 | Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD). ( Brüggemann, RJ; Burn, J; Hoogerbrugge, N; Jongmans, MCJ; Kratz, C; Leenders, EKSM; Loeffen, J; Westdorp, H, 2018) |
| "Aspirin use was associated with a 29% lower colorectal cancer risk among never-smokers [odds ratios (OR) = 0." | 2.58 | Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-Inflammatory Drugs on Colorectal Cancer Risk. ( Brenner, H; Caan, B; Chan, AT; Chang-Claude, J; Gallinger, S; Hoffmeister, M; Hsu, L; Lampe, JW; Le Marchand, L; Newcomb, PA; Peters, U; Potter, JD; Schoen, RE; Slattery, ML; Wang, X; White, E; Zubair, N, 2018) |
| "Aspirin has been extensively investigated in the context of the prevention of cardiovascular disease." | 2.52 | Can We Select Patients for Colorectal Cancer Prevention with Aspirin? ( Arber, N; Kraus, S; Sion, D, 2015) |
| "Aspirin has been one of the most widely used medications since its first synthesis more than 100 years ago." | 2.52 | Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence. ( Huang, WK; See, LC; Tu, HT, 2015) |
| " Long-term use of NSAIDs has been associated with lowered risk of colorectal cancer (CRC), but the use is hampered by adverse effects." | 2.50 | Systematic review: interactions between aspirin, and other nonsteroidal anti-inflammatory drugs, and polymorphisms in relation to colorectal cancer. ( Andersen, V; Vogel, U, 2014) |
| "Several key factors involved in colorectal cancer pathogenesis have already been identified including cyclooxygenase 2 (COX-2), nuclear factor kappa B (NF-κB), survivin and insulin-like growth factor-I (IGF-I)." | 2.49 | Potential targets for colorectal cancer prevention. ( Mukherji, D; Shamseddine, A; Temraz, S, 2013) |
| "Aspirin reduced reported colorectal cancer (CRC) incidence (OR 0." | 2.49 | Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. ( Clarke, A; Connock, M; Freeman, K; Grove, A; Gurung, B; Gurung, T; Johnson, S; Kandala, NB; Morrow, S; Sutcliffe, P, 2013) |
| "Observational but also some randomized trials suggest that regular long-term use of aspirin (acetylsalicylic acid) might reduce the risk of colorectal carcinomas by 15-40%." | 2.49 | [Aspirin in primary and secondary prevention of colorectal carcinomas]. ( Rauch, B; Schrör, K, 2013) |
| "Over 600,000 people worldwide die of colorectal cancer (CRC) annually, highlighting the importance of developing effective prevention strategies." | 2.47 | Aspirin for the prevention of colorectal cancer. ( Chan, AT; Garcia-Albeniz, X, 2011) |
| "Recently, their potential roles as cancer chemopreventive agents have been subject to intensive studies." | 2.44 | Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. ( Xiao, H; Yang, CS, 2008) |
| " Optimal chemoprevention requires long-term use and high dose of aspirin that may increase the risk of gastrointestinal bleeding." | 2.44 | Chemoprevention of colorectal cancer: feasibility in everyday practice? ( Farinati, F; Herszényi, L; Miheller, P; Tulassay, Z, 2008) |
| "Colorectal cancer is a leading cause of cancer-related death globally, though in theory at least, it is eminently preventable in many cases." | 2.44 | Colorectal cancer prevention: choosing the most effective population strategy using bio-mathematical approaches. ( Luebeck, G; Renehan, AG, 2007) |
| " Long-term use of high-dose aspirin and NSAIDs is associated with significant gastrointestinal side effects." | 2.44 | Diabetes, colorectal cancer and cyclooxygenase 2 inhibition. ( Fisher, M; McKay, GA; Smith, CJ, 2008) |
| "Colorectal cancer is the second leading cause of mortality in the United States." | 2.43 | Colorectal cancer prevention. ( Hawk, ET; Levin, B, 2005) |
| " As well, we highlight current research around optimal dosage and other issues related to aspirin administration." | 2.43 | What every emergency nurse needs to know about aspirin. ( Smith, S; Turris, SA, 2005) |
| "Chemoprevention of colorectal cancer involves the long-term use of pharmacologic agents that can prevent neoplasms from developing in the large bowel." | 2.43 | Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer. ( Benamouzig, R; Chaussade, S; Little, J; Uzzan, B, 2005) |
| "For the prevention of oesophageal cancer, antitumour-B and retinamide have provided hopeful results, although it is not clear that these findings can be extrapolated from the study populations in Asia to western countries." | 2.43 | Chemoprevention in gastrointestinal cancers: current status. ( Baron, JA; Grau, MV; Rees, JR, 2006) |
| " However, long-term use of NSAIDs is associated with substantial gastrointestinal toxicity and may cause an exacerbation in IBD patients." | 2.43 | Chemoprevention for colon cancer: new opportunities, fact or fiction? ( Mulder, CJ; Terhaar Sive Droste, JS; Tuynman, JB; Van Dullemen, HM, 2006) |
| " Although NSAIDs are thought to protect from CRC, and long-term use of NSAIDs is common in the elderly, little is known about the impact of NSAID use on CRC risk at advanced age." | 2.43 | Do older adults using NSAIDs have a reduced risk of colorectal cancer? ( Brenner, H; Chang-Claude, J; Hoffmeister, M, 2006) |
| "Loss of function of the adenomatous polyposis coli (APC) tumour suppressor gene through truncating mutations or other means is an early event in most colo-rectal cancer (CRC)." | 2.42 | Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study. ( Bishop, DT; Burn, J; Chapman, PC; Mathers, JC; Mickleburgh, I, 2003) |
| "In the Sandler study 635 patients with colorectal cancer were randomised to receive 325 mg aspirin or placebo daily." | 2.42 | Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. ( Huls, G; Kleibeuker, JH; Koornstra, JJ, 2003) |
| "Evidence that chronic intake of non-steroidal anti-inflammatory drugs, especially aspirin, prevents cancer development continues to accumulate." | 2.42 | Cyclooxygenase inhibitors: drugs for cancer prevention. ( Santini, DL; Shiff, SJ; Shivaprasad, P, 2003) |
| "Nine trials with 150 familial adenomatous polyposis (FAP) and 24,143 population subjects met the inclusion criteria." | 2.42 | Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. ( Asano, TK; McLeod, RS, 2004) |
| "In familial and sporadic colorectal cancer, aspirin, other nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors have been tested for their ability to reduce polyp and cancer development in clinical studies." | 2.42 | Review article: the chemoprevention of colorectal carcinoma. ( Gasche, C, 2004) |
| " Chemoprevention of colorectal cancer that involves the long-term use of pharmacological agents as aspirin also seems to be effective." | 2.42 | Is colorectal cancer an avoidable disease nowadays? ( Benamouzig, R, 2004) |
| " There are now more than 15 epidemiological (case-control and cohort) studies indicating that long-term use of aspirin is associated with a reduced risk of colorectal cancer." | 2.41 | Aspirin and cancer risk: an update to 2001. ( Bosetti, C; Gallus, S; La Vecchia, C, 2002) |
| "The relative risk of colorectal cancer is about 0." | 2.41 | Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects. ( Sjödahl, R, 2001) |
| "Aspirin was introduced into clinical practice more than 100 years ago." | 2.41 | Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer. ( Lawrence, JR; Paterson, JR, 2001) |
| " The challenge for researchers and clinicians is to further understand which NSAIDs and what dosage and duration may provide the optimal benefit (if any), and to accurately construe the available current data on these agents for patients inquiring about these compounds." | 2.41 | An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II. ( Moyad, MA, 2001) |
| " Many epidemiologic studies have found that long-term use of NSAIDs is associated with a lower risk of colorectal cancer, adenomatous polyps, and, to some extent, other cancers." | 2.41 | Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. ( Henley, SJ; Patrono, C; Thun, MJ, 2002) |
| " When used long term, aspirin has significant adverse effects and is poorly tolerated." | 2.40 | Use and safety of aspirin in the chemoprevention of colorectal cancer. ( Singh, AK; Trotman, BW, 1998) |
| "Gastrointestinal cancers are among the leading sites of cancer and leading causes of cancer-related deaths." | 2.39 | Prevention of gastrointestinal cancer--the potential role of NSAIDs in colorectal cancer. ( Luk, GD, 1996) |
| " Existing epidemiological studies are limited by a lack of information about dosage and duration of aspirin use." | 2.39 | Aspirin and other nonsteroid anti-inflammatory drugs as cancer-preventive agents. ( Baron, JA; Greenberg, ER, 1996) |
| "Aspirin is a well-known non-steroid anti-inflammatory drug." | 1.91 | Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner. ( Hu, LP; Huang, S; Huang, WQ; Ji, J; Jiang, SH; Li, DX; Li, J; Sundquist, J; Sundquist, K; Xing, X; Xu, CJ; Yao, LL; Zhang, NQ; Zhang, XL; Zhang, ZG, 2023) |
| "Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent." | 1.91 | In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023) |
| "Antibiotics may alter colorectal cancer (CRC) risk due to gut dysbiosis." | 1.72 | Association between antibiotic consumption and colon and rectal cancer development in older individuals: A territory-wide study. ( Chan, EW; Cheung, KS; Hung, IFN; Leung, WK; Seto, WK; Tam, A; Wong, ICK; Wong, IOL, 2022) |
| "MUTYH carriers have an increased colorectal cancer risk in case-control studies, with loss of heterozygosity (LOH) as the presumed mechanism." | 1.72 | Incident Cancer Risk and Signatures Among Older MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts. ( Chan, AT; Downie, JM; Gala, M; Gibbs, P; Lacaze, P; Lee, M; Macrae, F; Mahady, SE; McNeil, JJ; Murray, AM; Orchard, SG; Riaz, M; Schadt, E; Sebra, RP; Woods, RL; Xie, J, 2022) |
| "Aspirin has recently been attracting attention as a cancer preventive drug, and its inhibitory effects on the development of various cancers have been reported in several large prospective studies." | 1.72 | Salicylic acid directly binds to ribosomal protein S3 and suppresses CDK4 expression in colorectal cancer cells. ( Aono, Y; Horinaka, M; Iizumi, Y; Imai, A; Ishikawa, H; Mutoh, M; Nishimoto, E; Ono, H; Sakai, T; Takakura, H; Taniguchi, K; Yasuda, S, 2022) |
| "In laparoscopic surgery for colorectal cancer (CRC) for patients who receive antiplatelet therapy (APT), it remains unclear whether APT should be continued or temporarily withdrawn." | 1.62 | Impact of perioperative aspirin continuation on bleeding complications in laparoscopic colorectal cancer surgery: a propensity score-matched analysis. ( Fujikawa, T; Takahashi, R, 2021) |
| "However, EPA has only modest anti-colorectal cancer (CRC) activity, when used alone." | 1.62 | Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. ( Coletta, PL; Hull, MA; Hutchinson, JM; Ingram, N; Loadman, PM; Marshall, C; Nicolaou, A; Perry, SL; Race, AD; Spencer, J; Volpato, M, 2021) |
| "Aspirin was viewed as a safe and cheap option for cancer prevention." | 1.62 | Clinicians' opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50-70 years: a qualitative study. ( Alphonse, P; Emery, J; Karnchanachari, N; Lau, P; Macrae, F; McIntosh, J; Milton, S; Nguyen, P; Saya, S; Yogaparan, T, 2021) |
| "Chemoprevention against colorectal cancer (CRC) is greatly needed." | 1.62 | Combined Use of Aspirin and Selective Serotonin Reuptake Inhibitors Is Associated With Lower Risk of Colorectal Cancer: A Nested Case-Control Study. ( Ji, J; Sundquist, J; Sundquist, K; Zhang, N; Zhang, ZG, 2021) |
| " An initial dosing study performed in healthy mice indicates that aspirin at a dose of 25 mg/kg/d has a similar pharmacodynamic effect as low-dose aspirin treatment in human subjects (100 mg/d)." | 1.56 | Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis. ( Hartung, NM; Kühl, AA; McDonald, FM; Ostermann, AI; Rohwer, N; Schebb, NH; Weylandt, KH; Zopf, D, 2020) |
| "Non-aspirin NSAIDs were associated with lower PCCRC risk after a negative baseline colonoscopy." | 1.56 | Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer. ( Chan, EW; Chen, L; Cheung, KS; Leung, WK; Seto, WK; Wong, ICK, 2020) |
| "Distant metastatic colorectal cancer (CRC) is present in approximately 25% of patients at initial diagnosis, and eventually half of CRC patients will develop metastatic disease." | 1.56 | Identification of the Effects of Aspirin and Sulindac Sulfide on the Inhibition of HMGA2-Mediated Oncogenic Capacities in Colorectal Cancer. ( Chang, HY; Chen, HY; Ekanem, TI; Huang, TC; Lee, KH; Lin, YH; Tan, WQ; Tsai, WL, 2020) |
| "Risk models for advanced colorectal neoplasms generally yielded modest discriminatory power, despite some variation in performance between models." | 1.51 | Head-to-Head Comparison of the Performance of 17 Risk Models for Predicting Presence of Advanced Neoplasms in Colorectal Cancer Screening. ( Balavarca, Y; Brenner, H; Hoffmeister, M; Peng, L; Weigl, K, 2019) |
| " The aspirin analogues fumaryldiaspirin (PN517) and the benzoylsalicylates (PN524, PN528 and PN529), were observed to be more toxic against the OC cell lines than aspirin." | 1.51 | The Cytotoxicity and Synergistic Potential of Aspirin and Aspirin Analogues Towards Oesophageal and Colorectal Cancer. ( Bashir, AIJ; Devitt, A; Kilari, RS; Nicholl, ID; Perry, CJ; Safrany, ST, 2019) |
| "Aspirin has been found to inhibit cancer cell viability and promote CRC cell apoptosis." | 1.51 | Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway. ( Du, Y; Duan, X; Li, H; Liu, J; Ma, B; Su, C; Yang, S; Yang, X; Zhang, D; Zhou, Q, 2019) |
| "Most colorectal cancers arise from preexisting adenomatous or serrated polyps." | 1.48 | Colorectal Cancer Screening and Prevention. ( McMechan, D; Talukder, A; Wilkins, T, 2018) |
| "A one-dose-fits-all approach to use of aspirin has yielded only modest benefits in long-term prevention of cardiovascular events, possibly due to underdosing in patients of large body size and excess dosing in patients of small body size, which might also affect other outcomes." | 1.48 | Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. ( Belch, JFF; Cook, NR; Gaziano, JM; Mehta, Z; Morimoto, T; Price, JF; Roncaglioni, MC; Rothwell, PM, 2018) |
| "Aspirin has been associated with reduced incidence and mortality of colorectal and a few other cancers." | 1.48 | Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy. ( Barchielli, A; Manneschi, G; Mantellini, P; Miccinesi, G; Orso, F; Puliti, D; Ventura, L; Zappa, M, 2018) |
| "FH of colorectal cancer (CRC) (8." | 1.43 | Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. ( Campana, D; Capurso, G; Cicchese, N; Delle Fave, G; Falconi, M; Fazio, N; Panzuto, F; Partelli, S; Rinzivillo, M; Spada, F; Tomassetti, P, 2016) |
| "Few large studies have evaluated the adverse events associated with therapeutic colonoscopy for colorectal neoplasia, including bleeding and bowel perforation." | 1.43 | Factors predicting adverse events associated with therapeutic colonoscopy for colorectal neoplasia: a retrospective nationwide study in Japan. ( Fushimi, K; Hirata, Y; Koike, K; Matsui, H; Niikura, R; Yamada, A; Yasunaga, H, 2016) |
| "Evidence for cancer prophylaxis is based on ASA doses of at least 75mg/day." | 1.43 | Aspirin for cancer is no mere antiplatelet prototype. There is potential in its ancient roots. ( Baxter, GJ; Lawrence, JR; Paterson, JR, 2016) |
| "We identified 14,743 individuals with colorectal cancer and 5888 with lung cancer." | 1.42 | Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis. ( Auer, G; Czene, K; Pawitan, Y; Setiawan, A; Smedby, KE; Yin, L, 2015) |
| " However, there are still open questions, regarding the benefit/risk ratio (bleedings) as well as dosage and duration of treatment during the probably long-term medication, before stringent recommendations regarding clinical use of aspirin can be made." | 1.39 | [Aspirin and prevention of colorectal carcinomas]. ( Rauch, BH; Schrör, K, 2013) |
| "Two SNPs in TXNRD3 were associated with rectal cancer (rs11718498 dominant OR 1." | 1.38 | Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer. ( Corcoran, C; Lundgreen, A; Slattery, ML; Welbourn, B; Wolff, RK, 2012) |
| "Aspirin was added to human colon cancer cells (HT-29 and RKO) or to PBMC incubated separately or jointly." | 1.37 | Inflammation and colorectal cancer: does aspirin affect the interaction between cancer and immune cells? ( Bergman, M; Bessler, H; Djaldetti, M; Salman, H, 2011) |
| "NSAID use prior to colorectal cancer diagnosis was associated with an ~20% lower rate of colorectal cancer mortality after diagnosis compared with never use (HR 0." | 1.37 | Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. ( Adams, SV; Burnett-Hartman, AN; Campbell, PT; Coghill, AE; Newcomb, PA; Poole, EM; Potter, JD; Ulrich, CM, 2011) |
| "Colorectal cancer is the third most common cancer and is associated with significant morbidity and mortality." | 1.37 | Activity of aspirin analogues and vanillin in a human colorectal cancer cell line. ( Deb, J; Dibra, H; Kankipati, CS; Manneh, J; Nicholl, ID; Perry, CJ; Rajan, S; Shan, S, 2011) |
| "Aspirin intake was associated with reduced risk for sinusoidal lesions (P = ." | 1.35 | Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. ( Beauchet, A; Benoist, S; Brouquet, A; Julie, C; Nordlinger, B; Penna, C; Rougier, P, 2009) |
| " We assessed the presence of duration-response and dose-response effects." | 1.34 | Chronic proton pump inhibitor therapy and the risk of colorectal cancer. ( Hennessy, S; Hwang, WT; Lewis, JD; Propert, K; Sedarat, A; Yang, YX, 2007) |
| "The associations between colorectal cancer risk and several chronic illnesses, operations and various medications were examined in 715 colorectal cancer cases and 727 age- and sex-matched controls in data derived from a large, comprehensive population-based study of this cancer conducted in Melbourne, Australia." | 1.34 | Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. ( Kune, GA; Kune, S; Watson, LF, 2007) |
| "In aspirin-treated cultures the mutation rate was 8." | 1.33 | Mesalazine improves replication fidelity in cultured colorectal cells. ( Boland, CR; Gasche, C; Goel, A; Natarajan, L, 2005) |
| "It has been suggested that Barrett's esophagus (BE) is associated with an increased risk of developing colorectal neoplasia, but this has not been reported consistently." | 1.33 | Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use. ( Kuipers, EJ; Sahbaie, P; Siersema, PD; Simpson, PW; Steyerberg, EW; Triadafilopoulos, G; Yu, S, 2006) |
| "In addition, diverticular bleeding in the elderly was highly associated with intake of Aspirin." | 1.33 | [Epidemiology of gastrointestinal bleeding in the elderly]. ( Bertschinger, P; Bühler, H; Geyer, M; Stamenic, I, 2006) |
| "The SIR for colorectal cancer was close to unity (SIR, 0." | 1.32 | A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. ( Blot, WJ; Friis, S; Johnsen, SP; McLaughlin, JK; Olsen, JH; Sørensen, HT, 2003) |
| "To prospectively examine the association between non-steroidal anti-inflammatory drugs (NSAIDs) use (including dose and dosage schedule) and the recurrence of colorectal adenomas among individuals who were diagnosed with an adenoma at entry into a clinical trial." | 1.32 | Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). ( Albert, PS; Burt, R; Caan, B; Corle, D; Hasson, M; Iber, F; Kikendall, JW; Lance, P; Lanza, E; Paskett, E; Schatzkin, A; Shike, M; Tangrea, JA; Weissfeld, J; Woodson, K, 2003) |
| "For people with an increased risk of colorectal cancer, acetylsalicylic acid only has a partial effect and therefore endoscopic surveillance is still indicated." | 1.32 | [Prevention of colorectal cancer: acetylsalicyclic acid and cyclo-oxygenase-2 inhibitors are only partially effective]. ( de Vries, EG; Kleibeuker, JH, 2003) |
| "The aspirin group also was modeled to have a decreased rate of coronary ischemic events; however, decreased CRC mortality was not modeled in either group based on the assumption that the two treatments were effective equally in this regard." | 1.32 | The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. ( Gazelle, GS; Hur, C; Simon, LS, 2004) |
| "Aspirin was the most prospective chemopreventive agents for colorectal polyp, colon and rectal carcinoma for its capability of reducing the risk of cardio-cerebral vascular disease as well." | 1.31 | [Nonsteroidal anti-inflammatory drugs and the risk of polyposis, colon carcinoma and rectal carcinoma]. ( Gao, X; Li, M; Song, S; Sun, F; Sun, H; Sun, S; Zhang, W, 2002) |
| "NSAIDs act on human colorectal cancer cells via different mechanisms." | 1.31 | The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. ( Hawcroft, G; Hull, MA; Smith, ML, 2000) |
| "Studies from hereditary and sporadic colorectal cancer (CRC) patients suggest that NSAIDs may interfere with initiating steps of carcinogenesis, i." | 1.31 | The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. ( Dihlmann, S; Siermann, A; von Knebel Doeberitz, M, 2001) |
| "Colorectal cancer is the second leading cause of death from cancer in the United States." | 1.29 | G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. ( Beauchamp, RD; DuBois, RN; Shao, J; Sheng, H; Tsujii, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.14) | 18.7374 |
| 1990's | 73 (10.52) | 18.2507 |
| 2000's | 199 (28.67) | 29.6817 |
| 2010's | 292 (42.07) | 24.3611 |
| 2020's | 129 (18.59) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, S | 1 |
| Obianom, ON | 1 |
| Ai, Y | 1 |
| Xiao, S | 1 |
| Xie, W | 1 |
| Fan, Y | 1 |
| Zhou, L | 1 |
| Yaqub, S | 3 |
| Bjørnbeth, BA | 3 |
| Angelsen, JH | 1 |
| Fristrup, CW | 1 |
| Grønbech, JE | 1 |
| Hemmingsson, O | 1 |
| Isaksson, B | 1 |
| Juel, IS | 1 |
| Larsen, PN | 1 |
| Lindell, G | 1 |
| Mortensen, FV | 1 |
| Mortensen, KE | 1 |
| Rizell, M | 1 |
| Sandström, P | 1 |
| Sandvik, OM | 1 |
| Sparrelid, E | 1 |
| Taflin, H | 1 |
| Taskén, K | 3 |
| Jung, YS | 2 |
| Im, E | 1 |
| Park, CH | 2 |
| Nounu, A | 2 |
| Richmond, RC | 2 |
| Stewart, ID | 1 |
| Surendran, P | 1 |
| Wareham, NJ | 1 |
| Butterworth, A | 1 |
| Weinstein, SJ | 2 |
| Albanes, D | 2 |
| Baron, JA | 43 |
| Hopper, JL | 5 |
| Figueiredo, JC | 9 |
| Newcomb, PA | 9 |
| Lindor, NM | 6 |
| Casey, G | 5 |
| Platz, EA | 2 |
| Marchand, LL | 3 |
| Ulrich, CM | 10 |
| Li, CI | 3 |
| van Dujinhoven, FJB | 1 |
| Gsur, A | 2 |
| Campbell, PT | 5 |
| Moreno, V | 3 |
| Vodicka, P | 2 |
| Vodickova, L | 2 |
| Amitay, E | 1 |
| Alwers, E | 1 |
| Chang-Claude, J | 7 |
| Sakoda, LC | 2 |
| Slattery, ML | 6 |
| Schoen, RE | 5 |
| Gunter, MJ | 2 |
| Castellví-Bel, S | 2 |
| Kim, HR | 2 |
| Kweon, SS | 2 |
| Chan, AT | 46 |
| Li, L | 3 |
| Zheng, W | 2 |
| Bishop, DT | 8 |
| Buchanan, DD | 4 |
| Giles, GG | 3 |
| Gruber, SB | 2 |
| Rennert, G | 2 |
| Stadler, ZK | 2 |
| Harrison, TA | 3 |
| Lin, Y | 3 |
| Keku, TO | 3 |
| Woods, MO | 2 |
| Schafmayer, C | 2 |
| Van Guelpen, B | 2 |
| Gallinger, S | 4 |
| Hampel, H | 2 |
| Berndt, SI | 4 |
| Pharoah, PDP | 2 |
| Lindblom, A | 5 |
| Wolk, A | 3 |
| Wu, AH | 2 |
| White, E | 4 |
| Peters, U | 5 |
| Drew, DA | 8 |
| Scherer, D | 4 |
| Bermejo, JL | 2 |
| Brenner, H | 11 |
| Hoffmeister, M | 8 |
| Williams, AC | 3 |
| Relton, CL | 2 |
| Wang, YS | 1 |
| Huang, NK | 1 |
| Lin, YC | 2 |
| Chang, WC | 1 |
| Huang, WC | 1 |
| Ishikawa, H | 8 |
| Harino, T | 1 |
| Noura, S | 1 |
| Hamabe, A | 1 |
| Ogino, T | 1 |
| Takeyama, H | 1 |
| Suzuki, Y | 1 |
| Tanida, T | 1 |
| Tomita, N | 1 |
| Dono, K | 1 |
| Mädge, JC | 1 |
| Stallmach, A | 1 |
| Kleebusch, L | 1 |
| Schlattmann, P | 1 |
| Arai, J | 1 |
| Suzuki, N | 2 |
| Niikura, R | 5 |
| Ooki, D | 1 |
| Kawahara, T | 1 |
| Honda, T | 1 |
| Hasatani, K | 1 |
| Yoshida, N | 2 |
| Nishida, T | 1 |
| Sumiyoshi, T | 1 |
| Kiyotoki, S | 1 |
| Ikeya, T | 1 |
| Arai, M | 1 |
| Ishibashi, R | 1 |
| Aoki, T | 2 |
| Tsuji, Y | 1 |
| Yamamichi, N | 1 |
| Hayakawa, Y | 2 |
| Fujishiro, M | 2 |
| Bakshi, A | 2 |
| Cao, Y | 9 |
| Orchard, SG | 3 |
| Carr, PR | 2 |
| Joshi, AD | 2 |
| Manning, AK | 1 |
| Umar, A | 4 |
| Winship, IM | 2 |
| Gibbs, P | 3 |
| Zalcberg, JR | 2 |
| Macrae, F | 11 |
| McNeil, JJ | 3 |
| Lacaze, P | 2 |
| Wang, Y | 3 |
| Boland, CR | 7 |
| Goel, A | 5 |
| Wodarz, D | 3 |
| Komarova, NL | 3 |
| Davidson, KW | 1 |
| Barry, MJ | 1 |
| Mangione, CM | 1 |
| Cabana, M | 1 |
| Chelmow, D | 1 |
| Coker, TR | 1 |
| Davis, EM | 1 |
| Donahue, KE | 1 |
| Jaén, CR | 1 |
| Krist, AH | 1 |
| Kubik, M | 1 |
| Ogedegbe, G | 1 |
| Pbert, L | 1 |
| Ruiz, JM | 1 |
| Stevermer, J | 1 |
| Tseng, CW | 1 |
| Wong, JB | 1 |
| Dehmer, SP | 3 |
| O'Keefe, LR | 1 |
| Evans, CV | 2 |
| Guirguis-Blake, JM | 2 |
| Perdue, LA | 2 |
| Maciosek, MV | 3 |
| Bean, SI | 1 |
| Senger, CA | 1 |
| Ji, YY | 1 |
| Jiang, TT | 1 |
| Sun, TK | 1 |
| Wang, ZD | 1 |
| Jodal, HC | 1 |
| Bretthauer, M | 4 |
| Kalager, M | 3 |
| Løberg, M | 3 |
| Cheung, KS | 6 |
| Chan, EW | 5 |
| Tam, A | 1 |
| Wong, IOL | 1 |
| Seto, WK | 2 |
| Hung, IFN | 1 |
| Wong, ICK | 5 |
| Leung, WK | 8 |
| Ho, PH | 1 |
| Hsiao, HC | 1 |
| Chen, CW | 1 |
| Chen, HM | 1 |
| Lim, SN | 1 |
| Yeh, CT | 1 |
| Kuo, CJ | 1 |
| Lin, WR | 1 |
| Pang, SJ | 1 |
| Lin, ZP | 1 |
| Sun, Z | 1 |
| Zhang, Y | 9 |
| Yuan, ZG | 1 |
| Yang, N | 1 |
| Downie, JM | 1 |
| Riaz, M | 1 |
| Xie, J | 1 |
| Lee, M | 2 |
| Mahady, SE | 1 |
| Sebra, RP | 1 |
| Murray, AM | 1 |
| Schadt, E | 1 |
| Woods, RL | 1 |
| Gala, M | 2 |
| Barry, EL | 18 |
| Fedirko, V | 4 |
| Jin, Y | 2 |
| Liu, K | 2 |
| Mott, LA | 10 |
| Peacock, JL | 2 |
| Passarelli, MN | 5 |
| Jones, DP | 2 |
| Shahrivar, M | 1 |
| Weibull, CE | 1 |
| Ekström Smedby, K | 1 |
| Glimelius, B | 1 |
| Syk, I | 1 |
| Matthiessen, P | 1 |
| Nordenvall, C | 1 |
| Martling, A | 1 |
| Kumar, VL | 3 |
| Verma, S | 3 |
| Das, P | 3 |
| Zaman, FY | 1 |
| Haydon, A | 1 |
| Hall, DCN | 1 |
| Benndorf, RA | 1 |
| Mathers, JC | 4 |
| Elliott, F | 3 |
| Mecklin, JP | 3 |
| Möslein, G | 2 |
| McRonald, FE | 1 |
| Bertario, L | 3 |
| Evans, DG | 3 |
| Gerdes, AM | 1 |
| Ho, JWC | 1 |
| Morrison, PJ | 3 |
| Rashbass, J | 1 |
| Ramesar, RS | 2 |
| Seppälä, TT | 1 |
| Thomas, HJW | 1 |
| Sheth, HJ | 1 |
| Pylvänäinen, K | 1 |
| Reed, L | 1 |
| Borthwick, GM | 1 |
| Burn, J | 11 |
| Grancher, A | 2 |
| Michel, P | 2 |
| Di Fiore, F | 2 |
| Sefrioui, D | 2 |
| Chen, Y | 4 |
| Sun, L | 1 |
| Li, D | 1 |
| Yin, X | 1 |
| Shang, G | 1 |
| Diao, T | 1 |
| Shi, L | 1 |
| Shureiqi, I | 3 |
| Otani, T | 2 |
| Goto, C | 2 |
| Matsuda, T | 2 |
| Takeuchi, Y | 2 |
| Sano, Y | 1 |
| Itoh, Y | 1 |
| Suzuki, S | 3 |
| Mutoh, M | 7 |
| Imai, A | 1 |
| Horinaka, M | 1 |
| Aono, Y | 1 |
| Iizumi, Y | 1 |
| Takakura, H | 1 |
| Ono, H | 1 |
| Yasuda, S | 1 |
| Taniguchi, K | 1 |
| Nishimoto, E | 1 |
| Sakai, T | 4 |
| Koulaouzidis, G | 1 |
| Charisopoulou, D | 1 |
| Marlicz, W | 1 |
| Davis, JS | 1 |
| Chavez, JC | 1 |
| Kok, M | 1 |
| San Miguel, Y | 1 |
| Lee, HY | 1 |
| Henderson, H | 1 |
| Overman, MJ | 1 |
| Morris, V | 1 |
| Kee, B | 1 |
| Fogelman, D | 1 |
| Advani, SM | 1 |
| Johnson, B | 1 |
| Parseghian, C | 1 |
| Shen, JP | 1 |
| Dasari, A | 1 |
| Shaw, KR | 1 |
| Vilar, E | 2 |
| Raghav, KP | 1 |
| Wolff, RA | 1 |
| Meric-Bernstam, F | 1 |
| Maru, D | 1 |
| Menter, DG | 1 |
| Kopetz, S | 1 |
| Chang, S | 1 |
| Star, J | 1 |
| Han, X | 1 |
| Makaroff, LA | 1 |
| Minihan, AK | 1 |
| Jemal, A | 1 |
| Bandi, P | 1 |
| Shami, JJP | 3 |
| Yan, VKC | 3 |
| Wei, Y | 3 |
| Alwafi, H | 3 |
| Blais, JE | 3 |
| Wan, E | 3 |
| Wong, CKH | 3 |
| Wong, MCS | 3 |
| Kowalczyk, M | 1 |
| Sigorski, D | 1 |
| Dyśko, Ł | 1 |
| Zieliński, E | 1 |
| Zupanovich Lucka, D | 1 |
| Klepacki, Ł | 1 |
| Nafisi, S | 1 |
| Randel, KR | 2 |
| Støer, NC | 1 |
| Veierød, MB | 1 |
| Hoff, G | 3 |
| Holme, Ø | 4 |
| Schult, AL | 1 |
| Botteri, E | 3 |
| Florensa, D | 1 |
| Mateo, J | 1 |
| Solsona, F | 1 |
| Galván, L | 1 |
| Mesas, M | 1 |
| Piñol, R | 1 |
| Espinosa-Leal, L | 1 |
| Godoy, P | 1 |
| Huang, S | 1 |
| Zhang, NQ | 1 |
| Xu, CJ | 1 |
| Huang, WQ | 1 |
| Li, DX | 1 |
| Li, J | 4 |
| Yao, LL | 1 |
| Sundquist, K | 2 |
| Sundquist, J | 2 |
| Jiang, SH | 1 |
| Xing, X | 1 |
| Hu, LP | 1 |
| Zhang, ZG | 2 |
| Ji, J | 2 |
| Zhang, XL | 1 |
| Elmowafy, M | 1 |
| Shalaby, K | 1 |
| Elkomy, MH | 1 |
| Alsaidan, OA | 1 |
| Gomaa, HAM | 1 |
| Hendawy, OM | 1 |
| Abdelgawad, MA | 1 |
| Ali, HM | 1 |
| Ahmed, YM | 1 |
| El-Say, KM | 1 |
| Monahan, KJ | 1 |
| Swinyard, O | 1 |
| Latchford, A | 1 |
| Ma, Y | 1 |
| You, W | 1 |
| He, X | 1 |
| Wang, J | 3 |
| Loomans-Kropp, HA | 2 |
| Patrono, C | 7 |
| Day, D | 1 |
| Toh, HC | 5 |
| Ali, R | 4 |
| Foo, EMJ | 1 |
| Simes, J | 1 |
| Chia, JWK | 1 |
| Segelov, E | 2 |
| Joharatnam-Hogan, N | 2 |
| Hatem, D | 1 |
| Cafferty, FH | 2 |
| Petrucci, G | 1 |
| Cameron, DA | 1 |
| Ring, A | 3 |
| Kynaston, HG | 1 |
| Gilbert, DC | 1 |
| Wilson, RH | 2 |
| Hubner, RA | 5 |
| Swinson, DEB | 1 |
| Cleary, S | 1 |
| Robbins, A | 1 |
| MacKenzie, M | 2 |
| Scott-Brown, MWG | 1 |
| Sothi, S | 2 |
| Dawson, LK | 1 |
| Capaldi, LM | 1 |
| Churn, M | 1 |
| Cunningham, D | 1 |
| Khoo, V | 1 |
| Armstrong, AC | 1 |
| Ainsworth, NL | 1 |
| Horan, G | 1 |
| Wheatley, DA | 1 |
| Mullen, R | 1 |
| Lofts, FJ | 1 |
| Walther, A | 1 |
| Herbertson, RA | 1 |
| Eaton, JD | 1 |
| O'Callaghan, A | 1 |
| Eichholz, A | 1 |
| Kagzi, MM | 1 |
| Patterson, DM | 1 |
| Narahari, K | 1 |
| Bradbury, J | 1 |
| Stokes, Z | 1 |
| Rizvi, AJ | 1 |
| Walker, GA | 1 |
| Kunene, VL | 1 |
| Srihari, N | 1 |
| Gentry-Maharaj, A | 1 |
| Meade, A | 1 |
| Rocca, B | 1 |
| Langley, RE | 3 |
| Shah, D | 1 |
| Di Re, A | 1 |
| Toh, JWT | 1 |
| Susan, M | 1 |
| Macasoi, I | 1 |
| Pinzaru, I | 1 |
| Dehelean, C | 1 |
| Ilia, I | 1 |
| Susan, R | 1 |
| Ionita, I | 1 |
| Downing, A | 2 |
| Fenton, H | 1 |
| Nickerson, C | 1 |
| Loadman, PM | 5 |
| Williams, EA | 3 |
| Rees, CJ | 5 |
| Brown, LC | 2 |
| Morris, EJA | 1 |
| Hull, MA | 10 |
| Park, JH | 1 |
| Barber, LE | 1 |
| Bertrand, KA | 1 |
| Sheehy, S | 1 |
| White, LF | 1 |
| Roy, HK | 2 |
| Rosenberg, L | 1 |
| Palmer, JR | 1 |
| Petrick, JL | 1 |
| Chen, D | 1 |
| Huang, F | 1 |
| Zhang, X | 5 |
| Zhou, Y | 2 |
| Xu, L | 2 |
| Davies, JR | 1 |
| Mell, T | 1 |
| Fuller, H | 1 |
| Harland, M | 1 |
| Saleh, RNM | 1 |
| Race, AD | 2 |
| Minihane, AM | 1 |
| Liu, C | 2 |
| Rokavec, M | 1 |
| Huang, Z | 1 |
| Hermeking, H | 1 |
| Onwuka, S | 1 |
| McIntosh, J | 4 |
| Boyd, L | 2 |
| Karnchanachari, N | 3 |
| Fishman, G | 2 |
| Emery, J | 3 |
| Shinozaki, T | 2 |
| Koike, K | 5 |
| Rees, JR | 5 |
| Zhang, D | 4 |
| Ahnen, DJ | 14 |
| Bresalier, RS | 12 |
| Haile, RW | 15 |
| McKeown-Eyssen, G | 7 |
| Snover, DC | 3 |
| Cole, BF | 8 |
| Fletcher, RH | 2 |
| Keum, N | 2 |
| Giovannucci, E | 11 |
| Peng, L | 1 |
| Balavarca, Y | 1 |
| Weigl, K | 1 |
| Cafferty, F | 1 |
| Hubner, R | 1 |
| Swinson, D | 1 |
| Gupta, K | 1 |
| Falk, S | 1 |
| Patel, K | 1 |
| Warner, N | 1 |
| Kunene, V | 1 |
| Rowley, S | 2 |
| Khabra, K | 1 |
| Underwood, T | 1 |
| Jankowski, J | 3 |
| Bridgewater, J | 1 |
| Crossley, A | 1 |
| Henson, V | 1 |
| Berkman, L | 2 |
| Gilbert, D | 2 |
| Kynaston, H | 2 |
| Cameron, D | 2 |
| Din, F | 1 |
| Graham, J | 1 |
| Iveson, T | 1 |
| Adams, R | 1 |
| Thomas, A | 1 |
| Wilson, R | 1 |
| Pramesh, CS | 2 |
| Langley, R | 1 |
| Seaton, ME | 1 |
| Johnson, KC | 2 |
| Kooperberg, C | 1 |
| Bafford, A | 1 |
| Zubair, N | 2 |
| Won, D | 1 |
| Kim, JS | 1 |
| Ji, JS | 1 |
| Kim, BW | 1 |
| Choi, H | 1 |
| Tran, PHL | 2 |
| Wang, T | 3 |
| Yin, W | 2 |
| Tran, TTD | 2 |
| Nguyen, TNG | 2 |
| Lee, BJ | 2 |
| Duan, W | 2 |
| Nguyen, P | 2 |
| Bickerstaffe, A | 1 |
| Maddumarachchi, S | 1 |
| Cummings, KL | 1 |
| Emery, JD | 1 |
| Sankaranarayanan, R | 4 |
| Valiveti, CK | 1 |
| Dachineni, R | 2 |
| Kumar, DR | 4 |
| Lick, T | 1 |
| Bhat, GJ | 4 |
| Wang, X | 4 |
| Luo, Y | 2 |
| Chen, T | 1 |
| Zhang, K | 1 |
| Miyamoto, K | 1 |
| Takashima, A | 1 |
| Mizusawa, J | 1 |
| Sato, Y | 2 |
| Shimada, Y | 1 |
| Katayama, H | 1 |
| Nakamura, K | 1 |
| Shibata, T | 1 |
| Fukuda, H | 1 |
| Shida, D | 1 |
| Kanemitsu, Y | 1 |
| Hamaguchi, T | 1 |
| Pinsky, P | 1 |
| Shimura, T | 1 |
| Toden, S | 1 |
| Boland, C | 1 |
| Ranger, GS | 1 |
| McKinley-Brown, C | 1 |
| Rogerson, E | 1 |
| Schimp-Manuel, K | 1 |
| Kwon, S | 1 |
| Low, EE | 1 |
| Demb, J | 1 |
| Liu, L | 3 |
| Earles, A | 1 |
| Bustamante, R | 1 |
| Williams, CD | 1 |
| Provenzale, D | 2 |
| Kaltenbach, T | 2 |
| Gawron, AJ | 1 |
| Martinez, ME | 4 |
| Gupta, S | 4 |
| Rohwer, N | 1 |
| Kühl, AA | 1 |
| Ostermann, AI | 1 |
| Hartung, NM | 1 |
| Schebb, NH | 1 |
| Zopf, D | 1 |
| McDonald, FM | 1 |
| Weylandt, KH | 1 |
| Chen, Z | 2 |
| Wang, C | 2 |
| Dong, H | 1 |
| Gao, F | 2 |
| Zhang, S | 1 |
| Ürün, YY | 1 |
| Aydemir, S | 1 |
| Zhuo, M | 1 |
| Chen, W | 3 |
| Shang, S | 1 |
| Guo, P | 1 |
| Peng, K | 1 |
| Li, M | 5 |
| Mo, P | 1 |
| Qiu, X | 1 |
| Li, W | 3 |
| Yu, C | 1 |
| Mak, JWY | 1 |
| So, J | 1 |
| Tang, W | 1 |
| Yip, TCF | 1 |
| Lo, FH | 1 |
| Ng, KM | 1 |
| Sze, SF | 1 |
| Leung, CM | 1 |
| Tsang, SWC | 1 |
| Shan, EHS | 1 |
| Chan, KH | 1 |
| Lam, BCY | 1 |
| Hui, AJ | 1 |
| Chow, WH | 1 |
| Chan, FKL | 2 |
| Ng, SC | 1 |
| Clapper, ML | 1 |
| Chang, WL | 1 |
| Cooper, HS | 1 |
| Chen, L | 1 |
| Bosetti, C | 3 |
| Santucci, C | 2 |
| Gallus, S | 3 |
| Martinetti, M | 1 |
| La Vecchia, C | 5 |
| Giorli, G | 1 |
| Rouette, J | 1 |
| Yin, H | 1 |
| Lapi, F | 1 |
| Simonetti, M | 1 |
| Cricelli, C | 1 |
| Pollak, M | 1 |
| Azoulay, L | 2 |
| Takahashi, R | 1 |
| Fujikawa, T | 2 |
| Meiser, B | 2 |
| Kaur, R | 2 |
| Kirk, J | 2 |
| Morrow, A | 1 |
| Peate, M | 2 |
| Wong, WKT | 1 |
| McPike, E | 1 |
| Cops, E | 1 |
| Dowson, C | 1 |
| Austin, R | 1 |
| Fine, M | 1 |
| Thrupp, L | 1 |
| Ward, R | 1 |
| Hiller, JE | 1 |
| Trainer, AH | 2 |
| Mitchell, G | 2 |
| Zhao, R | 1 |
| Coker, OO | 1 |
| Wu, J | 2 |
| Zhao, L | 2 |
| Nakatsu, G | 2 |
| Bian, X | 1 |
| Wei, H | 1 |
| Chan, AWH | 1 |
| Sung, JJY | 2 |
| El-Omar, E | 1 |
| Yu, J | 1 |
| Patel, J | 1 |
| Jacobsen, AP | 1 |
| Khiew, YC | 1 |
| Blumenthal, RS | 1 |
| Martin, SS | 1 |
| Ray, K | 1 |
| Yurgelun, MB | 1 |
| Lin, JL | 1 |
| Lin, JX | 1 |
| Zheng, CH | 1 |
| Li, P | 2 |
| Xie, JW | 1 |
| Wang, JB | 1 |
| Lu, J | 2 |
| Chen, QY | 1 |
| Cao, LL | 1 |
| Lin, M | 1 |
| Huang, CM | 1 |
| Uppal, K | 1 |
| Ma, C | 1 |
| Troelsen, FS | 1 |
| Farkas, DK | 1 |
| Erichsen, R | 2 |
| Sørensen, HT | 6 |
| Prizment, AE | 3 |
| Staley, C | 1 |
| Onyeaghala, GC | 2 |
| Vivek, S | 1 |
| Thyagarajan, B | 1 |
| Straka, RJ | 1 |
| Demmer, RT | 1 |
| Knights, D | 1 |
| Meyer, KA | 1 |
| Shaukat, A | 2 |
| Sadowsky, MJ | 1 |
| Church, TR | 6 |
| Diao, F | 1 |
| Cai, S | 1 |
| Ekanem, TI | 1 |
| Tsai, WL | 1 |
| Lin, YH | 1 |
| Tan, WQ | 1 |
| Chang, HY | 1 |
| Huang, TC | 1 |
| Chen, HY | 1 |
| Lee, KH | 1 |
| Soualy, A | 1 |
| Deutsch, D | 1 |
| Benallaoua, M | 1 |
| Ait-Omar, A | 1 |
| Mary, F | 1 |
| Helfen, S | 1 |
| Boubaya, M | 1 |
| Levy, V | 1 |
| Benamouzig, R | 14 |
| Chapelle, N | 1 |
| Martel, M | 1 |
| Toes-Zoutendijk, E | 1 |
| Barkun, AN | 1 |
| Bardou, M | 1 |
| Shen, X | 2 |
| Koi, M | 1 |
| Okita, Y | 1 |
| Takeda, K | 1 |
| Koeppe, ES | 1 |
| Stoffel, EM | 1 |
| Galanko, JA | 1 |
| McCoy, AN | 1 |
| Keku, T | 1 |
| Carethers, JM | 1 |
| Volpato, M | 1 |
| Ingram, N | 1 |
| Perry, SL | 1 |
| Spencer, J | 1 |
| Marshall, C | 1 |
| Hutchinson, JM | 1 |
| Nicolaou, A | 1 |
| Coletta, PL | 1 |
| Higurashi, T | 2 |
| Arimoto, J | 2 |
| Ashikari, K | 1 |
| Takatsu, T | 1 |
| Misawa, N | 1 |
| Yoshihara, T | 1 |
| Matsuura, T | 1 |
| Fuyuki, A | 1 |
| Ohkubo, H | 2 |
| Nakajima, A | 2 |
| O'Grady, J | 1 |
| Quigley, EMM | 1 |
| Li, S | 3 |
| Peng, F | 1 |
| Hua, L | 1 |
| Xue, L | 1 |
| Onyeaghala, G | 1 |
| Lin, HD | 1 |
| Vora, P | 2 |
| Soriano-Gabarró, M | 4 |
| Chan, KA | 1 |
| Altinoz, MA | 1 |
| Greenhough, A | 2 |
| Heesom, KJ | 1 |
| Zheng, J | 1 |
| Le Marchand, L | 5 |
| van Duijnhoven, FJB | 1 |
| Tantai, XX | 1 |
| Liu, N | 1 |
| Wang, JH | 1 |
| Lynch, PM | 1 |
| Belayneh, YM | 1 |
| Amare, GG | 1 |
| Meharie, BG | 1 |
| Faruk, M | 1 |
| Ibrahim, S | 1 |
| Aminu, SM | 1 |
| Adamu, A | 1 |
| Abdullahi, A | 1 |
| Suleiman, AM | 1 |
| Rafindadi, AH | 1 |
| Mohammed, A | 2 |
| Iliyasu, Y | 1 |
| Idoko, J | 1 |
| Saidu, R | 1 |
| Randawa, AJ | 1 |
| Musa, HS | 1 |
| Ntekim, A | 1 |
| Shah, KZ | 1 |
| Abubakar, S | 1 |
| Adoke, KU | 1 |
| Manko, M | 1 |
| Awasum, CA | 1 |
| Guo, CG | 1 |
| Ma, W | 1 |
| Nguyen, LH | 1 |
| Ng, K | 1 |
| Ogino, S | 17 |
| Meyerhardt, JA | 7 |
| Song, M | 4 |
| Giovannucci, EL | 14 |
| Shoji, K | 1 |
| Zen, K | 1 |
| Ookura, T | 1 |
| Yanishi, K | 1 |
| Matoba, S | 1 |
| Jacobs, EJ | 2 |
| Newton, CC | 1 |
| Guinter, MA | 1 |
| Cance, WG | 1 |
| Breiburg, A | 1 |
| Kuschner, WG | 1 |
| Soodi, D | 1 |
| VanWormer, JJ | 1 |
| Rezkalla, SH | 1 |
| Milton, S | 2 |
| Yogaparan, T | 1 |
| Alphonse, P | 1 |
| Saya, S | 2 |
| Lau, P | 1 |
| Liang, PS | 1 |
| Crockett, SD | 1 |
| Ma, S | 1 |
| Han, T | 1 |
| Sun, C | 1 |
| Cheng, C | 1 |
| Zhang, H | 2 |
| Qu, G | 1 |
| Bhan, C | 1 |
| Yang, H | 1 |
| Guo, Z | 1 |
| Yan, Y | 1 |
| Cao, C | 1 |
| Ji, Z | 1 |
| Zhou, Q | 2 |
| Zhang, N | 1 |
| Ghaddaf, AA | 1 |
| Aziz, M | 1 |
| Alomari, MS | 1 |
| Abdulhamid, AS | 1 |
| Alharbi, FA | 1 |
| Mullah, AN | 1 |
| Zaidi, SF | 1 |
| Veettil, SK | 2 |
| Kew, ST | 1 |
| Lim, KG | 2 |
| Phisalprapa, P | 2 |
| Kumar, S | 1 |
| Lee, YY | 1 |
| Chaiyakunapruk, N | 2 |
| Kane, AM | 1 |
| Fennell, LJ | 1 |
| McKeone, DM | 1 |
| Bond, CE | 1 |
| Pollock, PM | 1 |
| Young, G | 1 |
| Leggett, BA | 1 |
| Whitehall, VLJ | 1 |
| Doyama, H | 1 |
| Tajika, M | 1 |
| Tanaka, S | 2 |
| Horimatsu, T | 2 |
| Kashida, H | 1 |
| Tashiro, J | 1 |
| Ezoe, Y | 1 |
| Nakajima, T | 1 |
| Ikematsu, H | 1 |
| Hori, S | 1 |
| Takayama, T | 1 |
| Ohda, Y | 1 |
| Mure, K | 1 |
| Wakabayashi, K | 3 |
| Brennan, CA | 1 |
| Gallini Comeau, CA | 1 |
| Glickman, JN | 1 |
| Garrett, WS | 2 |
| Tervonen, T | 1 |
| Seo, J | 1 |
| Krucien, N | 1 |
| Marsh, K | 1 |
| De Caterina, R | 2 |
| Wissinger, U | 1 |
| Soriano Gabarró, M | 1 |
| Biltaji, E | 1 |
| Walker, B | 1 |
| Au, TH | 1 |
| Rivers, Z | 1 |
| Ose, J | 1 |
| Brixner, DI | 1 |
| Stenehjem, DD | 1 |
| Chudy-Onwugaje, K | 1 |
| Huang, WY | 1 |
| Su, LJ | 1 |
| Purdue, MP | 2 |
| Johnson, CC | 1 |
| Wang, L | 2 |
| Katki, HA | 2 |
| Barry, KH | 1 |
| Semedo, L | 1 |
| Lifford, KJ | 1 |
| Edwards, A | 1 |
| Seddon, K | 1 |
| Brain, K | 1 |
| Smits, S | 1 |
| Dolwani, S | 1 |
| Wang, IE | 1 |
| Yi, S | 1 |
| Block, RC | 1 |
| Mousa, SA | 1 |
| Chondros, P | 1 |
| Trevena, L | 1 |
| Jenkins, M | 2 |
| Walter, FM | 1 |
| Taylor, N | 1 |
| Novy, K | 1 |
| Forbes, C | 1 |
| Gutierrez, JM | 1 |
| Broun, K | 1 |
| Whitburn, S | 1 |
| McGill, S | 1 |
| Marker, J | 1 |
| Shub, M | 1 |
| Frouws, MA | 2 |
| Rademaker, E | 1 |
| Bastiaannet, E | 2 |
| van Herk-Sukel, MPP | 2 |
| Lemmens, VE | 1 |
| Van de Velde, CJH | 2 |
| Portielje, JEA | 2 |
| Liefers, GJ | 2 |
| Maas, HA | 1 |
| LaFrance, AB | 2 |
| Flottemesch, TJ | 2 |
| Hamada, T | 2 |
| Qian, ZR | 4 |
| Masugi, Y | 1 |
| Nowak, JA | 2 |
| Yang, J | 2 |
| Mima, K | 2 |
| Kosumi, K | 1 |
| Shi, Y | 2 |
| da Silva, A | 1 |
| Gu, M | 1 |
| Wu, K | 6 |
| Giannakis, M | 1 |
| Rodig, SJ | 1 |
| Freeman, GJ | 1 |
| Nevo, D | 2 |
| Wang, M | 6 |
| Fuchs, CS | 21 |
| Nishihara, R | 6 |
| Campos-Outcalt, D | 2 |
| Richman, IB | 1 |
| Owens, DK | 2 |
| Hua, X | 1 |
| Phipps, AI | 1 |
| Burnett-Hartman, AN | 2 |
| Adams, SV | 2 |
| Hardikar, S | 1 |
| Cohen, SA | 1 |
| Kocarnik, JM | 1 |
| Murphy, L | 1 |
| Brown, C | 1 |
| Smith, A | 1 |
| Cranfield, F | 1 |
| Sharp, L | 2 |
| Visvanathan, K | 1 |
| Bennett, K | 1 |
| Barron, TI | 1 |
| García Rodríguez, LA | 6 |
| Bromley, S | 1 |
| Lanas, A | 3 |
| Cea Soriano, L | 3 |
| Andreotti, F | 1 |
| Crea, F | 1 |
| Reblin, M | 1 |
| Birmingham, WC | 1 |
| Kohlmann, W | 1 |
| Graff, T | 1 |
| Callegari, E | 1 |
| Kesharwani, SS | 1 |
| Seefeldt, T | 1 |
| Tummala, H | 1 |
| Ching, SM | 1 |
| Saokaew, S | 1 |
| Moayyedi, P | 1 |
| Wang, H | 1 |
| Liu, B | 1 |
| Gong, Y | 1 |
| Cui, B | 1 |
| Xue, X | 2 |
| Yang, M | 1 |
| Fan, W | 1 |
| Kang, Z | 1 |
| Kamran, M | 1 |
| Xu, J | 2 |
| Tian, P | 1 |
| Hou, Z | 1 |
| Dong, L | 1 |
| Ren, Y | 1 |
| Wen, Q | 1 |
| Cheng, W | 1 |
| Liu, Q | 1 |
| Lin, D | 1 |
| Soetikno, RM | 1 |
| McQuaid, K | 1 |
| Pham, C | 1 |
| Doan, G | 1 |
| Mou, S | 1 |
| Shergill, AK | 1 |
| Somsouk, M | 1 |
| Rouse, RV | 1 |
| Bains, SJ | 2 |
| Mahic, M | 2 |
| Myklebust, TÅ | 2 |
| Småstuen, MC | 2 |
| Dørum, LM | 2 |
| Møller, B | 2 |
| Brudvik, KW | 2 |
| Yang, L | 1 |
| Lv, Z | 1 |
| Xia, W | 1 |
| Zhang, W | 2 |
| Xin, Y | 1 |
| Yuan, H | 1 |
| Hu, X | 1 |
| Lv, Y | 1 |
| Xu, Q | 1 |
| Weng, X | 1 |
| Ni, C | 1 |
| Sheth, H | 2 |
| Northwood, E | 1 |
| Barrett, JH | 1 |
| Forman, D | 2 |
| Wolf, CR | 1 |
| Smith, G | 1 |
| Jackson, MS | 1 |
| Santibanez-Koref, M | 1 |
| Haile, R | 1 |
| Win, AK | 3 |
| Thibodeau, SN | 3 |
| Potter, JD | 9 |
| Ebell, MH | 1 |
| Gray, RT | 1 |
| Coleman, HG | 1 |
| Hughes, C | 2 |
| Murray, LJ | 2 |
| Cardwell, CR | 2 |
| Jensen, TSR | 1 |
| Mahmood, B | 1 |
| Damm, MB | 1 |
| Backe, MB | 1 |
| Dahllöf, MS | 1 |
| Poulsen, SS | 1 |
| Hansen, MB | 1 |
| Bindslev, N | 1 |
| Gangar, P | 1 |
| Karagas, MR | 1 |
| Olver, I | 1 |
| Tsoi, KK | 1 |
| Chan, FC | 1 |
| Hirai, HW | 1 |
| Sung, JJ | 1 |
| Zarà, M | 1 |
| Canobbio, I | 1 |
| Visconte, C | 1 |
| Canino, J | 1 |
| Torti, M | 1 |
| Guidetti, GF | 1 |
| Wilkins, T | 1 |
| McMechan, D | 1 |
| Talukder, A | 1 |
| Leenders, EKSM | 1 |
| Westdorp, H | 1 |
| Brüggemann, RJ | 1 |
| Loeffen, J | 1 |
| Kratz, C | 1 |
| Hoogerbrugge, N | 1 |
| Jongmans, MCJ | 1 |
| Caan, B | 3 |
| Lampe, JW | 2 |
| Hsu, L | 3 |
| Rothwell, PM | 7 |
| Cook, NR | 4 |
| Gaziano, JM | 2 |
| Price, JF | 1 |
| Belch, JFF | 1 |
| Roncaglioni, MC | 1 |
| Morimoto, T | 1 |
| Mehta, Z | 1 |
| Yarla, NS | 1 |
| Madka, V | 1 |
| Rao, CV | 1 |
| Limburg, PJ | 2 |
| Qiu, F | 1 |
| Huang, Q | 1 |
| Jiang, Z | 1 |
| Ye, J | 1 |
| Cheng, P | 1 |
| Low, C | 1 |
| Guo, Y | 1 |
| Yi, X | 1 |
| Yu, Y | 1 |
| Han, Y | 1 |
| Jin, S | 1 |
| Kong, D | 1 |
| Huang, J | 1 |
| Tikk, K | 2 |
| Czock, D | 2 |
| Haefeli, WE | 2 |
| Kopp-Schneider, A | 2 |
| Seewaldt, VL | 1 |
| Amitay, EL | 1 |
| Jansen, L | 1 |
| Walter, V | 1 |
| Roth, W | 2 |
| Herpel, E | 1 |
| Kloor, M | 1 |
| Bläker, H | 1 |
| Yamada, A | 4 |
| Tanaka, K | 1 |
| Matsuda, K | 1 |
| Saito, Y | 1 |
| Ohtsuka, K | 1 |
| Oda, I | 1 |
| Katada, C | 1 |
| Kato, M | 2 |
| Kida, M | 1 |
| Kobayashi, K | 1 |
| Hoteya, S | 1 |
| Kodashima, S | 1 |
| Muto, M | 1 |
| Yamamoto, H | 1 |
| Ryozawa, S | 1 |
| Iwakiri, R | 1 |
| Kutsumi, H | 1 |
| Miyata, H | 1 |
| Haruma, K | 1 |
| Fujimoto, K | 1 |
| Uemura, N | 1 |
| Kaminishi, M | 1 |
| Tajiri, H | 1 |
| Kilari, RS | 2 |
| Bashir, AIJ | 2 |
| Devitt, A | 1 |
| Perry, CJ | 4 |
| Safrany, ST | 2 |
| Nicholl, ID | 5 |
| Dekker, E | 1 |
| Kaminski, MF | 1 |
| Sprange, K | 1 |
| Hepburn, T | 1 |
| Tan, W | 1 |
| Shafayat, A | 1 |
| Clifford, G | 1 |
| Logan, RF | 8 |
| Whitham, D | 2 |
| Montgomery, AA | 2 |
| Çelik, O | 1 |
| Çil, C | 1 |
| Özlek, B | 1 |
| Özlek, E | 1 |
| Doğan, V | 1 |
| Başaran, Ö | 1 |
| Demirci, E | 1 |
| Bekar, L | 1 |
| Kalçık, M | 1 |
| Karaarslan, O | 1 |
| Yetim, M | 1 |
| Doğan, T | 1 |
| Demir, V | 1 |
| Kalkan, S | 1 |
| Özkan, B | 1 |
| Hidayet, Ş | 1 |
| Taylan, G | 1 |
| Küçüksu, Z | 1 |
| Çelik, Y | 1 |
| Efe, SÇ | 1 |
| Aslan, O | 1 |
| Biteker, M | 1 |
| Petrera, M | 1 |
| Paleari, L | 2 |
| Clavarezza, M | 2 |
| Puntoni, M | 2 |
| Caviglia, S | 1 |
| Briata, IM | 1 |
| Oppezzi, M | 1 |
| Mislej, EM | 1 |
| Stabuc, B | 1 |
| Gnant, M | 1 |
| Bachleitner-Hofmann, T | 1 |
| DeCensi, A | 3 |
| Ho, JMW | 1 |
| Chan, FCH | 1 |
| Tsoi, KKF | 1 |
| Yang, T | 1 |
| Li, X | 2 |
| Montazeri, Z | 1 |
| Little, J | 8 |
| Farrington, SM | 2 |
| Ioannidis, JPA | 1 |
| Dunlop, MG | 9 |
| Campbell, H | 2 |
| Timofeeva, M | 1 |
| Theodoratou, E | 2 |
| Rodríguez-Miguel, A | 1 |
| García-Rodríguez, LA | 2 |
| Gil, M | 1 |
| Montoya, H | 1 |
| Rodríguez-Martín, S | 1 |
| de Abajo, FJ | 1 |
| Dickson, I | 1 |
| He, P | 1 |
| Yang, C | 3 |
| Ye, G | 1 |
| Xie, H | 1 |
| Zhong, W | 1 |
| Romstad, KMK | 1 |
| Frigstad, SO | 1 |
| de Lange, T | 1 |
| Gescher, A | 1 |
| Ihara, S | 1 |
| Hikiba, Y | 1 |
| Kinoshita, H | 1 |
| Higashishima, N | 1 |
| Hirata, Y | 3 |
| Nakata, R | 1 |
| Okamoto, M | 1 |
| Sano, M | 1 |
| Kushiyama, A | 1 |
| Ichinose, M | 1 |
| Woods, SL | 1 |
| Worthley, D | 1 |
| Iwamoto, Y | 1 |
| Kankipati, CS | 3 |
| Jones, S | 1 |
| Newman, RM | 1 |
| Jovani, M | 1 |
| Danış, N | 1 |
| Tekin, F | 1 |
| Spaander, MCW | 1 |
| Kuipers, EJ | 2 |
| Podhorec, J | 1 |
| Hrstka, R | 1 |
| Bílek, O | 1 |
| Tuček, Š | 1 |
| Navrátil, J | 1 |
| Michalová, E | 1 |
| Vojtěšek, B | 1 |
| Hickner, J | 1 |
| Smith, DK | 1 |
| Demetriou, T | 1 |
| Weber, C | 1 |
| Calderazzo, S | 1 |
| Seufferlein, T | 1 |
| Ludwig, L | 1 |
| Dikopoulos, N | 1 |
| Mangold, J | 1 |
| Böck, W | 1 |
| Stolz, T | 1 |
| Eisenbach, T | 1 |
| Block, T | 1 |
| Ma, B | 1 |
| Duan, X | 1 |
| Liu, J | 2 |
| Yang, X | 1 |
| Yang, S | 1 |
| Du, Y | 1 |
| Li, H | 2 |
| Su, C | 1 |
| Yoshimoto, Y | 1 |
| Tanaka, A | 1 |
| Hayashi, H | 1 |
| Shimoike, N | 1 |
| Kawamoto, H | 2 |
| Nakasuga, C | 1 |
| Yamamoto, T | 1 |
| Olejniczak-Kęder, A | 1 |
| Szaryńska, M | 1 |
| Wrońska, A | 1 |
| Siedlecka-Kroplewska, K | 1 |
| Kmieć, Z | 1 |
| Väyrynen, JP | 1 |
| Väyrynen, SA | 1 |
| Sirniö, P | 1 |
| Minkkinen, I | 1 |
| Klintrup, K | 1 |
| Karhu, T | 1 |
| Mäkelä, J | 1 |
| Herzig, KH | 1 |
| Karttunen, TJ | 1 |
| Tuomisto, A | 1 |
| Mäkinen, MJ | 1 |
| Barua, HT | 1 |
| Midge, SB | 1 |
| Parkin, CJ | 1 |
| Bell, SW | 1 |
| Mirbagheri, N | 1 |
| Bagheri, M | 1 |
| Tabatabae Far, MA | 1 |
| Mirzaei, H | 1 |
| Ghasemi, F | 1 |
| Ye, X | 1 |
| Fu, J | 1 |
| Yang, Y | 1 |
| Chen, S | 1 |
| Sahin, IH | 2 |
| McCowan, C | 2 |
| Donnan, PT | 2 |
| Munro, AJ | 2 |
| Steele, RJ | 4 |
| Komiya, M | 1 |
| Fujii, G | 2 |
| Takahashi, M | 1 |
| Iigo, M | 1 |
| Yoshikawa, Y | 1 |
| Kamikubo, Y | 1 |
| Sonoda, H | 1 |
| Yamakage, M | 1 |
| Bujanda, L | 1 |
| Quintero, E | 1 |
| Castells, A | 2 |
| Sarasqueta, C | 1 |
| Cubiella, J | 1 |
| Hernandez, V | 1 |
| Morillas, JD | 1 |
| Perez-Fernández, T | 1 |
| Salas, D | 1 |
| Andreu, M | 1 |
| Carballo, F | 1 |
| Bessa, X | 1 |
| Cosme, A | 1 |
| Jover, R | 1 |
| Mansouri, D | 1 |
| McMillan, DC | 1 |
| Roxburgh, CS | 1 |
| Crighton, EM | 1 |
| Horgan, PG | 1 |
| Schrör, K | 5 |
| Rauch, BH | 1 |
| Lochhead, P | 4 |
| Huang, WK | 2 |
| Chiou, MJ | 1 |
| Yu, KH | 1 |
| Yang, TS | 1 |
| Chen, JS | 1 |
| Kuo, CF | 1 |
| See, LC | 2 |
| Kuchiba, A | 4 |
| Jung, S | 2 |
| Yamauchi, M | 4 |
| Liao, X | 3 |
| Imamura, Y | 3 |
| Morikawa, T | 5 |
| Spiegelman, D | 2 |
| Cho, E | 2 |
| Pasche, B | 2 |
| Lee, IM | 5 |
| Zhang, SM | 2 |
| Moorthy, MV | 1 |
| Buring, JE | 8 |
| Jonsson, F | 1 |
| Yin, L | 2 |
| Lundholm, C | 1 |
| Smedby, KE | 2 |
| Czene, K | 2 |
| Pawitan, Y | 2 |
| Sandell, AC | 1 |
| Clifford, GM | 2 |
| Burr, N | 1 |
| Colussi, D | 1 |
| Brandi, G | 1 |
| Bazzoli, F | 1 |
| Ricciardiello, L | 1 |
| Temraz, S | 1 |
| Mukherji, D | 1 |
| Shamseddine, A | 1 |
| Domingo, E | 1 |
| Church, DN | 1 |
| Sieber, O | 1 |
| Ramamoorthy, R | 1 |
| Yanagisawa, Y | 1 |
| Johnstone, E | 1 |
| Davidson, B | 1 |
| Kerr, DJ | 1 |
| Tomlinson, IP | 1 |
| Midgley, R | 1 |
| Sutcliffe, P | 1 |
| Connock, M | 1 |
| Gurung, T | 1 |
| Freeman, K | 1 |
| Johnson, S | 1 |
| Kandala, NB | 1 |
| Grove, A | 1 |
| Gurung, B | 1 |
| Morrow, S | 1 |
| Clarke, A | 1 |
| Hreinsson, JP | 1 |
| Jonasson, JG | 1 |
| Bjornsson, ES | 1 |
| Dovizio, M | 4 |
| Alberti, S | 2 |
| Guillem-Llobat, P | 2 |
| Patrignani, P | 9 |
| Hirata, K | 1 |
| Nakamura, T | 2 |
| Takeyama, I | 1 |
| Kawano, A | 2 |
| Gondo, N | 2 |
| Abe, T | 1 |
| Tokudome, S | 1 |
| Matsuura, N | 1 |
| Massat, NJ | 1 |
| Moss, SM | 1 |
| Halloran, SP | 1 |
| Duffy, SW | 1 |
| Kunzmann, AT | 1 |
| Cantwell, MM | 1 |
| Powe, DG | 1 |
| Nolfo, F | 1 |
| Rametta, S | 1 |
| Marventano, S | 1 |
| Grosso, G | 1 |
| Mistretta, A | 1 |
| Drago, F | 1 |
| Gangi, S | 1 |
| Basile, F | 1 |
| Biondi, A | 1 |
| Thompson, PA | 1 |
| Nan, H | 3 |
| Suuriniemi, M | 1 |
| Werner, L | 1 |
| Hunter, DJ | 7 |
| Kraft, P | 1 |
| Freedman, ML | 1 |
| Tougeron, D | 1 |
| Sha, D | 1 |
| Manthravadi, S | 1 |
| Sinicrope, FA | 4 |
| Chan, A | 2 |
| Peura, DA | 1 |
| Wilcox, CM | 4 |
| Mehta, RS | 1 |
| Bezawada, N | 1 |
| Garcia-Albeniz, X | 2 |
| Kirstein, MM | 1 |
| Vogel, A | 1 |
| Rauch, B | 1 |
| Fink, SP | 1 |
| Markowitz, SD | 3 |
| Andersen, V | 1 |
| Vogel, U | 2 |
| Noreen, F | 1 |
| Röösli, M | 1 |
| Gaj, P | 1 |
| Pietrzak, J | 1 |
| Weis, S | 1 |
| Urfer, P | 1 |
| Regula, J | 1 |
| Schär, P | 1 |
| Truninger, K | 1 |
| Claudius, AK | 1 |
| Hassan, S | 1 |
| Guest, K | 1 |
| Russell, ST | 1 |
| Stark, LA | 6 |
| Ye, XF | 1 |
| Shi, WT | 1 |
| He, J | 1 |
| Printz, C | 2 |
| Wu, H | 1 |
| Ye, Y | 2 |
| Xia, D | 1 |
| Cai, J | 1 |
| Wu, Y | 2 |
| Soon, SS | 1 |
| Chia, WK | 5 |
| Chan, ML | 1 |
| Ho, GF | 1 |
| Jian, X | 1 |
| Deng, YH | 1 |
| Tan, CS | 1 |
| Sharma, A | 1 |
| Mehta, S | 1 |
| Wee, HL | 1 |
| Lin, CC | 1 |
| Lai, MS | 1 |
| Shau, WY | 1 |
| Su, B | 1 |
| Xu, B | 1 |
| Wan, J | 1 |
| Gala, MK | 1 |
| Goh, CH | 1 |
| Goh, HH | 1 |
| Leong, WQ | 1 |
| Chew, MH | 1 |
| Pan, YS | 1 |
| Tony, LK | 1 |
| Chew, L | 1 |
| Tan, IB | 1 |
| Tang, CL | 2 |
| Fu, WP | 1 |
| Principi, M | 1 |
| De Censi, A | 1 |
| Kothari, N | 1 |
| Kim, R | 1 |
| Jorissen, RN | 1 |
| Desai, J | 1 |
| Tie, J | 1 |
| Wong, HL | 1 |
| Faragher, I | 1 |
| Jones, I | 1 |
| Day, FL | 1 |
| Sakthinandeswaren, A | 1 |
| Palmieri, M | 1 |
| Lipton, L | 1 |
| Schell, M | 1 |
| Teer, JK | 1 |
| Shibata, D | 1 |
| Yeatman, T | 1 |
| Sieber, OM | 1 |
| Tran, B | 1 |
| Ninomiya, Y | 1 |
| Oka, S | 1 |
| Nishiyama, S | 1 |
| Tamaru, Y | 1 |
| Asayama, N | 1 |
| Shigita, K | 1 |
| Hayashi, N | 1 |
| Chayama, K | 1 |
| Lang Kuhs, KA | 1 |
| Hildesheim, A | 1 |
| Trabert, B | 1 |
| Kemp, TJ | 1 |
| Wentzensen, N | 1 |
| Pinto, LA | 1 |
| Loftfield, E | 1 |
| Safaeian, M | 1 |
| Chaturvedi, AK | 1 |
| Shiels, MS | 1 |
| Setiawan, A | 1 |
| Auer, G | 1 |
| Wender, RC | 2 |
| Hutter, CM | 1 |
| Butterbach, K | 1 |
| Caan, BJ | 1 |
| Carlson, CS | 1 |
| Chanock, SJ | 1 |
| Cotterchio, M | 1 |
| Duggan, D | 1 |
| Gong, J | 1 |
| Hayes, RB | 1 |
| Hudson, TJ | 1 |
| Jenkins, MA | 2 |
| Jiao, S | 1 |
| Lemire, M | 1 |
| Pflugeisen, BM | 1 |
| Qu, C | 1 |
| Rosse, SA | 1 |
| Rudolph, A | 1 |
| Schumacher, FR | 1 |
| Seminara, D | 1 |
| Thomas, F | 1 |
| Thornquist, M | 1 |
| Warnick, GS | 1 |
| Zanke, BW | 1 |
| Gauderman, WJ | 1 |
| Ye, H | 1 |
| Chen, P | 1 |
| Dai, W | 1 |
| Zheng, Q | 1 |
| Wu, F | 1 |
| Ait Ouakrim, D | 2 |
| Dashti, SG | 2 |
| Chau, R | 1 |
| Clendenning, M | 1 |
| Rosty, C | 1 |
| Young, JP | 1 |
| Leggett, B | 1 |
| Macrae, FA | 1 |
| Zanders, MM | 1 |
| van Herk-Sukel, MP | 1 |
| Vissers, PA | 1 |
| Herings, RM | 1 |
| Haak, HR | 1 |
| van de Poll-Franse, LV | 1 |
| Sehdev, A | 1 |
| O'Neil, BH | 1 |
| Timmons, JA | 1 |
| Jung, YR | 1 |
| Kim, EJ | 1 |
| Choi, HJ | 1 |
| Park, JJ | 1 |
| Kim, HS | 2 |
| Lee, YJ | 1 |
| Park, MJ | 1 |
| Movahedi, M | 1 |
| Moeslein, G | 1 |
| Olschwang, S | 2 |
| Eccles, D | 2 |
| Maher, ER | 2 |
| Bisgaard, ML | 2 |
| Ho, JW | 2 |
| Hodgson, SV | 1 |
| Lubinski, J | 2 |
| Murday, V | 1 |
| Side, L | 2 |
| Scott, RJ | 2 |
| Thomas, HJ | 2 |
| Vasen, HF | 2 |
| Friis, S | 5 |
| Riis, AH | 1 |
| Bradshaw, PT | 1 |
| Sandler, RS | 22 |
| Milne, GL | 2 |
| Mayor, S | 1 |
| Rinzivillo, M | 1 |
| Capurso, G | 1 |
| Campana, D | 1 |
| Fazio, N | 1 |
| Panzuto, F | 1 |
| Spada, F | 1 |
| Cicchese, N | 1 |
| Partelli, S | 1 |
| Tomassetti, P | 1 |
| Falconi, M | 1 |
| Delle Fave, G | 1 |
| Watanabe, Y | 1 |
| Yamaji, Y | 1 |
| Kobayashi, Y | 1 |
| Yoshida, S | 1 |
| Sugimoto, T | 1 |
| Watabe, H | 1 |
| Di Francesco, L | 1 |
| López Contreras, LA | 1 |
| Sacco, A | 2 |
| Kraus, S | 3 |
| Sion, D | 1 |
| Arber, N | 9 |
| Tu, HT | 1 |
| Pommergaard, HC | 1 |
| Burcharth, J | 1 |
| Rosenberg, J | 1 |
| Raskov, H | 1 |
| Wilson, LF | 1 |
| Green, AC | 1 |
| Kendall, BJ | 1 |
| Jordan, SJ | 1 |
| Nagle, CM | 1 |
| Bain, CJ | 1 |
| Neale, RE | 1 |
| Whiteman, DC | 1 |
| Goldberg, RM | 1 |
| Liesenfeld, DB | 1 |
| Botma, A | 1 |
| Habermann, N | 1 |
| Toth, R | 1 |
| Weigel, C | 1 |
| Popanda, O | 1 |
| Klika, KD | 1 |
| Ladabaum, U | 3 |
| Wakeman, C | 1 |
| Keenan, J | 1 |
| Eteuati, J | 1 |
| Hollington, P | 1 |
| Eglinton, T | 1 |
| Frizelle, F | 1 |
| Tuccori, M | 1 |
| Filion, KB | 1 |
| DeCensi, M | 1 |
| Cuzick, J | 2 |
| Crosta, C | 1 |
| Bagnardi, V | 1 |
| Tamayo, D | 1 |
| Sonzogni, AM | 1 |
| De Roberto, G | 1 |
| de Leone, A | 1 |
| Lowenfels, A | 1 |
| Maisonneuve, P | 1 |
| Jensen, JD | 1 |
| Holton, AE | 1 |
| Krakow, M | 1 |
| Weaver, J | 1 |
| Donovan, E | 1 |
| Tavtigian, S | 1 |
| Guo, H | 1 |
| Ben, Q | 1 |
| Qu, Y | 1 |
| Zhang, J | 1 |
| Maresso, KC | 1 |
| Hawk, ET | 6 |
| Willett, WC | 6 |
| Wilson, N | 1 |
| Selak, V | 1 |
| Blakely, T | 1 |
| Leung, W | 1 |
| Clarke, P | 2 |
| Jackson, R | 1 |
| Knight, J | 1 |
| Nghiem, N | 1 |
| Burr, NE | 1 |
| Subramanian, V | 1 |
| Reibetanz, J | 1 |
| Germer, CT | 1 |
| Chubak, J | 1 |
| Whitlock, EP | 2 |
| Williams, SB | 1 |
| Kamineni, A | 1 |
| Burda, BU | 1 |
| Buist, DS | 1 |
| Anderson, ML | 1 |
| Bibbins-Domingo, K | 1 |
| McCarthy, M | 1 |
| Bruno, A | 2 |
| Ricciotti, E | 2 |
| Cufino, V | 1 |
| Grande, R | 1 |
| Arena, V | 1 |
| Cirillo, M | 1 |
| FitzGerald, GA | 1 |
| Steinhilber, D | 1 |
| Sgambato, A | 1 |
| Yip, WK | 1 |
| Bonetti, M | 1 |
| Barcella, W | 1 |
| Wang, XV | 1 |
| Lazar, A | 1 |
| Gelber, RD | 1 |
| Endo, H | 1 |
| Kato, T | 1 |
| Sakai, E | 1 |
| Taniguchi, L | 1 |
| Kawamura, H | 1 |
| Nonaka, T | 1 |
| Taguri, M | 1 |
| Inamori, M | 1 |
| Yamanaka, T | 1 |
| Sakaguchi, T | 1 |
| Hata, Y | 1 |
| Nagase, H | 1 |
| Yasunaga, H | 1 |
| Matsui, H | 1 |
| Fushimi, K | 1 |
| Zhao, TY | 1 |
| Tu, J | 1 |
| Cheng, DW | 1 |
| Gao, XK | 1 |
| Luo, H | 1 |
| Yan, BC | 1 |
| Xu, XL | 1 |
| Zhang, HL | 1 |
| Lu, XJ | 1 |
| Wang, YJ | 1 |
| Singh Ranger, G | 1 |
| Mora, S | 2 |
| Manson, JE | 6 |
| Ames, JM | 1 |
| Miyamoto, S | 1 |
| Inamura, K | 1 |
| Nosho, K | 2 |
| Kim, C | 1 |
| Sesso, HD | 3 |
| Rifai, N | 1 |
| Stampfer, MJ | 5 |
| Ma, J | 3 |
| Lawrence, JR | 2 |
| Baxter, GJ | 1 |
| Paterson, JR | 2 |
| Giampieri, R | 1 |
| Restivo, A | 1 |
| Pusceddu, V | 1 |
| Del Prete, M | 1 |
| Maccaroni, E | 1 |
| Bittoni, A | 1 |
| Faloppi, L | 1 |
| Andrikou, K | 1 |
| Bianconi, M | 1 |
| Cabras, F | 1 |
| Berardi, R | 1 |
| Zorcolo, L | 1 |
| Scintu, F | 1 |
| Cascinu, S | 1 |
| Scartozzi, M | 1 |
| Wong, T | 1 |
| Ward, RL | 1 |
| Goodwin, A | 1 |
| Hiller, J | 1 |
| Park, SY | 1 |
| Wilkens, LR | 1 |
| Kolonel, LN | 2 |
| Monroe, KR | 1 |
| Haiman, CA | 1 |
| Coyle, C | 1 |
| Ventura, L | 1 |
| Miccinesi, G | 1 |
| Barchielli, A | 1 |
| Manneschi, G | 1 |
| Puliti, D | 1 |
| Mantellini, P | 1 |
| Orso, F | 1 |
| Zappa, M | 1 |
| Emilsson, L | 1 |
| Adami, HO | 1 |
| Gaziano, MJ | 1 |
| Dulai, PS | 1 |
| Singh, S | 1 |
| Marquez, E | 1 |
| Khera, R | 1 |
| Prokop, LJ | 1 |
| Murad, MH | 1 |
| McNellis, RJ | 1 |
| Beswick-Escanlar, V | 1 |
| Chen, G | 1 |
| Chin, SM | 1 |
| Gilpin, KK | 1 |
| Parziale, M | 1 |
| Pond, E | 1 |
| Schuck, MM | 1 |
| Stewart, K | 1 |
| Flagg, M | 1 |
| Rawlings, CA | 1 |
| Backman, V | 1 |
| Carolan, PJ | 1 |
| Chung, DC | 2 |
| Colizzo, FP | 1 |
| Freedman, M | 1 |
| Garber, JJ | 1 |
| Huttenhower, C | 1 |
| Kedrin, D | 1 |
| Khalili, H | 1 |
| Kwon, DS | 1 |
| Nishioka, NS | 1 |
| Richter, JM | 1 |
| Staller, K | 1 |
| Zhu, Y | 1 |
| Weng, M | 1 |
| Yang, W | 1 |
| He, Y | 1 |
| Wang, G | 1 |
| RajkumarEzakiel Redpath, RJ | 1 |
| Zhang, L | 1 |
| Jin, X | 1 |
| Liu, Y | 1 |
| Sun, Y | 1 |
| Ning, N | 1 |
| Qiao, Y | 1 |
| Zhang, F | 1 |
| Li, Z | 1 |
| Xiao, H | 1 |
| Yang, CS | 1 |
| Leshno, M | 1 |
| Moshkowitz, M | 2 |
| Rostom, A | 2 |
| Adams, PC | 1 |
| Hunt, R | 1 |
| Levine, AJ | 5 |
| Grau, MV | 10 |
| Midttun, O | 1 |
| Ueland, PM | 5 |
| Tsang, S | 3 |
| Munroe, D | 1 |
| Ali, I | 1 |
| Wallace, K | 2 |
| Saibil, F | 5 |
| Ahnen, D | 2 |
| Munroe, DJ | 2 |
| Ali, IU | 2 |
| Ueland, P | 1 |
| Byers, T | 3 |
| Summers, RW | 5 |
| Bond, J | 1 |
| McKeown-Eyssen, GE | 5 |
| Tsai, CS | 1 |
| Luo, SF | 1 |
| Ning, CC | 1 |
| Lin, CL | 1 |
| Jiang, MC | 1 |
| Liao, CF | 1 |
| Herszényi, L | 2 |
| Farinati, F | 1 |
| Miheller, P | 1 |
| Tulassay, Z | 2 |
| Bazuro, GE | 1 |
| Torino, F | 1 |
| Gasparini, G | 1 |
| Capurso, L | 1 |
| Liao, C | 1 |
| Tan, A | 1 |
| Mo, Z | 1 |
| Hur, C | 2 |
| Broughton, DE | 1 |
| Kong, CY | 1 |
| Ozanne, EM | 1 |
| Richards, EB | 1 |
| Truong, T | 1 |
| Gazelle, GS | 2 |
| Ramesar, R | 1 |
| Jarvinen, HJ | 1 |
| Dunlop, M | 1 |
| Barker, G | 1 |
| Jass, JR | 1 |
| Fodde, R | 1 |
| Lynch, HT | 1 |
| Quyn, AJ | 1 |
| Carey, FA | 2 |
| Näthke, IS | 1 |
| Poulsen, AH | 1 |
| Tjønneland, A | 1 |
| Overvad, K | 1 |
| McLaughlin, JK | 2 |
| Blot, WJ | 2 |
| Olsen, JH | 3 |
| Gui, J | 2 |
| Halabi, S | 2 |
| Grainge, MJ | 6 |
| Chaussade, S | 9 |
| Lin, KW | 1 |
| Burke, CA | 6 |
| Levi, Z | 1 |
| Rozen, P | 1 |
| Hazazi, R | 1 |
| Vilkin, A | 1 |
| Waked, A | 1 |
| Maoz, E | 1 |
| Birkenfeld, S | 1 |
| Lieberman, N | 1 |
| Klang, S | 1 |
| Niv, Y | 1 |
| Brouquet, A | 1 |
| Benoist, S | 1 |
| Julie, C | 1 |
| Penna, C | 1 |
| Beauchet, A | 1 |
| Rougier, P | 1 |
| Nordlinger, B | 1 |
| Shen, L | 1 |
| Hamdan, R | 1 |
| Chen, X | 1 |
| Issa, JP | 1 |
| Yang, F | 1 |
| Jin, C | 1 |
| Fu, D | 1 |
| Topping, DL | 1 |
| Bird, AR | 1 |
| Young, GP | 1 |
| Otto, F | 1 |
| Brown, PH | 1 |
| Greenwald, P | 1 |
| Meyskens, F | 1 |
| Senn, HJ | 1 |
| Thun, M | 1 |
| Morgan, G | 9 |
| Elwood, P | 3 |
| Neugut, AI | 1 |
| Sansbury, LB | 1 |
| Burke, C | 1 |
| Ho, GY | 1 |
| Cushman, M | 1 |
| Rohan, TE | 1 |
| Zell, JA | 2 |
| Ziogas, A | 2 |
| Bernstein, L | 2 |
| Clarke, CA | 2 |
| Deapen, D | 2 |
| Largent, JA | 2 |
| Neuhausen, SL | 2 |
| Stram, DO | 2 |
| Ursin, G | 2 |
| Anton-Culver, H | 2 |
| Hazra, A | 1 |
| Selhub, J | 2 |
| Chao, WH | 1 |
| Coghill, AE | 2 |
| Bergman, M | 1 |
| Djaldetti, M | 1 |
| Salman, H | 1 |
| Bessler, H | 1 |
| Voutsadakis, IA | 1 |
| Patrikidou, A | 1 |
| Tsapakidis, K | 1 |
| Karagiannaki, A | 1 |
| Hatzidaki, E | 1 |
| Stathakis, NE | 1 |
| Papandreou, CN | 1 |
| Uzzan, B | 4 |
| Martin, A | 4 |
| Deyra, J | 4 |
| Girard, B | 3 |
| Dibra, HK | 1 |
| Brown, JE | 1 |
| Hooley, P | 1 |
| Rufner, KL | 1 |
| Park, MK | 1 |
| Tweed, EM | 1 |
| Din, FV | 5 |
| Tenesa, A | 1 |
| Barnetson, RA | 1 |
| Cetnarskyj, R | 1 |
| Stark, L | 1 |
| Porteous, ME | 1 |
| Tian, Y | 1 |
| Gao, W | 1 |
| Chen, H | 1 |
| Song, T | 1 |
| Wang, D | 1 |
| Mao, X | 1 |
| Ren, C | 1 |
| Wilson, M | 1 |
| Elwin, CE | 1 |
| Norrving, B | 1 |
| Algra, A | 1 |
| Warlow, CP | 1 |
| Meade, TW | 1 |
| Poole, EM | 2 |
| Tao, S | 1 |
| Haug, U | 1 |
| Tebbutt, NC | 1 |
| Murphy, F | 1 |
| Zannino, D | 1 |
| Wilson, K | 1 |
| Cummins, MM | 1 |
| Abdi, E | 1 |
| Strickland, AH | 1 |
| Lowenthal, RM | 1 |
| Marx, G | 1 |
| Karapetis, C | 1 |
| Shannon, J | 1 |
| Goldstein, D | 1 |
| Nayagam, SS | 1 |
| Blum, R | 1 |
| Chantrill, L | 1 |
| Simes, RJ | 1 |
| Price, TJ | 1 |
| Mandelli, G | 1 |
| Radaelli, F | 1 |
| Paggi, S | 1 |
| Terreni, N | 1 |
| Gola, G | 1 |
| Gramegna, M | 1 |
| Bonaffini, A | 1 |
| Terruzzi, V | 1 |
| Chan, YH | 1 |
| Schooling, CM | 1 |
| Ruder, EH | 1 |
| Laiyemo, AO | 1 |
| Graubard, BI | 1 |
| Hollenbeck, AR | 1 |
| Schatzkin, A | 2 |
| Cross, AJ | 1 |
| Zubiaurre, L | 1 |
| Bujanda Fernández de Pierola, L | 1 |
| Spicak, J | 2 |
| Rácz, I | 2 |
| Zavoral, M | 2 |
| Breazna, A | 1 |
| Gerletti, P | 2 |
| Lechuga, MJ | 2 |
| Collins, N | 1 |
| Rosenstein, RB | 3 |
| Eagle, CJ | 3 |
| Levin, B | 4 |
| Brady, RR | 1 |
| Loveridge, CJ | 1 |
| Deb, J | 1 |
| Dibra, H | 1 |
| Shan, S | 1 |
| Rajan, S | 1 |
| Manneh, J | 1 |
| Hassan, C | 1 |
| Rex, DK | 2 |
| Cooper, GS | 1 |
| Zullo, A | 1 |
| Launois, R | 1 |
| Hsu, M | 1 |
| Zauber, AG | 3 |
| Bertagnolli, MM | 3 |
| Beaugerie, L | 1 |
| Zhou, X | 1 |
| Huang, SY | 1 |
| Feng, JX | 1 |
| Gao, YY | 1 |
| Huang, BQ | 1 |
| McNeil, C | 1 |
| Izbicki, JR | 1 |
| Hofmann, BT | 1 |
| Nitschmann, S | 2 |
| Avivi, D | 1 |
| Detering, E | 1 |
| Lee, SH | 1 |
| Shin, SJ | 1 |
| Park, DI | 1 |
| Kim, SE | 1 |
| Hong, SP | 1 |
| Hong, SN | 1 |
| Yang, DH | 1 |
| Lee, BI | 1 |
| Kim, YH | 1 |
| Yang, SK | 1 |
| Kim, HJ | 2 |
| Kim, SH | 1 |
| Valanciute, A | 1 |
| Houde, VP | 1 |
| Zibrova, D | 1 |
| Green, KA | 1 |
| Sakamoto, K | 1 |
| Alessi, DR | 1 |
| Lee, CS | 1 |
| McNamara, D | 1 |
| O'Morain, CA | 1 |
| Ockenga, J | 1 |
| Lee, TJ | 1 |
| Rajasekhar, PT | 1 |
| Ritchie, M | 1 |
| James, P | 1 |
| McNally, RJ | 1 |
| Rutter, MD | 1 |
| Casado-Arroyo, R | 1 |
| Gargallo, C | 1 |
| Lanas Arbeloa, A | 1 |
| Ferrández, A | 1 |
| Piazuelo, E | 1 |
| Thiagarajan, P | 1 |
| Jankowski, JA | 1 |
| Lundgreen, A | 1 |
| Welbourn, B | 1 |
| Corcoran, C | 1 |
| Wolff, RK | 1 |
| Kim, VA | 1 |
| Lazebnik, LV | 1 |
| Drozdov, VN | 1 |
| Silva, MT | 1 |
| Galvao, TF | 1 |
| Zimmerman, IR | 1 |
| Pereira, MG | 1 |
| Lopes, LC | 1 |
| Manzano, A | 1 |
| Pérez-Segura, P | 1 |
| Tacconelli, S | 2 |
| Walker, AJ | 1 |
| Card, TR | 1 |
| Smartt, HJ | 1 |
| Ordóñez-Morán, P | 1 |
| Al-Kharusi, M | 1 |
| Collard, TJ | 1 |
| Mariadason, JM | 1 |
| Huelsken, J | 1 |
| Paraskeva, C | 3 |
| Püllen, R | 1 |
| Dovjak, P | 1 |
| Makar, KW | 1 |
| Baba, Y | 1 |
| Shima, K | 1 |
| Sun, R | 1 |
| Pence, BC | 1 |
| Belasco, EJ | 1 |
| Lyford, CP | 1 |
| Viúdez, A | 1 |
| Hernandez, I | 1 |
| Vera, R | 1 |
| Garrett, C | 1 |
| Yıldız, H | 1 |
| Oztas, H | 1 |
| Yıldız, D | 1 |
| Koc, A | 1 |
| Kalipci, E | 1 |
| Ono, K | 1 |
| Idani, H | 1 |
| Hidaka, H | 1 |
| Kusudo, K | 1 |
| Koyama, Y | 1 |
| Taguchi, S | 1 |
| Menzel, T | 1 |
| Schauber, J | 1 |
| Kreth, F | 1 |
| Kudlich, T | 1 |
| Melcher, R | 1 |
| Gostner, A | 1 |
| Scheppach, W | 1 |
| Lührs, H | 1 |
| Mølck, AM | 1 |
| Poulsen, M | 1 |
| Meyer, O | 1 |
| Gao, X | 1 |
| Sun, S | 1 |
| Sun, F | 1 |
| Sun, H | 1 |
| Song, S | 1 |
| Jacobs, ET | 1 |
| Giuliano, AR | 1 |
| Roe, DJ | 1 |
| Guillén-Rodríguez, JM | 1 |
| Alberts, DS | 1 |
| Lin, HJ | 1 |
| Lakkides, KM | 1 |
| Reddy, ST | 1 |
| Louie, AD | 1 |
| Kau, IH | 1 |
| Zhou, H | 1 |
| Gim, JS | 1 |
| Ma, HL | 1 |
| Matthies, CF | 1 |
| Dai, A | 1 |
| Huang, HF | 1 |
| Materi, AM | 1 |
| Lin, JH | 1 |
| Frankl, HD | 1 |
| Lee, ER | 1 |
| Hardy, SI | 1 |
| Herschman, HR | 1 |
| Henderson, BE | 1 |
| Garavito, RM | 1 |
| Smith, WL | 1 |
| Johnsen, SP | 1 |
| Imperiale, TF | 1 |
| Budinger, S | 1 |
| Paskett, E | 2 |
| Keresztes, R | 1 |
| Petrelli, N | 1 |
| Pipas, JM | 1 |
| Karp, DD | 1 |
| Loprinzi, CL | 1 |
| Steinbach, G | 1 |
| Schilsky, R | 1 |
| Bresalier, R | 1 |
| Rothstein, R | 1 |
| Allen, JI | 2 |
| Beach, M | 1 |
| Beck, GJ | 2 |
| Bond, JH | 2 |
| Greenberg, ER | 5 |
| Mandel, JS | 3 |
| Marcon, N | 2 |
| Pearson, L | 1 |
| van Stolk, RU | 1 |
| Nørgård, B | 1 |
| Laurberg, S | 1 |
| Kronberg, O | 1 |
| Bauer, WM | 1 |
| Lashner, B | 1 |
| Mickleburgh, I | 1 |
| Chapman, PC | 1 |
| Viner, JL | 3 |
| Hassan, Y | 1 |
| Berman, KS | 1 |
| Levenson, D | 1 |
| Huls, G | 1 |
| Koornstra, JJ | 1 |
| Kleibeuker, JH | 2 |
| Jullian, E | 1 |
| Piednoir, B | 1 |
| Couturier, D | 3 |
| Coste, T | 2 |
| Dubois, RN | 5 |
| Shiff, SJ | 1 |
| Shivaprasad, P | 1 |
| Santini, DL | 1 |
| Tangrea, JA | 1 |
| Albert, PS | 1 |
| Lanza, E | 1 |
| Woodson, K | 1 |
| Corle, D | 2 |
| Hasson, M | 1 |
| Burt, R | 1 |
| Iber, F | 1 |
| Kikendall, JW | 1 |
| Lance, P | 2 |
| Shike, M | 1 |
| Weissfeld, J | 1 |
| Shpitz, B | 1 |
| Klein, E | 1 |
| Buklan, G | 1 |
| Neufeld, D | 1 |
| Nissan, A | 1 |
| Freund, HR | 1 |
| Grankin, M | 1 |
| Bernheim, J | 1 |
| González-Pérez, A | 1 |
| López-Ridaura, R | 1 |
| de Vries, EG | 1 |
| Schmiegel, W | 3 |
| Reinacher-Schick, A | 1 |
| Schernhammer, ES | 3 |
| Colditz, GA | 3 |
| Asano, TK | 2 |
| McLeod, RS | 2 |
| Samowitz, W | 1 |
| Hoffman, M | 1 |
| Ma, KN | 1 |
| Levin, TR | 1 |
| Neuhausen, S | 1 |
| Krishnan, K | 4 |
| Ruffin, MT | 4 |
| Normolle, DP | 1 |
| Brenner, DE | 4 |
| Juhász, M | 1 |
| Prónai, L | 1 |
| Simon, LS | 1 |
| Florent, C | 1 |
| Meary, N | 1 |
| Tranah, GJ | 2 |
| Ritt, M | 1 |
| Gasche, C | 3 |
| Scovern, H | 1 |
| Kruis, W | 1 |
| Schreiber, S | 1 |
| Pox, C | 2 |
| Kroesen, A | 1 |
| Taxonera, C | 1 |
| Mendoza, JL | 1 |
| Sciulli, MG | 1 |
| Filabozzi, P | 1 |
| Padovano, R | 1 |
| Capone, ML | 1 |
| Grana, M | 1 |
| Carnevale, V | 1 |
| Miliaras, S | 1 |
| Miliaras, D | 1 |
| Vrettou, E | 1 |
| Zavitsanakis, A | 1 |
| Kiskinis, D | 1 |
| Vermel', AE | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Oxenius, B | 1 |
| Horgan, K | 1 |
| Lines, C | 1 |
| Riddell, R | 1 |
| Morton, D | 1 |
| Konstam, MA | 1 |
| Gill, S | 1 |
| Scheiman, J | 1 |
| Turris, SA | 1 |
| Smith, S | 1 |
| Masmoudi, A | 1 |
| Chevalier, TL | 1 |
| Sabatier, L | 1 |
| Soria, JC | 1 |
| Natarajan, L | 1 |
| Macarthur, M | 1 |
| Hold, GL | 1 |
| El-Omar, EM | 1 |
| Gondal, G | 1 |
| Grotmol, T | 1 |
| Hofstad, B | 1 |
| Eide, TJ | 1 |
| Curhan, GC | 1 |
| Vachon, GC | 1 |
| Raskov, HH | 1 |
| Beresford, SA | 1 |
| Ritenbaugh, C | 1 |
| Lasser, NL | 1 |
| Snetselaar, LG | 1 |
| Black, HR | 1 |
| Anderson, GL | 1 |
| Assaf, AR | 1 |
| Bassford, T | 1 |
| Bowen, D | 1 |
| Brunner, RL | 1 |
| Brzyski, RG | 1 |
| Chlebowski, RT | 1 |
| Gass, M | 1 |
| Harrigan, RC | 1 |
| Hays, J | 1 |
| Heber, D | 1 |
| Heiss, G | 1 |
| Hendrix, SL | 1 |
| Howard, BV | 1 |
| Hsia, J | 1 |
| Hubbell, FA | 1 |
| Jackson, RD | 1 |
| Kotchen, JM | 1 |
| Kuller, LH | 1 |
| LaCroix, AZ | 1 |
| Lane, DS | 1 |
| Langer, RD | 1 |
| Lewis, CE | 1 |
| Margolis, KL | 1 |
| Mossavar-Rahmani, Y | 1 |
| Ockene, JK | 1 |
| Parker, LM | 1 |
| Perri, MG | 1 |
| Phillips, L | 1 |
| Prentice, RL | 1 |
| Robbins, J | 1 |
| Rossouw, JE | 1 |
| Sarto, GE | 1 |
| Stefanick, ML | 1 |
| Van Horn, L | 1 |
| Vitolins, MZ | 1 |
| Wactawski-Wende, J | 1 |
| Wallace, RB | 1 |
| Whitlock, E | 1 |
| Ruminski, W | 1 |
| Jensen, K | 1 |
| Kringelbach, TM | 1 |
| Vang, O | 1 |
| Bouchelouche, PN | 1 |
| Munck, LK | 1 |
| Siersema, PD | 1 |
| Yu, S | 1 |
| Sahbaie, P | 1 |
| Steyerberg, EW | 1 |
| Simpson, PW | 1 |
| Triadafilopoulos, G | 1 |
| Sheng, JQ | 1 |
| Li, SR | 1 |
| Yang, XY | 1 |
| Zhang, YH | 1 |
| Su, H | 1 |
| Yu, DL | 1 |
| Yan, W | 1 |
| Geng, HG | 1 |
| Jack, F | 1 |
| Geyer, M | 1 |
| Stamenic, I | 1 |
| Bühler, H | 1 |
| Bertschinger, P | 1 |
| Stürmer, T | 3 |
| Kurth, T | 1 |
| Glynn, RJ | 4 |
| Saif, MW | 1 |
| Mehra, R | 1 |
| Terhaar Sive Droste, JS | 1 |
| Tuynman, JB | 1 |
| Van Dullemen, HM | 1 |
| Mulder, CJ | 1 |
| Allison, M | 1 |
| Garland, C | 1 |
| Chlebowski, R | 1 |
| Criqui, M | 1 |
| Langer, R | 1 |
| Wu, L | 1 |
| Roy, H | 1 |
| McTiernan, A | 1 |
| Kuller, L | 1 |
| Redston, M | 1 |
| Solomon, SD | 2 |
| Kim, K | 1 |
| Tang, J | 2 |
| Wittes, J | 2 |
| Hess, TM | 1 |
| Woloj, GM | 1 |
| Boisserie, F | 1 |
| Anderson, WF | 1 |
| Bagheri, D | 1 |
| Dewar, T | 1 |
| Foley, TR | 1 |
| Hoffman, N | 1 |
| Pruitt, RE | 1 |
| Saltzman, JR | 1 |
| Salzberg, B | 1 |
| Sylwestrowicz, T | 1 |
| Gordon, GB | 1 |
| Dite, P | 1 |
| Hajer, J | 1 |
| Macdonald, K | 1 |
| Bhadra, P | 1 |
| Fowler, R | 1 |
| Lin, J | 1 |
| Bhat, S | 1 |
| O'Brien, TG | 1 |
| Larsson, SC | 1 |
| Muir, KR | 5 |
| Liu, JF | 4 |
| Grainge, M | 1 |
| Armitage, N | 1 |
| Shepherd, V | 1 |
| Popat, S | 1 |
| Houlston, RS | 4 |
| Kim, S | 1 |
| Reid, K | 1 |
| Sansom, OJ | 1 |
| Guichard, S | 1 |
| Mayer, I | 1 |
| Jodrell, DI | 1 |
| Clarke, AR | 1 |
| Hall, MN | 1 |
| Campos, H | 1 |
| Thoms, HC | 1 |
| Dubé, C | 1 |
| Lewin, G | 1 |
| Tsertsvadze, A | 1 |
| Barrowman, N | 1 |
| Code, C | 1 |
| Sampson, M | 1 |
| Moher, D | 1 |
| Cen, YY | 1 |
| Renehan, AG | 1 |
| Luebeck, G | 1 |
| Flossmann, E | 2 |
| Rothstein, RI | 1 |
| Robertson, DJ | 2 |
| Pearson, LH | 1 |
| DuPont, AW | 1 |
| Arguedas, MR | 1 |
| Logan, RFA | 1 |
| Larsson, H | 1 |
| Pedersen, L | 1 |
| Yang, YX | 1 |
| Hennessy, S | 1 |
| Propert, K | 1 |
| Hwang, WT | 1 |
| Sedarat, A | 1 |
| Lewis, JD | 1 |
| Kauh, J | 1 |
| Khuri, FR | 1 |
| Benelli, R | 1 |
| Murashige, N | 1 |
| Kami, M | 1 |
| Ikeda, M | 1 |
| Chae, YK | 1 |
| Yun, JH | 1 |
| Logan, R | 1 |
| Kune, G | 1 |
| Kune, GA | 2 |
| Kune, S | 1 |
| Watson, LF | 1 |
| Shepherd, VC | 1 |
| Armitage, NC | 1 |
| Yasuda, O | 1 |
| Takemura, Y | 1 |
| Rakugi, H | 1 |
| Smith, CJ | 1 |
| McKay, GA | 1 |
| Fisher, M | 1 |
| Lundberg, GD | 1 |
| Möhler, M | 1 |
| Gutzler, F | 1 |
| Paganini-Hill, A | 1 |
| Sullivan, JL | 1 |
| Burkhart, GA | 1 |
| Egan, KM | 1 |
| Speizer, FE | 1 |
| Marcus, AJ | 1 |
| Gumaste, VV | 1 |
| Eisen, GM | 1 |
| Wurzelmann, JI | 1 |
| Ransohoff, DF | 1 |
| Talal, A | 1 |
| Morgan, GP | 1 |
| Trujillo, MA | 1 |
| Garewal, HS | 2 |
| Sampliner, RE | 1 |
| Rimm, EB | 1 |
| Ascherio, A | 1 |
| Hennekens, CH | 4 |
| Waterhouse, DM | 1 |
| Brenner, D | 1 |
| Peleg, II | 2 |
| Maibach, HT | 1 |
| Brown, SH | 1 |
| Schreinemachers, DM | 1 |
| Everson, RB | 1 |
| Gann, PH | 1 |
| Lo, SV | 1 |
| Perry, HU | 1 |
| Lyons, R | 1 |
| Johnson, KA | 1 |
| Prindiville, SA | 1 |
| van Bodegraven, AA | 1 |
| Lourens, J | 1 |
| Sindram, JW | 1 |
| Kaufmann, HJ | 1 |
| Roychowdhury, DF | 1 |
| Schuler, M | 1 |
| Goldberg, Y | 1 |
| Burney, KD | 1 |
| Elder, DJ | 2 |
| Hague, A | 1 |
| Hicks, DJ | 1 |
| Shao, J | 1 |
| Tsujii, M | 1 |
| Sheng, H | 1 |
| Beauchamp, RD | 1 |
| Lubin, MF | 1 |
| Cotsonis, GA | 1 |
| Clark, WS | 1 |
| Luk, GD | 1 |
| Alderman, C | 1 |
| Brawley, OW | 1 |
| Phillips, PH | 1 |
| Cheson, BD | 1 |
| Csordas, A | 1 |
| Weiss, HA | 2 |
| Reeves, MJ | 1 |
| Trentham-Dietz, A | 1 |
| Storer, BE | 1 |
| Remington, PL | 1 |
| Giardiello, FM | 1 |
| Smalley, WE | 2 |
| Braun, EM | 1 |
| Artigas, C | 1 |
| Fuchs, C | 1 |
| Rozen, R | 1 |
| Levy, GN | 1 |
| Bosch, FX | 1 |
| Munoz, N | 1 |
| Rautureau, J | 1 |
| McPherson, RS | 1 |
| Glober, GA | 1 |
| Rock, CL | 2 |
| Normolle, D | 2 |
| Vaerten, MA | 1 |
| Peters-Golden, M | 2 |
| Crowell, J | 1 |
| Kelloff, G | 1 |
| Williams, CS | 1 |
| Smalley, W | 1 |
| Negri, E | 1 |
| Franceschi, S | 1 |
| Conti, E | 1 |
| Montella, M | 1 |
| Giacosa, A | 1 |
| Falcini, A | 1 |
| Decarli, A | 1 |
| Sánchez García, P | 1 |
| Vainio, H | 2 |
| Vanchieri, C | 1 |
| Galanko, JC | 1 |
| Murray, SC | 1 |
| Helm, JF | 1 |
| Woosley, JT | 1 |
| Thun, MJ | 2 |
| Moreno González, A | 1 |
| Freedman, AN | 1 |
| Michalek, AM | 1 |
| Zhang, ZF | 1 |
| Marshall, JR | 1 |
| Mettlin, CJ | 1 |
| Asirwatham, JE | 1 |
| Petrelli, NJ | 1 |
| Caporaso, NE | 1 |
| Singh, AK | 1 |
| Trotman, BW | 1 |
| Chapman, PD | 1 |
| Mathers, J | 1 |
| Marchesi, VT | 1 |
| Sowers, M | 1 |
| Seidensticker, F | 1 |
| Schmiegel, WH | 1 |
| Faivre, J | 1 |
| Bonithon-Kopp, C | 1 |
| del Soldato, P | 1 |
| Sorrentino, R | 1 |
| Pinto, A | 1 |
| Wallinger, S | 1 |
| Dietmaier, W | 1 |
| Beyser, K | 1 |
| Bocker, T | 1 |
| Hofstädter, F | 1 |
| Fishel, R | 1 |
| Rüschoff, J | 1 |
| Smith, ML | 1 |
| Hawcroft, G | 1 |
| Mabro, M | 1 |
| de Gramont, A | 1 |
| Huerta-Alvarez, C | 2 |
| Strul, H | 1 |
| Sharma, RA | 1 |
| Sjödahl, R | 1 |
| Dihlmann, S | 1 |
| Siermann, A | 1 |
| von Knebel Doeberitz, M | 1 |
| Burney, K | 1 |
| Bailey, J | 1 |
| Chambers, S | 1 |
| Evans, L | 1 |
| Krishnan, A | 1 |
| Yoon, H | 1 |
| Nakamura, H | 1 |
| Chopra, CL | 1 |
| Huang, G | 1 |
| Scheiman, JM | 1 |
| Chernew, ME | 1 |
| Fendrick, AM | 1 |
| Bakhle, YS | 1 |
| Moyad, MA | 1 |
| Suleiman, S | 1 |
| Sonnenberg, A | 1 |
| North, GL | 1 |
| Henley, SJ | 1 |
| Sample, D | 1 |
| Wargovich, M | 1 |
| Fischer, SM | 1 |
| Inamdar, N | 1 |
| Schwartz, P | 1 |
| Do, KA | 1 |
| Sample, DA | 1 |
| Sinicrope, PS | 1 |
| Wargovich, MJ | 1 |
| Evans, RC | 1 |
| Fear, S | 1 |
| Ashby, D | 1 |
| Hackett, A | 1 |
| Williams, E | 1 |
| Van Der Vliet, M | 1 |
| Dunstan, FD | 1 |
| Rhodes, JM | 1 |
| Stemmermann, GN | 1 |
| Nomura, AM | 1 |
| Grove, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Acetylsalicylic Acid as Secondary Prevention in Colorectal Cancer[NCT03326791] | Phase 2/Phase 3 | 466 participants (Actual) | Interventional | 2017-12-15 | Active, not recruiting | ||
| Aspirin/Folate Prevention of Large Bowel Polyps[NCT00272324] | Phase 2/Phase 3 | 1,121 participants | Interventional | 1992-02-29 | Completed | ||
| The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer[NCT05590117] | Early Phase 1 | 48 participants (Anticipated) | Interventional | 2022-10-11 | Enrolling by invitation | ||
| Diet obEsity sMoking Epigenetics geneTics biomaRkers Physical Activity: An International Multicenter Case-control Study on Endogenous and Exogenous Risk Factors in Early-onset Colorectal Cancer[NCT05732623] | 2,300 participants (Anticipated) | Observational [Patient Registry] | 2022-12-05 | Recruiting | |||
| Effects of Antiplatelets Discontinuation in Patients Receiving Polypectomy: Randomized Controlled Trial[NCT02865824] | 180 participants (Anticipated) | Interventional | 2016-01-31 | Enrolling by invitation | |||
| Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome[NCT02813824] | Phase 3 | 852 participants (Anticipated) | Interventional | 2017-11-14 | Recruiting | ||
| ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis[NCT02328677] | 5,000 participants (Anticipated) | Observational | 2007-03-31 | Recruiting | |||
| [NCT02602938] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study[NCT03387384] | 5,000 participants (Anticipated) | Observational [Patient Registry] | 2018-06-30 | Recruiting | |||
| A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2x2 Factorial Design Biomarker Tertiary Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. The ASAMET Trial[NCT03047837] | Phase 2 | 160 participants (Anticipated) | Interventional | 2017-03-15 | Recruiting | ||
| Colorectal Cancer Screening in Norway: Pilot Study of a National Screening Programme With Randomised Comparison of Different Screening Strategies to Provide the Best Possible Service to the Population[NCT01538550] | 140,000 participants (Actual) | Interventional | 2012-03-31 | Active, not recruiting | |||
| Colorectal Cancer Screening in Average-risk Population: a Multicenter, Randomized Control Trial Comparing Immunochemical Fecal Occult Blood Testing Versus Colonoscopy.[NCT00906997] | Phase 3 | 55,498 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| The Oncopanel Pilot (TOP) Study[NCT02171286] | 432 participants (Actual) | Observational | 2014-10-31 | Completed | |||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| A Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal Adenomas[NCT00486512] | Phase 3 | 350 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to The overall program was terminated) | ||
| Association of PeriOPerative Aspirin-ResisTance and CardioVascular Outcome[NCT04053894] | 220 participants (Anticipated) | Observational | 2019-08-31 | Not yet recruiting | |||
| Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease[NCT03757156] | 4,118 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | |||
| Nurses' Health Study (Cardiovascular Component)[NCT00005152] | 121,700 participants (Actual) | Observational | 1980-08-31 | Active, not recruiting | |||
| Effects on Omission of NSAIDs on the Consumption of Opioids in the Standard Analgesic Regimen After Elective Laparoscopic Colorectal Cancer Resection in an ERAS Setting. A Retrospective Single-center Cohort Study.[NCT04448652] | 502 participants (Actual) | Observational [Patient Registry] | 2015-01-01 | Completed | |||
| ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk[NCT02394769] | 180 participants (Actual) | Interventional | 2015-07-06 | Active, not recruiting | |||
| Comparative Effectiveness of Fecal Immunochemical Tests With Optical Colonoscopy[NCT03264898] | 3,600 participants (Anticipated) | Observational | 2017-10-02 | Recruiting | |||
| Validation of Advanced Colorectal Neoplasm Risk Categories in Screening Colonoscopy and Identification of Biomarkers in a Prospective Cohort in Mexico.[NCT05661292] | 2,000 participants (Anticipated) | Observational | 2019-08-01 | Recruiting | |||
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193] | Phase 3 | 1,561 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence[NCT00224679] | Phase 3 | 300 participants | Interventional | 1997-03-31 | Terminated | ||
| Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial[NCT00565708] | Phase 3 | 1,587 participants (Actual) | Interventional | 2008-12-31 | Active, not recruiting | ||
| Comparison of Small Colorectal Polyp Removal Using Cold Endoscopic Mucosal Resection With Hot Endoscopic Mucosal Resection: a Pilot Study[NCT03000868] | 0 participants (Actual) | Interventional | 2016-12-01 | Withdrawn (stopped due to No participants were enrolled.) | |||
| A Placebo-controlled Study of Efficacy & Safety of Aspirin as an add-on Treatment in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Seizures[NCT03356769] | Phase 2 | 98 participants (Anticipated) | Interventional | 2017-11-20 | Recruiting | ||
| Prevention of Females Malignancies in Families With Hereditary Breast Cancer by Personalized Optimization of Se Levels in the Organism.[NCT04014283] | 7,000 participants (Anticipated) | Interventional | 2014-10-31 | Active, not recruiting | |||
| A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.[NCT02084615] | 300 participants (Anticipated) | Interventional | 2014-08-31 | Enrolling by invitation | |||
| Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study[NCT00002527] | Phase 3 | 635 participants (Actual) | Interventional | 1993-05-31 | Completed | ||
| The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia[NCT02324374] | 50 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386] | Phase 3 | 2,586 participants (Actual) | Interventional | 1999-12-23 | Completed | ||
| Norwegian Colorectal Cancer Prevention Trial[NCT00119912] | 100,000 participants (Actual) | Interventional | 1999-01-31 | Active, not recruiting | |||
| [NCT00000611] | Phase 3 | 0 participants | Interventional | Completed | |||
| Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094] | Phase 3 | 1,170 participants (Anticipated) | Interventional | 2000-03-31 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| 0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients[NCT00771953] | Phase 2 | 109 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Combined Analyses and Long-term Follow-up in the Two Norwegian Homocysteine-Lowering B-Vitamin Trials NORVIT and WENBIT[NCT00671346] | 6,839 participants (Anticipated) | Observational | 1998-12-31 | Active, not recruiting | |||
| [NCT00005182] | 50,000 participants (Actual) | Observational | 1985-12-31 | Completed | |||
| Impact of Folates in the Care of the Male Infertility[NCT01407432] | Phase 3 | 162 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer[NCT00798876] | 56 participants (Actual) | Interventional | 2001-12-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
Measured using liquid chromatography/mass spectrometry (NCT02394769)
Timeframe: 8-12 weeks
| Intervention | ng/mg cr (Mean) | ||
|---|---|---|---|
| Baseline urinary PGE-M | Post-intervention urinary PGE-M | Change in urinary PGE-M | |
| Low Dose Aspirin | 17.7 | 13.1 | -4.6 |
| Placebo (For Aspirin) | 15.5 | 16.4 | 0.8 |
| Standard Dose Aspirin | 14.3 | 9.4 | -4.9 |
For determining progression-free survival, progression was determined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progression was defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00771953)
Timeframe: From the date of randomization until the first date that recurrent or progressive disease is objectively documented.
| Intervention | days (Median) |
|---|---|
| Apricoxib Plus Docetaxel | 75 |
| Placebo Plus Docetaxel | 97 |
| Apricoxib Plus Pemetrexed | 103 |
| Placebo Plus Pemetrexed | 98 |
180 reviews available for aspirin and Colorectal Neoplasms
| Article | Year |
|---|---|
Timing of Aspirin Use Among Patients With Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Colorectal Neoplasms; Confidence I | 2021 |
Impact of antiplatelet agents and anticoagulants on the performance of fecal immunochemical tests: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Colorectal Neoplasms; Early Detection of Cancer; Feces; Fibrinolytic Agents | 2022 |
Meta-analysis of aspirin-guided therapy of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neoplasms; Cycloo | 2022 |
Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.
Topics: Adult; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Computer Simulation; Hemorrhage; Huma | 2022 |
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Hemorrhage; Humans; Primary Prevention; Rand | 2022 |
Impact of antithrombotic drugs on the accuracy of fecal occult blood testing for advanced colorectal neoplasia screening: a meta-analysis and systematic review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorectal Neoplasms; Early Detection | 2023 |
Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies.
Topics: Adenoma; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neop | 2022 |
Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited.
Topics: Aspirin; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Cyclooxygenase 2; Humans; Mut | 2022 |
Colorectal cancer chemoprevention: is aspirin still in the game?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms; Hu | 2022 |
Biology of Precancers and Opportunities for Cancer Interception: Lesson from Colorectal Cancer Susceptibility Syndromes.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biology; Colorectal Ne | 2023 |
Chemoprevention of colorectal cancer in general population and high-risk population: a systematic review and network meta-analysis.
Topics: Adenoma; Aspirin; Calcium; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Human | 2023 |
Cyclooxygenase Inhibitors and Cancer: The Missing Pieces.
Topics: Aspirin; Carcinogenesis; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 | 2023 |
Aspirin chemoprevention in colorectal cancer: network meta-analysis of low, moderate, and high doses.
Topics: Aspirin; Chemoprevention; Colorectal Neoplasms; Humans; Network Meta-Analysis | 2023 |
Impact of proton pump inhibitors on the risk of small bowel or colorectal bleeding: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Gastrointestinal Hemorrhage; | 2023 |
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies.
Topics: Age Factors; Age of Onset; Aspirin; Calcium; Carcinogenesis; Colorectal Neoplasms; Diet; Early Detec | 2019 |
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies.
Topics: Age Factors; Age of Onset; Aspirin; Calcium; Carcinogenesis; Colorectal Neoplasms; Diet; Early Detec | 2019 |
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies.
Topics: Age Factors; Age of Onset; Aspirin; Calcium; Carcinogenesis; Colorectal Neoplasms; Diet; Early Detec | 2019 |
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies.
Topics: Age Factors; Age of Onset; Aspirin; Calcium; Carcinogenesis; Colorectal Neoplasms; Diet; Early Detec | 2019 |
Low-dose aspirin use and cancer-specific mortality: a meta-analysis of cohort studies.
Topics: Aspirin; China; Cohort Studies; Colorectal Neoplasms; Databases, Factual; Humans | 2021 |
Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention.
Topics: Aberrant Crypt Foci; Adenoma; Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; As | 2020 |
Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019.
Topics: Aspirin; Cohort Studies; Colorectal Neoplasms; Gastrointestinal Neoplasms; Humans | 2020 |
Do Aspirin and Flavonoids Prevent Cancer through a Common Mechanism Involving Hydroxybenzoic Acids?-The Metabolite Hypothesis.
Topics: Animals; Aspirin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms | 2020 |
Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Esophageal Neoplasms; Humans | 2020 |
Recent advances in clinical practice: colorectal cancer chemoprevention in the average-risk population.
Topics: Alcohol Drinking; Allium; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Caffeine; | 2020 |
A potential role for aspirin in the prevention and treatment of cholangiocarcinoma.
Topics: Animals; Aspirin; Bile Duct Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Humans; Incidence | 2021 |
Aspirin in the Prevention of Colorectal Neoplasia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms; Humans; Pre | 2021 |
Mechanisms of Colorectal Cancer Prevention by Aspirin-A Literature Review and Perspective on the Role of COX-Dependent and -Independent Pathways.
Topics: Animals; Aspirin; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Gastrointestinal | 2020 |
Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Colorectal Neoplasms; Cyclooxy | 2021 |
AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review.
Topics: Aspirin; Chemoprevention; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Neoplasm Recurren | 2021 |
Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Incidence; Neoplasm | 2021 |
Influence of aspirin on prevention of colorectal cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Humans; Incidence; Randomized Controlled Trials as Topic | 2021 |
Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis.
Topics: Adenoma; Aspirin; Colonoscopy; Colorectal Neoplasms; Cost-Benefit Analysis; Humans; Network Meta-Ana | 2021 |
Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas.
Topics: Adenoma; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Dietary Supplements; Docosahexaenoi | 2022 |
The mortality reducing effect of aspirin in colorectal cancer patients: Interpreting the evidence.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Cardiovascular Diseases; Colorectal Neoplasm | 2017 |
Aspirin for Primary Prevention.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Diabetes Mellitus; Gastrointest | 2017 |
Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.
Topics: Adenoma; Anti-Inflammatory Agents; Aspirin; Colorectal Neoplasms; Humans; Incidence; Neoplasm Recurr | 2017 |
[Aspirin and colorectal cancer].
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Class I Phosphat | 2018 |
Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations.
Topics: Aspirin; Australia; Canada; Case-Control Studies; Colorectal Neoplasms; Humans; Polymorphism, Single | 2018 |
Bowel cancer screening for women at midlife.
Topics: Aged; Aspirin; Australia; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Female; Huma | 2018 |
Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD).
Topics: Aspirin; Brain Neoplasms; Child; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis | 2018 |
Influence of Smoking, Body Mass Index, and Other Factors on the Preventive Effect of Nonsteroidal Anti-Inflammatory Drugs on Colorectal Cancer Risk.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Colorectal Neoplasms; Diet; | 2018 |
Aspirin and Delayed Chemoprevention of Colorectal Cancer.
Topics: Anticarcinogenic Agents; Aspirin; Chemoprevention; Colorectal Neoplasms; Humans; Randomized Controll | 2018 |
Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Ce | 2018 |
Chemoprevention of colorectal cancer: aspirin and beyond.
Topics: Aspirin; Colorectal Neoplasms; Humans; Incidence | 2018 |
Gene-environment interactions and colorectal cancer risk: An umbrella review of systematic reviews and meta-analyses of observational studies.
Topics: Aspirin; Chromosomes, Human, Pair 8; Colorectal Neoplasms; Gene-Environment Interaction; Genetic Pre | 2019 |
Risks of colorectal neoplasms and cardiovascular thromboembolic events after the combined use of selective COX-2 inhibitors and aspirin with 5-year follow-up: a meta-analysis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase | 2019 |
Acetylsalicylic Acid and its Potential for Chemoprevention of Colorectal Carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Chemoprevention; Colorect | 2018 |
Aspirin for primary prevention: USPSTF recommendations for CVD and colorectal cancer.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Colorectal Neoplasms; Dose-Respons | 2019 |
Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies.
Topics: Aspirin; Cohort Studies; Colorectal Neoplasms; Female; Humans; Male; Research Design; Risk | 2013 |
Prevention and intervention trials for colorectal cancer.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; An | 2013 |
Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Topics: Animals; Antineoplastic Agents; Aspirin; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; | 2014 |
Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Aspirin; Chromosomal Instab | 2013 |
Potential targets for colorectal cancer prevention.
Topics: Animals; Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; Humans; Inhibitor of Apoptosis Proteins; I | 2013 |
Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Confidence Intervals; Female; G | 2013 |
Role of platelets in inflammation and cancer: novel therapeutic strategies.
Topics: Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Colorectal Neoplasms; Cyclooxygenase 2; | 2014 |
Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences.
Topics: Aged; Aspirin; Colorectal Neoplasms; England; Female; Humans; Incidence; Male; Mass Screening; Middl | 2013 |
Pharmacological and dietary prevention for colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Calcium; Colorectal Neoplasms; Diet; | 2013 |
Aspirin and colorectal cancer: back to the future.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; H | 2014 |
Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
Topics: Aspirin; Barrett Esophagus; Cardiovascular Diseases; Colorectal Neoplasms; Drug Combinations; Gastro | 2014 |
[Aspirin in primary and secondary prevention of colorectal carcinomas].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Observational Studie | 2013 |
Systematic review: interactions between aspirin, and other nonsteroidal anti-inflammatory drugs, and polymorphisms in relation to colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arachidonic Acid; Aspirin; Colorecta | 2014 |
Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies.
Topics: Aspirin; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Humans; Observational Studies | 2014 |
Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Class I Phosphatid | 2015 |
Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Molecular T | 2015 |
[Association of long-term oral low-dose aspirin and survival in colorectal cancer: a meta-analysis].
Topics: Aspirin; Colorectal Neoplasms; Humans | 2015 |
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin.
Topics: Aspirin; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Dementia, Vascular; Human | 2015 |
The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms; Diet; Exerc | 2015 |
New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Colorectal Neoplasms; Dose-Response Rela | 2015 |
Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Colonic Polyps; Colorectal Ne | 2015 |
Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neopl | 2015 |
Where Do We Stand With Aspirin for the Prevention of Colorectal Cancer? The USPSTF Recommendations.
Topics: Aged; Aspirin; Chemoprevention; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Adminis | 2016 |
Chemoprevention of colorectal neoplasia.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, No | 2017 |
PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Class I Phosphatidylinositol 3-Kinases; Colorectal | 2016 |
Aspirin and colorectal cancer: the promise of precision chemoprevention.
Topics: Aspirin; Chemoprevention; Colorectal Neoplasms; Humans; Precision Medicine | 2016 |
Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer.
Topics: Adult; Aged; Aspirin; Colorectal Neoplasms; Female; Follow-Up Studies; Gastrointestinal Neoplasms; H | 2016 |
Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Evi | 2016 |
Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Inci | 2016 |
The Efficacy of Aspirin in Preventing the Recurrence of Colorectal Adenoma: a Renewed Meta-Analysis of Randomized Trials.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Neoplasm Re | 2016 |
The role of aspirin in colorectal cancer chemoprevention.
Topics: Animals; Aspirin; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Humans; Observat | 2016 |
Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
Topics: Aspirin; Cardiovascular Diseases; Chemoprevention; Colorectal Neoplasms; Evidence-Based Medicine; Fe | 2016 |
The role of aspirin in preventing colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Gastrointestinal Hemorrhage; | 2016 |
Aspirin and Cancer.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Pl | 2016 |
Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention.
Topics: Aspirin; Colorectal Neoplasms; Early Detection of Cancer; Humans; Incidence; Mass Screening; Randomi | 2017 |
Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bayes Theorem; Calcium; Chemoprevention; Colorecta | 2016 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Ce | 2008 |
Point/Counterpoint: Aspirin is clinically effective in chemoprevention of colorectal neoplasia: point.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms; Humans; Tre | 2008 |
Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint.
Topics: Animals; Aspirin; Cardiovascular Diseases; Chemoprevention; Clinical Trials as Topic; Colorectal Neo | 2008 |
Chemoprevention of colorectal cancer: feasibility in everyday practice?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Chemoprevention; Clinical T | 2008 |
Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all?
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; ErbB Recepto | 2008 |
The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Humans; Neoplasm Recurrence, Loca | 2009 |
Prognostic and therapeutic implications of Apc mutations in colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Catenin; Colorectal Neoplasms; Cytoskeleton; | 2008 |
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal | 2009 |
Aspirin and NSAIDs for the prevention of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans | 2009 |
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Digestive | 2009 |
Clinical inquiries. Is aspirin effective for primary prevention of colon cancer?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplasms; | 2010 |
Effect of aspirin and NSAIDs on risk and survival from colorectal cancer.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; | 2010 |
Aspirin in the chemoprevention of colorectal neoplasia: an overview.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans | 2012 |
Aspirin for the prevention of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Chemoprevention; Colorect | 2011 |
Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Chemoprevention; | 2011 |
Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?
Topics: Aspirin; Colitis; Colorectal Neoplasms; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammat | 2012 |
The role of low-dose aspirin in the prevention of colorectal cancer.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cardiova | 2012 |
Aspirin as a chemoprevention agent for colorectal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl | 2012 |
Balancing the risk and benefits of low-dose aspirin in clinical practice.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Gastrointestinal Hemorrhage; Hemorrhage; Hum | 2012 |
Aspirin and the prevention of colorectal cancer.
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Ne | 2012 |
Aspirin and NSAIDs; benefits and harms for the gut.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cardiovascular Disease | 2012 |
Non-aspirin non-steroidal anti-inflammatory drugs for the primary chemoprevention of non-gastrointestinal cancer: summary of evidence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms; Hu | 2012 |
Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspiri | 2012 |
Mode of action of aspirin as a chemopreventive agent.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Colorectal Neoplasms; Cyclooxygenase Inh | 2013 |
Aspirin in prevention of sporadic colorectal cancer: current clinical evidence and overall balance of risks and benefits.
Topics: Aspirin; Colorectal Neoplasms; Humans; Randomized Controlled Trials as Topic; Risk | 2013 |
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Huma | 2012 |
Inhibitory effects of acetylsalicylic acid on exocrine pancreatic carcinogenesis.
Topics: Acinar Cells; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Az | 2013 |
Aspirin and cancer risk: an update to 2001.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Cohort Stu | 2002 |
Chemoprevention of colorectal cancer: slow, steady progress.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; | 2003 |
Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Aspirin; Colonic Neoplasms; Colorect | 2003 |
Chemoprevention of colorectal cancer--experimental approach and clinical applications.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms; Cy | 2003 |
Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Colorectal Neoplasms; Cy | 2003 |
Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle; Chem | 2003 |
Cyclooxygenase inhibitors: drugs for cancer prevention.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; | 2003 |
Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Color | 2003 |
Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Case-Control Studies; Coh | 2003 |
The potential of non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Arachidonic Acid | 2003 |
Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Neoplastic | 2004 |
Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Co | 2004 |
[Chemoprevention of colorectal cancer].
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agent | 2004 |
[Cyclooxygenase 2 inhibitors and adenomatous polyposis coli].
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2004 |
Review article: the chemoprevention of colorectal carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Chemoprevention; Chromosoma | 2004 |
Is colorectal cancer an avoidable disease nowadays?
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; | 2004 |
Colorectal cancer prevention.
Topics: Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Colo | 2005 |
[Pharmacological capacities of the prevention of colorectal cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Calcium; Colorectal Neopl | 2004 |
Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Calcium | 2005 |
What every emergency nurse needs to know about aspirin.
Topics: Aspirin; Colorectal Neoplasms; Coronary Disease; Delayed-Action Preparations; Drug Administration Sc | 2005 |
[Cyclooxygenase 2 inhibitors and cancer chemoprevention].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl | 2004 |
Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Case-Co | 2005 |
[Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2006 |
Chemoprevention in gastrointestinal cancers: current status.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Clinical Trials as Topi | 2006 |
Incidence and management of bevacizumab-related toxicities in colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoa | 2006 |
Chemoprevention for colon cancer: new opportunities, fact or fiction?
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplas | 2006 |
Do older adults using NSAIDs have a reduced risk of colorectal cancer?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Colore | 2006 |
The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colonic P | 2007 |
Colorectal cancer prevention: choosing the most effective population strategy using bio-mathematical approaches.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Feeding Behavior; Female; Humans; Male; Mass Screening; Mode | 2007 |
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal | 2007 |
Aspirin chemoprevention in patients with increased risk for colorectal cancer: a cost-effectiveness analysis.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colonoscopy; Colorectal N | 2007 |
Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: recommendation statement.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplas | 2007 |
Aspirin: recent developments.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; H | 2008 |
Diabetes, colorectal cancer and cyclooxygenase 2 inhibition.
Topics: Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Cost-Benefit Analysis; Cyclooxygenase 2 Inhi | 2008 |
Aspirin and cancer.
Topics: Aspirin; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Epidemiologic Methods; Humans; Ne | 1995 |
Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer. At what cost?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Colorectal Neop | 1994 |
Prevention of gastrointestinal cancer--the potential role of NSAIDs in colorectal cancer.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 1996 |
Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-S | 1996 |
Butyrate, aspirin and colorectal cancer.
Topics: Acetylation; Apoptosis; Aspirin; Butyrates; Cell Division; Colorectal Neoplasms; Humans; In Vitro Te | 1996 |
Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neoplasm | 1996 |
Aspirin and other nonsteroid anti-inflammatory drugs as cancer-preventive agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Case-Control Studies; Col | 1996 |
Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agent | 1996 |
[Diet factors and risk of the development of colorectal cancer].
Topics: Adult; Aged; Alcohol Drinking; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium, D | 1996 |
Aspirin chemoprevention of colorectal and oesophageal cancers. An overview of the literature and homeopathic explanation.
Topics: Aspirin; Colorectal Neoplasms; Esophageal Neoplasms; Homeopathy; Humans; Risk Factors | 1996 |
Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arachido | 1997 |
Colorectal cancer and nonsteroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Colorectal Neop | 1997 |
[Aspirin, non-steroidal anti-inflammatory agents and colonic carcinogenesis].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplasms; | 1997 |
Aspirin use and potential mechanisms for colorectal cancer prevention.
Topics: Adenocarcinoma; Adenomatous Polyps; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Color | 1997 |
Aspirin for the second hundred years: new uses for an old drug.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Disea | 1997 |
Aspirin and gastrointestinal cancer.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinoge | 1997 |
Use and safety of aspirin in the chemoprevention of colorectal cancer.
Topics: Aspirin; Cerebral Hemorrhage; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Humans; Incidence; Pe | 1998 |
Diet and cancer prevention: the concerted action polyp prevention (CAPP) studies.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Diet; Dietary Carbohyd | 1998 |
[Practice-relevant intestinal diseases: prevention of colon carcinoma].
Topics: Adenomatous Polyposis Coli; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyp | 1998 |
Chemoprevention of colorectal cancer.
Topics: Anticarcinogenic Agents; Antioxidants; Aspirin; Calcium; Colorectal Neoplasms; Dietary Fiber; Humans | 1999 |
NO-aspirins: a class of new anti-inflammatory and antithrombotic agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhi | 1999 |
The prevention of colorectal cancer by aspirin use.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Colorectal Neop | 1999 |
Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Ne | 2000 |
[Aspirin against cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Clinical T | 2000 |
Colorectal cancer chemoprevention: aspirin, other NSAID and COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; Humans; Is | 2000 |
Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2000 |
Cancer chemoprevention: a clinical reality.
Topics: Antineoplastic Agents, Hormonal; Aspirin; Breast Neoplasms; Chemoprevention; Colorectal Neoplasms; C | 2000 |
Non-steroidal anti-inflammatory drugs and chemoprevention of cancer.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Carotene; Case-Control Studie | 2000 |
Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl | 2001 |
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova | 2001 |
Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; D | 2001 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
COX-2 and cancer: a new approach to an old problem.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; E | 2001 |
An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxyge | 2001 |
The cost-effectiveness of aspirin for chemoprevention of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cost-Benefit Analysis; Human | 2002 |
Celecoxib as adjunctive therapy for treatment of colorectal cancer.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Chemotherap | 2001 |
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.
Topics: Adenomatous Polyposis Coli; Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroida | 2002 |
[Chemoprevention of colorectal cancer].
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2002 |
83 trials available for aspirin and Colorectal Neoplasms
| Article | Year |
|---|---|
Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial.
Topics: Aspirin; Colorectal Neoplasms; Double-Blind Method; Humans; Liver Neoplasms; Multicenter Studies as | 2021 |
[Aspirin for Chemoprevention of Colorectal Adenoma and Cancer].
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Cohort Studies; Colorect | 2021 |
Aspirin and the Risk of Colorectal Cancer According to Genetic Susceptibility among Older Individuals.
Topics: Aged; Aspirin; Colorectal Neoplasms; Genetic Predisposition to Disease; Humans; Prospective Studies; | 2022 |
Plasma Metabolomics Analysis of Aspirin Treatment and Risk of Colorectal Adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl | 2022 |
Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up.
Topics: Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Follow-Up Studies; Hum | 2022 |
Analysis of Body Mass Index in Early and Middle Adulthood and Estimated Risk of Gastrointestinal Cancer.
Topics: Adult; Aspirin; Body Mass Index; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; M | 2023 |
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.
Topics: Aspirin; Biomarkers; Colorectal Neoplasms; Creatinine; Female; Humans; Male; Middle Aged; Thromboxan | 2023 |
Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use.
Topics: Aspirin; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; Humans | 2023 |
Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplasms; Cyclooxygena | 2023 |
Folic acid supplementation and risk of colorectal neoplasia during long-term follow-up of a randomized clinical trial.
Topics: Aged; Aspirin; Colorectal Neoplasms; Dietary Supplements; Female; Folic Acid; Follow-Up Studies; Hum | 2019 |
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
Topics: Aged; Antineoplastic Agents; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Ther | 2019 |
Cold Snare Polypectomy in Patients Taking Dual Antiplatelet Therapy: A Randomized Trial of Discontinuation of Thienopyridines.
Topics: Aged; Aspirin; Atherosclerosis; Blood Loss, Surgical; Colonic Polyps; Colonoscopy; Colorectal Neopla | 2019 |
Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial).
Topics: Adult; Aged; Aspirin; Colorectal Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; | 2019 |
Metabolomics Analysis of Aspirin's Effects in Human Colon Tissue and Associations with Adenoma Risk.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colon; Colore | 2020 |
Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk.
Topics: Aged; Aspirin; Bacteria; Colorectal Neoplasms; Double-Blind Method; Female; Gastrointestinal Microbi | 2020 |
Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial.
Topics: Adenoma; Adult; Aspirin; Chemoprevention; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Non | 2020 |
The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.
Topics: Aberrant Crypt Foci; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Double- | 2020 |
Aspirin Use and Risk of Colorectal Cancer Among Older Adults.
Topics: Aged; Aspirin; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Risk Fact | 2021 |
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control St | 2021 |
An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial.
Topics: Aged; Aspirin; Chronic Disease; Colorectal Neoplasms; Decision Support Techniques; Humans; Middle Ag | 2021 |
The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomar | 2018 |
Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Basal Cell; Colorectal N | 2018 |
Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms.
Topics: Aspirin; Clinical Protocols; Colorectal Neoplasms; Early Detection of Cancer; Humans; Immunochemistr | 2018 |
Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
Topics: Adenoma; Aged; Anticarcinogenic Agents; Aspirin; Colonoscopy; Colorectal Neoplasms; Double-Blind Met | 2018 |
The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bi | 2018 |
Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Double-Blind Method; Early D | 2019 |
Body Composition and Aspirin Dose for Colorectal Adenoma Prevention in a Randomized Clinical Trial.
Topics: Adenoma; Aged; Aspirin; Body Composition; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; R | 2019 |
Effect of aspirin and antiplatelet drugs on the outcome of the fecal immunochemical test.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Immuno | 2013 |
A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized cont
Topics: Adenoma; Aged; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Clinical Protocols; Colonoscopy; | 2013 |
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adju | 2013 |
Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogeni | 2013 |
Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Colorectal Neoplasms; Early Dete | 2015 |
Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.
Topics: Adaptor Proteins, Signal Transducing; Adiposity; Adult; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2015 |
Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS).
Topics: Adenoma; Administration, Oral; Aged; Aspirin; Chromatography, Gas; Chromatography, Liquid; Colonosco | 2015 |
Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial.
Topics: Adenoma; Adult; Aged; Aspirin; Calcitriol; Calcium; Chemoprevention; Colectomy; Colorectal Neoplasms | 2016 |
Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial.
Topics: Adult; Alcohol Oxidoreductases; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplas | 2016 |
Inflammatory biomarkers, aspirin, and risk of colorectal cancer: Findings from the physicians' health study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; C-Reactive Protein; Case-Control Studies; Colorectal Neopla | 2016 |
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Chemotherapy, Adjuvant; Colorect | 2016 |
ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Aspirin; Biomarkers, T | 2017 |
Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation.
Topics: Adenoma; Alcohol Drinking; Aspirin; Chemoprevention; Colorectal Neoplasms; Double-Blind Method; Fema | 2008 |
MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial.
Topics: Adenoma; Alleles; Aspirin; Chi-Square Distribution; Colorectal Neoplasms; Double-Blind Method; Femal | 2008 |
Colorectal adenomas in a randomized folate trial: the role of baseline dietary and circulating folate levels.
Topics: Adenoma; Aspirin; Colonoscopy; Colorectal Neoplasms; Confidence Intervals; Diet; Female; Folic Acid; | 2008 |
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Topics: Adenoma; Adult; Aged; Aspirin; Carcinoma; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Non | 2008 |
Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colonoscop | 2009 |
Folic acid and risk of prostate cancer: results from a randomized clinical trial.
Topics: Adenoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neopl | 2009 |
Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors.
Topics: Adenoma; Alcohol Drinking; Aspirin; Colon; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; CpG Is | 2009 |
Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Topics: Adenoma; Aged; Aspirin; Cohort Studies; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2009 |
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.
Topics: Adenoma; Adolescent; Adult; Aged; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Colorectal Ne | 2010 |
Baseline plasma total homocysteine and adenoma recurrence: results from a double blind randomized clinical trial of aspirin and folate supplementation.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Double-Blind Method; Folic A | 2010 |
Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humani | 2011 |
Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.
Topics: Adenomatous Polyposis Coli; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Aspirin; Col | 2011 |
Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial.
Topics: Adenoma; Adenomatous Polyps; Aged; Aspirin; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase Inhibi | 2012 |
Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; Fem | 2011 |
Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Col | 2012 |
The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colorec | 2012 |
The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Double-Blind Method; | 2011 |
CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.
Topics: Adenoma; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Chemoprevention; Colorectal Neoplasms; Cytoch | 2013 |
Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial.
Topics: Adenoma; Aged; Aspirin; Colorectal Neoplasms; Dietary Fiber; Educational Status; Exercise; Female; F | 2002 |
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colonoscopy; | 2003 |
A randomized trial of aspirin to prevent colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colonoscopy; Colorectal N | 2003 |
Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neopla | 2003 |
[Acetylsalicylic acid for prevention of colorectal adenomas. The APP Study].
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorecta | 2003 |
Platelet activation in patients with colorectal cancer.
Topics: Aged; Aspirin; Biomarkers; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Female | 2005 |
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin | 2005 |
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
Topics: Adenoma; Aged; Aspirin; Colonic Polyps; Colorectal Neoplasms; Diet, Fat-Restricted; Estrogen Replace | 2006 |
[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non- | 2006 |
Colorectal cancer after start of nonsteroidal anti-inflammatory drug use.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of sporadic colorectal adenomas.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Celecoxib for the prevention of colorectal adenomatous polyps.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Total magnesium intake and colorectal cancer incidence in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dietary Supplements; Female; | 2006 |
Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Genetic Pre | 2006 |
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Col | 2007 |
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Col | 2007 |
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Col | 2007 |
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chi-Square Distribution; Col | 2007 |
Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Female; Follow-Up Studie | 2007 |
Aspirin and folic acid for the prevention of recurrent colorectal adenomas.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; Colo | 2008 |
Low-dose aspirin and incidence of colorectal tumors in a randomized trial.
Topics: Adult; Aged; Aspirin; Colorectal Neoplasms; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; | 1993 |
Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring.
Topics: Adult; Aspirin; Colorectal Neoplasms; Drug Administration Schedule; Drug Packaging; Electronics; Fem | 1996 |
Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neop | 1996 |
Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Case-Control Studies; Coca | 1997 |
Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colon; Colorectal Neoplasms; Drug Administr | 1997 |
Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplas | 1998 |
Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Aspirin; Biomarkers, Tumor; Biopsy, Needle; Carcinoma; Colorectal | 2001 |
APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings.
Topics: Adenoma; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colono | 2001 |
A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers, Tumor; Chemoprevention; Colorectal Neoplasms; C | 2002 |
431 other studies available for aspirin and Colorectal Neoplasms
| Article | Year |
|---|---|
Novel cinnamaldehyde-based aspirin derivatives for the treatment of colorectal cancer.
Topics: Acrolein; Animals; Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle Checkpoints; Cell Line, Tum | 2018 |
Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study.
Topics: Aspirin; Case-Control Studies; Colorectal Neoplasms; Diet; Female; Genome-Wide Association Study; Ge | 2021 |
Aspirin and Sulindac act via different mechanisms to inhibit store-operated calcium channel: Implications for colorectal cancer metastasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caco-2 Cells; Calcium Channel Blockers; Calcium Ch | 2022 |
Impact of aspirin discontinuation on thrombotic complications in laparoscopic colorectal cancer surgery.
Topics: Aspirin; Colorectal Neoplasms; Humans; Laparoscopy; Platelet Aggregation Inhibitors; Postoperative C | 2022 |
Chemoprevention for Colorectal Cancers: Are Chemopreventive Effects Different Between Left and Right Sided Colorectal Cancers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Colorectal Neoplasms; Cyclooxygen | 2022 |
Aspirin's effect on kinetic parameters of cells contributes to its role in reducing incidence of advanced colorectal adenomas, shown by a multiscale computational study.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Incidence; | 2022 |
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Female; Gastrointestinal Hemorr | 2022 |
Letter: long-term colorectal cancer incidence and mortality after adenoma removal associated with heritable factors, colonoscopic surveillance and aspirin.
Topics: Adenoma; Aspirin; Colonoscopy; Colorectal Neoplasms; Humans; Incidence; Risk Factors | 2022 |
Letter: long-term colorectal cancer incidence and mortality after adenoma removal associated with heritable factors, colonoscopic surveillance and aspirin-authors' reply.
Topics: Adenoma; Aspirin; Colonoscopy; Colorectal Neoplasms; Humans; Incidence | 2022 |
Association between antibiotic consumption and colon and rectal cancer development in older individuals: A territory-wide study.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorect | 2022 |
Anticoagulant drugs with or without proton pump inhibitor and colorectal cancer risk: a population-based, case-control study.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Colorectal Neoplasms; Drug Therapy, Comb | 2022 |
Incident Cancer Risk and Signatures Among Older MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts.
Topics: Aged; Aspirin; Colorectal Neoplasms; DNA Glycosylases; Female; Genetic Predisposition to Disease; Ge | 2022 |
Low-dose aspirin use and colorectal cancer survival in 32,195 patients-A national cohort study.
Topics: Aspirin; Cohort Studies; Colorectal Neoplasms; Digestive System Surgical Procedures; Humans; Hyperte | 2023 |
Anti-inflammatory and antioxidant effect of methanol extract of latex of Calotropis procera in rat model of colorectal cancer.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aspirin; Calotropis; Carcinogens; Colorectal Neopla | 2022 |
Aspirin Inhibits Carcinogenesis of Intestinal Mucosal Cells in UC Mice Through Inhibiting IL-6/JAK/STAT3 Signaling Pathway and Modulating Apoptosis and Proliferation.
Topics: Animals; Apoptosis; Aspirin; Azoxymethane; Carcinogenesis; Cell Proliferation; Colitis, Ulcerative; | 2022 |
Aspirin for Colorectal Cancer Prevention: Age Matters.
Topics: Aged; Aspirin; Colorectal Neoplasms; Double-Blind Method; Genetic Predisposition to Disease; Humans | 2022 |
Aspirin-Mediated Prevention of Colorectal Adenomas Recurrence is Affected by Blood Biochemistry and Nutritional Intake.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Eating; Female; Humans; Male; Triglycerides | 2022 |
Salicylic acid directly binds to ribosomal protein S3 and suppresses CDK4 expression in colorectal cancer cells.
Topics: Aspirin; Colorectal Neoplasms; Cyclin-Dependent Kinase 4; Humans; Prospective Studies; Ribosomal Pro | 2022 |
Aspirin, Risk of Colorectal Cancer, & Genetic Risk-Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Risk Factors | 2022 |
Aspirin, Risk of Colorectal Cancer, & Genetic Risk-Letter.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Risk Factors | 2022 |
Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer.
Topics: Aged; Aspirin; Body Mass Index; Colorectal Neoplasms; Cross-Sectional Studies; Female; Humans; Male; | 2022 |
The First Year of the COVID-19 Pandemic: Changes in Preventive Services in Community Health Centers.
Topics: Aspirin; Colorectal Neoplasms; Community Health Centers; COVID-19; Early Detection of Cancer; Female | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin.
Topics: Adult; Aspirin; Cohort Studies; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2023 |
The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci.
Topics: Aberrant Crypt Foci; Adenoma; Aspirin; Colorectal Neoplasms; Humans; Rectum | 2022 |
Association between use of low-dose aspirin and detection of colorectal polyps and cancer in a screening setting.
Topics: Adenoma; Aspirin; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Huma | 2023 |
Acetylsalicylic Acid Effect in Colorectal Cancer Taking into Account the Role of Tobacco, Alcohol and Excess Weight.
Topics: Aspirin; Cohort Studies; Colorectal Neoplasms; Ethanol; Female; Humans; Male; Nicotiana; Overweight; | 2023 |
Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Aspirin; Colorectal Neoplasms; Dipyridamole; Humans; M | 2023 |
Exploring the potential of quercetin/aspirin-loaded chitosan nanoparticles coated with Eudragit L100 in the treatment of induced-colorectal cancer in rats.
Topics: Animals; Aspirin; Chitosan; Colorectal Neoplasms; Drug Carriers; Nanoparticles; Particle Size; Querc | 2023 |
Operational Challenges of an Asia-Pacific Academic Oncology Clinical Trial.
Topics: Asia; Aspirin; Colorectal Neoplasms; COVID-19; Humans; Pandemics | 2023 |
In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; bcl-2-Associated X Protein; Caspases; Colorectal Neo | 2023 |
Aspirin and nonaspirin nonsteroidal antiinflammatory drug use and occurrence of colorectal adenoma in Black American women.
Topics: Acetaminophen; Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black or African Am | 2023 |
The underlying regulatory mechanisms of colorectal carcinoma by combining Vitexin and Aspirin: based on systems biology, molecular docking, molecular dynamics simulation, and
Topics: Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; Humans; Molecular Biology; Molecular Docking Simula | 2023 |
Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis.
Topics: AMP-Activated Protein Kinases; Aspirin; Cell Line, Tumor; Colorectal Neoplasms; Gene Expression Regu | 2023 |
Should I take aspirin? A qualitative study on the implementation of a decision aid on taking aspirin for bowel cancer prevention.
Topics: Aspirin; Australia; Colorectal Neoplasms; COVID-19; Decision Support Techniques; Humans; Pandemics | 2023 |
RE: Effects of Oral Anticoagulants and Aspirin on Performance of Fecal Immunochemical Tests in Colorectal Cancer Screening.
Topics: Anticoagulants; Aspirin; Colorectal Neoplasms; Early Detection of Cancer; Feces; Humans; Mass Screen | 2023 |
Aspirin before fecal immunochemical testing did not increase sensitivity for detecting advanced colorectal neoplasms.
Topics: Aspirin; Colorectal Neoplasms; Humans; Occult Blood | 2019 |
Head-to-Head Comparison of the Performance of 17 Risk Models for Predicting Presence of Advanced Neoplasms in Colorectal Cancer Screening.
Topics: Adenoma; Age Factors; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Area Under Cu | 2019 |
Artesunate suppresses inflammation and oxidative stress in a rat model of colorectal cancer.
Topics: 1,2-Dimethylhydrazine; Administration, Oral; Animals; Anti-Inflammatory Agents; Antineoplastic Agent | 2019 |
Effects of Colorectal Cancer Risk Factors on the Association Between Aspirin and Colorectal Cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Com | 2019 |
Aspirin-loaded nanoexosomes as cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; Autophagy; Breast Neoplasms; Colorectal Neoplasm | 2019 |
Benefits and harms of aspirin to reduce colorectal cancer risk: a cross-sectional study of methods to communicate risk in primary care.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Colorectal Neoplasms; Cross-Secti | 2019 |
Aspirin metabolites 2,3‑DHBA and 2,5‑DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention.
Topics: Aspirin; Cell Cycle; Colorectal Neoplasms; Cyclin-Dependent Kinases; HCT116 Cells; HT29 Cells; Human | 2020 |
Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Topics: Aged; Aspirin; Body Mass Index; Clinical Trials as Topic; Cohort Studies; Colorectal Neoplasms; Fema | 2019 |
A comprehensive in vivo and mathematic modeling-based kinetic characterization for aspirin-induced chemoprevention in colorectal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Cell Proliferation; Colorectal | 2020 |
Aspirin Use, Compliance, and Knowledge of Anticancer Effect in the Community.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; As | 2020 |
Extracting the benefits of berberine for colorectal cancer.
Topics: Adenoma; Antineoplastic Agents, Phytogenic; Aspirin; Berberine; Cardiovascular Diseases; Case-Contro | 2020 |
Risk Factors for Early-Onset Colorectal Cancer.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Aspirin; Case-Control Studies; Colonoscopy; Colorectal | 2020 |
Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Azoxymethane; Carcinogens; Cel | 2020 |
Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
Topics: Aspirin; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class I Phosphatidylinosito | 2020 |
Single dose aspirin affects fecal immunohistochemical test sensitivity in detecting advanced colorectal neoplasms: Truth or expectation?
Topics: Aspirin; Colorectal Neoplasms; Feces; Humans; Immunohistochemistry; Motivation | 2020 |
Inflammation-induced JMJD2D promotes colitis recovery and colon tumorigenesis by activating Hedgehog signaling.
Topics: Anilides; Animals; Aspirin; Carcinogenesis; Cell Proliferation; Colitis; Colorectal Neoplasms; Disea | 2020 |
Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Cohort Studies; Colitis, Ulcerative; | 2020 |
Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Co | 2020 |
Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer.
Topics: Aspirin; Cohort Studies; Colorectal Neoplasms; Humans; Proportional Hazards Models; Risk | 2020 |
Impact of perioperative aspirin continuation on bleeding complications in laparoscopic colorectal cancer surgery: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Anastomosis, Surgical; Aspirin; Blood Loss, Surgical; Blood Transfusion; Co | 2021 |
Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Colonoscopy; Colorectal Neoplasms; Colorectal Neoplasms, He | 2020 |
Aspirin Reduces Colorectal Tumor Development in Mice and Gut Microbes Reduce its Bioavailability and Chemopreventive Effects.
Topics: Adenomatous Polyposis Coli Protein; Animals; Anti-Bacterial Agents; Anticarcinogenic Agents; Aspirin | 2020 |
Aspirin to prevent gastrointestinal cancer - but recent trial data do not fit.
Topics: Aspirin; Colorectal Neoplasms; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans | 2020 |
Microbiota modulates aspirin chemoprevention in CRC.
Topics: Animals; Aspirin; Biological Availability; Chemoprevention; Colorectal Neoplasms; Gastrointestinal M | 2020 |
Reply to the Letter to the Editor 'Aspirin to prevent gastrointestinal cancer - but recent trial data don't fit' by Jacobsen and colleagues.
Topics: Aspirin; Colorectal Neoplasms; Gastrointestinal Neoplasms; Humans | 2020 |
Aspirin for Lynch syndrome: a legacy of prevention.
Topics: Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Double-Blind Method; F | 2020 |
Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Coloni | 2020 |
Aspirin-based chemoprevention of colorectal cancer: The role for gut microbiota.
Topics: Animals; Aspirin; Biological Availability; Chemoprevention; Colorectal Neoplasms; Gastrointestinal M | 2020 |
Identification of the Effects of Aspirin and Sulindac Sulfide on the Inhibition of HMGA2-Mediated Oncogenic Capacities in Colorectal Cancer.
Topics: Aspirin; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Cytotoxins; HMGA2 Protein; Humans; | 2020 |
Co-morbid risk factors and NSAID use among white and black Americans that predicts overall survival from diagnosed colon cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black or African American; Cohort Studies; | 2020 |
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Celecoxib; Cell Li | 2021 |
Letter: synergistic role of gut flora with aspirin to prevent colorectal cancers-authors' reply.
Topics: Aspirin; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Microbiome; Humans; Risk | 2020 |
Editorial: the microbiome, aspirin and colorectal cancer.
Topics: Aspirin; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Microbiome; Humans; Microbiota | 2020 |
Letter: synergistic role of gut flora with aspirin to prevent colorectal cancers.
Topics: Aspirin; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Microbiome; Humans; Risk | 2020 |
Editorial: the microbiome, aspirin and colorectal cancer-authors' reply.
Topics: Aspirin; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Microbiome; Humans; Microbiota | 2020 |
Association Between Low-Dose Aspirin Use and Colorectal Cancer Incidence in Taiwan.
Topics: Adult; Age Factors; Aged; Aspirin; Case-Control Studies; Colorectal Neoplasms; Female; Humans; Male; | 2020 |
A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer.
Topics: Aspirin; Colorectal Neoplasms; Humans; Mendelian Randomization Analysis; Proteomics; Risk Factors | 2021 |
Letter: non-steroidal anti-inflammatory drugs reduce the risk of post-colonoscopy colorectal cancer-authors' reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorectal Neoplasms; Humans; Pharmac | 2021 |
Letter: nonsteroidal anti-inflammatory drugs reduce the risk of post-colonoscopy colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorectal Neoplasms; Humans; Pharmac | 2021 |
The CAPP II trial of aspirin in Lynch syndrome/HNPCC: is it time for everyone to be treated?
Topics: Age Factors; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Drug Admi | 2021 |
Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Topics: Adaptor Proteins, Signal Transducing; Animals; Annexin A5; Antineoplastic Combined Chemotherapy Prot | 2021 |
Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report.
Topics: Aged; Angiogenesis Inhibitors; Aspirin; Colorectal Neoplasms; Coronary Artery Disease; Coronary Thro | 2021 |
Associations of Aspirin and Non-Aspirin Non-Steroidal Anti-Inflammatory Drugs With Colorectal Cancer Mortality After Diagnosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Male; Odds R | 2021 |
Timing of Aspirin Use in Colorectal Cancer Chemoprevention: A Prospective Cohort Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; Follow-Up St | 2021 |
Aspirin and Primary Prevention of Colorectal Cancer: A Still-Evolving Story.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Primary Prevention | 2021 |
Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease and Colorectal Carcinomas.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Primary Prevention | 2021 |
Author Response to "Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease and Colorectal Carcinomas".
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Primary Prevention | 2021 |
Clinicians' opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50-70 years: a qualitative study.
Topics: Adult; Aged; Aspirin; Australia; Colorectal Neoplasms; Humans; Middle Aged; Primary Health Care; Qua | 2021 |
Combined Use of Aspirin and Selective Serotonin Reuptake Inhibitors Is Associated With Lower Risk of Colorectal Cancer: A Nested Case-Control Study.
Topics: Aged; Aspirin; Case-Control Studies; Colorectal Neoplasms; Drug Therapy, Combination; Female; Humans | 2021 |
Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
Topics: Adenoma; Animals; Aspirin; Colorectal Neoplasms; Disease Models, Animal; Female; Incidence; Male; Mi | 2021 |
Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum.
Topics: Adenoma; Animals; Aspirin; Bacteria; Carcinogenesis; Cell Transformation, Neoplastic; Colon; Colorec | 2021 |
Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Cross-Sectional Studies; Diabetes Mellitus, | 2021 |
Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?
Topics: Aspirin; Colorectal Neoplasms; Computer Simulation; Cost-Benefit Analysis; Dose-Response Relationshi | 2021 |
Aspirin, ibuprofen, and reduced risk of advanced colorectal adenoma incidence and recurrence and colorectal cancer in the PLCO Cancer Screening Trial.
Topics: Adenoma; Aged; Aspirin; Colorectal Neoplasms; Early Detection of Cancer; Female; Humans; Ibuprofen; | 2021 |
Development and user-testing of a brief decision aid for aspirin as a preventive approach alongside colorectal cancer screening.
Topics: Aspirin; Colorectal Neoplasms; Decision Making; Decision Support Techniques; Early Detection of Canc | 2021 |
The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Colorectal Neoplasms; Dipyridamole; Drug Thera | 2017 |
Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.
Topics: Adolescent; Adult; Aged; Aspirin; Colorectal Neoplasms; Cost-Benefit Analysis; Counseling; Ethnicity | 2017 |
Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; B7-H1 Antigen; Cohort Studies; Colorectal Ne | 2017 |
USPSTF recommendations: A 2017 roundup.
Topics: Advisory Committees; Aspirin; Breast Feeding; Cardiovascular Diseases; Colorectal Neoplasms; Dose-Re | 2017 |
Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Fem | 2017 |
End-of-life prescribing of aspirin in patients with breast or colorectal cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Breast Neoplasms; Cancer Survivors; Cardiovascular Agents; Cardiov | 2019 |
Effect of aspirin on tumour cell colony formation and evolution.
Topics: Aspirin; Caco-2 Cells; Cell Death; Cell Division; Colorectal Neoplasms; Humans; Models, Biological; | 2017 |
New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case-control study in UK general practice.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Colorectal Neoplasms; Comorbidity; Fe | 2017 |
Incidence of colorectal cancer in new users and non-users of low-dose aspirin without existing cardiovascular disease: A cohort study using The Health Improvement Network.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cohort Studies; Colorectal Neoplas | 2017 |
Aspirin and the prevention of a common disease: Colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans | 2017 |
Support and negation of colorectal cancer risk prevention behaviors: analysis of spousal discussions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Communication; Diet; Diet, H | 2018 |
Chemoprevention by artesunate in a preclinical model of colorectal cancer involves down regulation of β-catenin, suppression of angiogenesis, cellular proliferation and induction of apoptosis.
Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Animals; Apoptosis; Artemisinins; Artesunate; Aspirin; b | 2017 |
Salicylic acid metabolites and derivatives inhibit CDK activity: Novel insights into aspirin's chemopreventive effects against colorectal cancer.
Topics: Acetylation; Anticarcinogenic Agents; Aspirin; CDC2 Protein Kinase; Colorectal Neoplasms; Cyclin B1; | 2017 |
Signature Celebration of Gastroenterology, Colorectal Cancer.
Topics: Adenomatous Polyps; Anticarcinogenic Agents; Aspirin; Biomedical Research; Colonic Polyps; Colorecta | 2018 |
Reduction of NANOG Mediates the Inhibitory Effect of Aspirin on Tumor Growth and Stemness in Colorectal Cancer.
Topics: Animals; Aspirin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; HCT116 | 2017 |
Risk factors for postpolypectomy bleeding in patients receiving anticoagulation or antiplatelet medications.
Topics: Aged; Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Colonic Polyps; Colonoscopy; Color | 2018 |
Reply to M. Løberg et al.
Topics: Aspirin; Cause of Death; Colonic Neoplasms; Colorectal Neoplasms; Death; Humans | 2017 |
Aspirin, Colorectal Cancer, and Cause of Death: A Complex Landscape.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Colorectal Neoplasms; Humans; Seco | 2017 |
USPSTF Recommendations: New and Updated in 2016.
Topics: Advisory Committees; Aspirin; Autism Spectrum Disorder; Breast Neoplasms; Cardiovascular Diseases; C | 2017 |
Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Femal | 2018 |
Combined activity of COX-1 and COX-2 is increased in non-neoplastic colonic mucosa from colorectal neoplasia patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Colon; Colorectal Neoplasms; Cycloox | 2018 |
Risk of gastrointestinal bleeding and benefit from colorectal cancer reduction from long-term use of low-dose aspirin: A retrospective study of 612 509 patients.
Topics: Aged; Aspirin; Cohort Studies; Colorectal Neoplasms; Female; Gastrointestinal Hemorrhage; Humans; In | 2018 |
Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells.
Topics: Amino Acid Chloromethyl Ketones; Aspirin; Blood Platelets; Breast Neoplasms; Caco-2 Cells; Calcium C | 2018 |
Colorectal Cancer Screening and Prevention.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorectal Neoplasms; Early Det | 2018 |
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.
Topics: Age Factors; Aged; Aspirin; Body Height; Body Weight; Cardiovascular Diseases; Colorectal Neoplasms; | 2018 |
Aspirin cooperates with p300 to activate the acetylation of H3K9 and promote FasL-mediated apoptosis of cancer stem-like cells in colorectal cancer.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Aspirin; Cell Line, Tumor; Colorectal Neoplasms; E1A- | 2018 |
Aspirin and Chemoprevention-Have We Arrived?
Topics: Aspirin; Carcinoma, Hepatocellular; Chemoprevention; Colorectal Neoplasms; Humans; Liver Neoplasms | 2018 |
A novel calibration framework for survival analysis when a binary covariate is measured at sparse time points.
Topics: Aspirin; Biostatistics; Calibration; Cohort Studies; Colorectal Neoplasms; Cyclooxygenase Inhibitors | 2020 |
Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neoplasms; | 2019 |
NSAIDs and Colorectal Cancer Phenotypes: What Now?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Colorectal Neoplasms; Humans; P | 2019 |
The Effects of Direct Oral Anticoagulants, Warfarin, Aspirin and Thienopyridine on the Performance of Immunochemical, Faecal, Occult Blood Tests.
Topics: Adenoma; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Case-Control Studie | 2019 |
The Cytotoxicity and Synergistic Potential of Aspirin and Aspirin Analogues Towards Oesophageal and Colorectal Cancer.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colorect | 2019 |
Take a pill for no more polyps: is it that simple?
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Double-Blind Method; Eicosapentaenoic Acid; Humans; Polyps | 2018 |
Design and rationale for the ASSOS study: Appropriateness of aspirin use in medical outpatients a multicenter and observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cohort Studies; Colorectal Neo | 2018 |
Low-dose aspirin can reduce colorectal cancer mortality after surgery: A 10-year follow-up of 13 528 colorectal cancer patients.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Colorectal Neoplasms; Digestive System Surgical Pr | 2019 |
Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Colorectal Neoplasms; Dual Anti | 2019 |
No risk reduction of colorectal adenoma with aspirin or eicosapentaenoic acid.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Double-Blind Method | 2019 |
Effects of Oral Anticoagulants and Aspirin on Performance of Fecal Immunochemical Tests in Colorectal Cancer Screening.
Topics: Adenoma; Administration, Oral; Aged; Anticoagulants; Aspirin; Colonoscopy; Colorectal Neoplasms; Cro | 2019 |
An Abstract Provides "seAFOod" for Thought.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Ome | 2019 |
Alpha-Blockers As Colorectal Cancer Chemopreventive: Findings from a Case-Control Study, Human Cell Cultures, and
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, | 2019 |
A novel mechanism for the anticancer activity of aspirin and salicylates.
Topics: Aspirin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Cyclin D1; Drug | 2019 |
Do Aspirin and Clopidogrel Follow the Same Road Toward Prevention of Colorectal Cancer?
Topics: Aspirin; Clopidogrel; Colonic Neoplasms; Colorectal Neoplasms; Humans; Platelet Aggregation Inhibito | 2019 |
Eicosapentaenoic acid and aspirin for colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Double-Blind Method | 2019 |
Effects of Oral Anticoagulant and Aspirin Use on Ability of Fecal Immunochemical Tests to Detect Advanced Neoplasia.
Topics: Anticoagulants; Aspirin; Colorectal Neoplasms; Early Detection of Cancer; Humans; Occult Blood | 2019 |
Aspirin for primary prevention: It depends.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Primary Prevention | 2019 |
Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 pathway.
Topics: Antigens, Differentiation, T-Lymphocyte; Apoptosis; Aspirin; bcl-2-Associated X Protein; Cell Moveme | 2019 |
Optimal use of antiplatelet agents, especially aspirin, in the perioperative management of colorectal cancer patients undergoing laparoscopic colorectal resection.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Colorectal Neoplasms; Female; Follow- | 2019 |
Effects of 5-FU and anti-EGFR antibody in combination with ASA on the spherical culture system of HCT116 and HT29 colorectal cancer cell lines.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Autophagy; Cell Cyc | 2019 |
Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Cohort Studies; Colorectal Neopla | 2019 |
Development of a nanoamorphous exosomal delivery system as an effective biological platform for improved encapsulation of hydrophobic drugs.
Topics: Antineoplastic Agents; Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colorectal Neopla | 2019 |
Colorectal cancer screening in Australia: An update
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Colonoscopy; Colorectal Neoplasms | 2018 |
Evaluation of antitumor effects of aspirin and LGK974 drugs on cellular signaling pathways, cell cycle and apoptosis in colorectal cancer cell lines compared to oxaliplatin drug.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Gene | 2020 |
The impact of aspirin use on colorectal cancer patients.
Topics: Aspirin; Carcinoma; Colorectal Neoplasms; Female; Humans; Male | 2013 |
Response to letter commenting on paper EJC-D-12-01401: Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality.
Topics: Aspirin; Carcinoma; Colorectal Neoplasms; Female; Humans; Male | 2013 |
Unexpectedly resolved multiple mobile thrombi in a normal thoracic aorta associated with colorectal cancer and protein C deficiency.
Topics: Aorta, Thoracic; Aspirin; Blood Coagulation Disorders; Colorectal Neoplasms; Humans; Male; Middle Ag | 2014 |
The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ch | 2013 |
[Aspirin and prevention of colorectal carcinomas].
Topics: Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Evidence-Based Medicine; Humans; Treatment | 2013 |
The association between low-dose aspirin use and the incidence of colorectal cancer: a nationwide cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Dis | 2013 |
Aspirin use and risk of colorectal cancer according to BRAF mutation status.
Topics: Aged; Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; Female; Follow-Up Studies; Genetic Predisposi | 2013 |
Differential effects of aspirin before and after diagnosis of colorectal cancer.
Topics: Aspirin; Colorectal Neoplasms; Female; Humans; Male; Prostaglandin Antagonists; Proto-Oncogene Prote | 2013 |
Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial.
Topics: Aged; Aspirin; Breast Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Female; Follow- | 2013 |
Low-dose aspirin use and cancer characteristics: a population-based cohort study.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; | 2013 |
Commentary: the association between low-dose aspirin use and the incidence of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fem | 2013 |
Bleeding-related symptoms in colorectal cancer: a 4-year nationwide population-based study.
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Anticoagulants; Aspirin; Colorectal Neoplasms; Fem | 2014 |
Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Class I Phosphatidylinositol 3-Kinases; Colorectal | 2013 |
Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2014 |
Genome-wide association studies meet chemoprevention.
Topics: Anticarcinogenic Agents; Aspirin; beta Catenin; Chromosomes, Human, Pair 8; Colorectal Neoplasms; Fe | 2013 |
Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; beta Catenin | 2013 |
A role for aspirin in cancer prevention?
Topics: Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Humans; Observational Studies as Topic; Sign | 2013 |
The role of aspirin in colorectal cancer prevention and treatment.
Topics: Aspirin; Colorectal Neoplasms; Humans | 2013 |
A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Case-Control Studies; Col | 2014 |
Protective effect of aspirin associated with SNP.
Topics: Antineoplastic Agents; Aspirin; Chromosomes, Human, Pair 8; Colorectal Neoplasms; Genetic Predisposi | 2014 |
[Aspirin and PIK3CA mutation in colorectal cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Lactones; Ma | 2014 |
Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD).
Topics: Aspirin; Colorectal Neoplasms; Demography; Female; Gene Expression Regulation, Enzymologic; Humans; | 2014 |
5 simple steps that may help prevent colorectal cancer. Screenings, exercise, and vitamin D may reduce your risks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorectal Neoplasms; Diet; Early Det | 2014 |
Aspirin, the new targeted therapy in colorectal cancer.
Topics: Antineoplastic Agents; Aspirin; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Cycloo | 2014 |
Modulation of age- and cancer-associated DNA methylation change in the healthy colon by aspirin and lifestyle.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colon; Colorect | 2014 |
Identification of aspirin analogues that repress NF-κB signalling and demonstrate anti-proliferative activity towards colorectal cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Cell Cycle; Ce | 2014 |
Aspirin can reduce risk of colorectal cancer in specific cases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Risk Factors | 2014 |
Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Aspirin; Capecitabin | 2014 |
Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; | 2015 |
Correlation between long-term aspirin use and F-fluorodeoxyglucose uptake in colorectal cancer measured by PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2014 |
Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Colorectal Neoplasms; Disease-Free Survival; | 2014 |
Prevention of colorectal adenomas.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Lig | 2015 |
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Class I Phosphatid | 2015 |
Risk of bleeding after endoscopic submucosal dissection for colorectal tumors in patients with continued use of low-dose aspirin.
Topics: Aged; Aspirin; Colonoscopy; Colorectal Neoplasms; Dissection; Dose-Response Relationship, Drug; Fema | 2015 |
Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Colorectal Neoplasms; Fe | 2015 |
Aspirin and NSAID chemoprevention, gene-environment interactions, and risk of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Gene-Environment Int | 2015 |
Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Chromosomes, Human, Pair 12; | 2015 |
[Chemoprevention of colorectal cancer for broad clinical use in the future].
Topics: Anticarcinogenic Agents; Aspirin; Chemoprevention; Clinical Trials as Topic; Colorectal Neoplasms; H | 2015 |
Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Anti-Inflammatory Agen | 2015 |
OTC Secondary Prevention of Metastatic Colorectal Cancer Moves Closer to Clinical Reality.
Topics: Aspirin; Colorectal Neoplasms; Humans; Nonprescription Drugs; Platelet Aggregation Inhibitors; Risk | 2015 |
COX-2 and EGFR: Partners in Crime Split by Aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; E | 2015 |
Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?
Topics: Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus; F | 2015 |
Single-Gene Genotyping and Personalized Preventive Care.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Gene-Environment Int | 2015 |
Single-Gene Genotyping and Personalized Preventive Care--Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Gene-Environment Int | 2015 |
Single-Gene Genotyping and Personalized Preventive Care--Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Gene-Environment Int | 2015 |
Aspirin Targets SIRT1 and AMPK to Induce Senescence of Colorectal Carcinoma Cells.
Topics: AMP-Activated Protein Kinases; Aspirin; Cellular Senescence; Colorectal Neoplasms; Drug Delivery Sys | 2015 |
Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neoplasms; Denmar | 2015 |
Summaries for Patients. Associations Between the Use of Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs and Colorectal Cancer Risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neoplasms; Denmar | 2015 |
Long term NSAIDs are associated with lower colorectal cancer risk, study shows.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Male | 2015 |
Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Colorectal Neoplasms; Fem | 2016 |
Association between colorectal polyps and hypertension treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Blood Pressure; Col | 2015 |
Cancers prevented in Australia in 2010 through the consumption of aspirin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Aspirin; Australia; Carcinoma, Squamous Cell; Colore | 2015 |
Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?
Topics: Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Databases, Genetic; Drug Resistance, Neoplasm; Gas | 2015 |
RE: Aspirin, Ibuprofen, and the Risk for Colorectal Cancer in Lynch Syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Col | 2016 |
Response.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Col | 2016 |
Predictors of advanced colorectal neoplasia at initial and surveillance colonoscopy after positive screening immunochemical faecal occult blood test.
Topics: Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorectal Ne | 2016 |
[Aspirin for the prevention of colorectal cancer].
Topics: Aspirin; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Humans; Prognosis; Risk F | 2015 |
Colorectal cancer prevention and intentions to use low-dose aspirin: A survey of 1000 U.S. adults aged 40-65.
Topics: Adult; Aged; Aspirin; Colorectal Neoplasms; Female; Humans; Intention; Male; Middle Aged; Surveys an | 2016 |
The aspirin-induced long non-coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation.
Topics: Animals; Apoptosis; Aspirin; Cell Line, Tumor; Cell Transformation, Neoplastic; Colorectal Neoplasms | 2016 |
Aspirin for Cancer Prevention: One Step Closer.
Topics: Aspirin; Colorectal Neoplasms; Gastrointestinal Neoplasms; Humans; Risk Assessment | 2016 |
Decision-making in an era of cancer prevention via aspirin: New Zealand needs updated guidelines and risk calculators.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Decision-M | 2016 |
[Aspirin intake improves survival of colorectal cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans | 2016 |
Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
Topics: Adult; Aged; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Decisi | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendations From the U.S. Preventive Services Task Force.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Aspirin; Cardiovascular Diseases; Cerebral Hemorrha | 2016 |
US panel recommends low dose aspirin to prevent cardiovascular disease and colorectal cancer.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Dose-Response Rel | 2016 |
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cell Communication; Cell | 2016 |
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes.
Topics: Adenoma; Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Data Interpretation, Statistical; Folic A | 2016 |
Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy?
Topics: Aged; Aged, 80 and over; Anemia; Aspirin; Capsule Endoscopy; Colonoscopy; Colorectal Neoplasms; Endo | 2017 |
Factors predicting adverse events associated with therapeutic colonoscopy for colorectal neoplasia: a retrospective nationwide study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ce | 2016 |
Aspirin As Secondary Prevention in Patients With Colorectal Cancer: An Unselected Population-Based Study.
Topics: Aged; Aged, 80 and over; Aspirin; Bias; Cohort Studies; Colorectal Neoplasms; Female; Humans; Male; | 2016 |
Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.
Topics: Age Factors; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Cause of Death; Colorectal Neoplasm | 2016 |
Where the colorectal cancer chemoprevention is and where it is going.
Topics: Aspirin; Chemoprevention; Colorectal Neoplasms; Genome, Human; Humans | 2016 |
Colorectal cancer prevention of familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Aspirin; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Humans | 2016 |
The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; As | 2016 |
Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; | 2016 |
Aspirin for cancer is no mere antiplatelet prototype. There is potential in its ancient roots.
Topics: Animals; Aspirin; Blood Platelets; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Gastrointestinal | 2016 |
Review: Aspirin reduces colorectal cancer incidence and mortality in patients at average risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Incidence; Risk | 2016 |
The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Capecit | 2017 |
Exploring clinicians' attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer.
Topics: Aspirin; Australia; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Cross-Secti | 2017 |
Exploring Differences in the Aspirin-Colorectal Cancer Association by Sex and Race/Ethnicity: The Multiethnic Cohort Study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; California; Colorectal Neoplasms; Ethnicity; | 2017 |
Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2018 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Colorectal Neoplasms; Femal | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendation Statement.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal N | 2016 |
[Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2017 |
Identification of TMEM208 and PQLC2 as reference genes for normalizing mRNA expression in colorectal cancer treated with aspirin.
Topics: Actins; Amino Acid Transport Systems, Basic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apopt | 2017 |
Aspirin for the Prevention of Cardiovascular Disease and Colorectal Cancer: New Recommendations from the USPSTF.
Topics: Aged; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Middle Aged; Platelet Aggregat | 2017 |
Should you screen--or not? The latest recommendations.
Topics: Adult; Alcohol Drinking; Anemia, Sickle Cell; Aspirin; Chlamydia Infections; Colorectal Neoplasms; F | 2008 |
Does one pill a day keep the colonoscopist away?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorectal Neop | 2008 |
Acetylsalicylic acid regulates MMP-2 activity and inhibits colorectal invasion of murine B16F0 melanoma cells in C57BL/6J mice: effects of prostaglandin F(2)alpha.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasm | 2009 |
Patient preferences for the chemoprevention of colorectal cancer.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colorectal Neo | 2009 |
Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; Denmark; Fem | 2009 |
Chemoprevention of colorectal cancer in Japan: a brief introduction to current clinical trials.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; Color | 2009 |
Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asian People; Aspirin; Colorectal Neoplasms; Genetic Predis | 2009 |
Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Colonic Polyps; Colonoscopy; Color | 2009 |
Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Colonic Polyps; Colonoscopy; Color | 2009 |
Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Colonic Polyps; Colonoscopy; Color | 2009 |
Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Colonic Polyps; Colonoscopy; Color | 2009 |
Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases.
Topics: Aged; Antineoplastic Agents; Aspirin; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; | 2009 |
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Confounding F | 2009 |
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Humans; Starc | 2009 |
Could recommendations about aspirin prophylaxis enhance colorectal cancer screening programmes?
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Early Detection of Cancer; Humans; Practice Guidelines as To | 2009 |
Aspirin use and survival after diagnosis of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspi | 2009 |
Aspirin as adjuvant therapy for colorectal cancer: a promising new twist for an old drug.
Topics: Antineoplastic Agents; Aspirin; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cyc | 2009 |
Colorectal cancer chemoprevention: ready for practice?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Colorectal Neoplasms; Cyclo | 2009 |
Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Col | 2009 |
Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Colorectal Neoplasms; Female; Fol | 2009 |
Uracil misincorporation into DNA and folic acid supplementation.
Topics: Adenoma; Aged; Alcohol Drinking; Aspirin; Colonoscopy; Colorectal Neoplasms; Dietary Supplements; DN | 2010 |
Aspirin use, colorectal cancer survival, and loss to follow-up.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; Humans | 2009 |
Inflammation and colorectal cancer: does aspirin affect the interaction between cancer and immune cells?
Topics: Aspirin; Cell Communication; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Culture Med | 2011 |
Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.
Topics: Apoptosis; Aspirin; bcl-Associated Death Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell | 2010 |
COX-2 expression in adenoma: an imperfect marker for chemoprevention.
Topics: Adenoma; Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Cyclooxygenase 2 | 2010 |
Aspirin and alterations in DNA repair proteins in the SW480 colorectal cancer cell line.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Cell Line, Tumor; Cell Survival; Colore | 2010 |
Meat consumption, nonsteroidal anti-inflammatory drug use, and mortality among colorectal cancer patients in the California Teachers Study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; California; Colore | 2010 |
Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway.
Topics: Animals; Apoptosis; Aspirin; bcl-X Protein; Body Weight; Colorectal Neoplasms; Disease Models, Anima | 2011 |
Aspirin to prevent colorectal cancer: time to act?
Topics: Aspirin; Colorectal Neoplasms; Female; Humans; Male; Risk Reduction Behavior | 2010 |
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Colonic Neoplasms; Colorectal Neoplasms; Follow-Up Studies; Humans | 2010 |
Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Drug Administra | 2011 |
Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Biomarkers; C-Reac | 2011 |
Low-dose aspirin use and performance of immunochemical fecal occult blood tests.
Topics: Aged; Aspirin; Colorectal Neoplasms; False Positive Reactions; Female; Gastrointestinal Hemorrhage; | 2010 |
Cancer: do aspirin and other NSAIDs protect against colorectal cancer?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-Response Relat | 2011 |
Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study.
Topics: Aged; Anticoagulants; Aspirin; Case-Control Studies; Cohort Studies; Colorectal Neoplasms; Early Det | 2011 |
Performance of immunochemical fecal occult blood tests among users of low-dose aspirin.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Gastrointestinal Hemorrhage; Humans; Occult | 2011 |
Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-R | 2011 |
[Aspirin in the prevention of colorectal cancer].
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Humans | 2011 |
c-Src dependency of NSAID-induced effects on NF-κB-mediated apoptosis in colorectal cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Blotting, Western; Cell Line, Tumor; Co | 2011 |
The role of aspirin in prevention and management of colorectal cancer.
Topics: Antineoplastic Agents; Aspirin; Colorectal Neoplasms; Contraindications; Humans; Risk Assessment | 2011 |
Activity of aspirin analogues and vanillin in a human colorectal cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Benzaldehydes; Camptothecin; Cell Line, Tumor; Cell Survi | 2011 |
Aspirin bleeding in perspective.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; He | 2011 |
[Essential acetylsalicylic acid: over 100 years old and still good for surprises (interview by Dr. med. Jochen Aumiller)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-Response Relationship, | 2011 |
SOX7 is involved in aspirin-mediated growth inhibition of human colorectal cancer cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line; Colorectal Neoplasms; Cyclooxy | 2011 |
New data on aspirin and colorectal cancer brings calls for new guidelines, more research.
Topics: Anticarcinogenic Agents; Aspirin; Biomarkers, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; | 2012 |
[Acetylsalicylic acid protects against solid tumors].
Topics: Aspirin; Colorectal Neoplasms; Drug Administration Schedule; Follow-Up Studies; Humans; Incidence; R | 2012 |
[Korean guidelines for colonoscopic polypectomy].
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colonoscopy; Colorectal N | 2012 |
Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agen | 2012 |
A further piece of the puzzle: positive FOBT, colonoscopy, aspirin and the prevention of colorectal cancer.
Topics: Aspirin; Celecoxib; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase Inhibitors; E | 2012 |
Aspirin users attending for NHS bowel cancer screening have less colorectal neoplasia: chemoprevention or false-positive faecal occult blood testing?
Topics: Aged; Aspirin; Body Mass Index; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase I | 2012 |
Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplas | 2012 |
[Oncogenesis humoral mechanisms regulation and NSAIDs ability in prevention of tumors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Transformation, Neoplastic; Colorectal Neopla | 2011 |
Aspirin and cancer prevention and treatment: are we there yet?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Male | 2012 |
Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; Female | 2012 |
β-catenin negatively regulates expression of the prostaglandin transporter PGT in the normal intestinal epithelium and colorectal tumour cells: a role in the chemopreventive efficacy of aspirin?
Topics: Animals; Anticarcinogenic Agents; Aspirin; beta Catenin; Cell Line, Tumor; Colorectal Neoplasms; HCT | 2012 |
[Journal club].
Topics: Adenoma; Adenomatous Polyps; Anticoagulants; Aspirin; Coffee; Colonic Polyps; Colonoscopy; Colorecta | 2012 |
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
Topics: Aged; Aspirin; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Cycl | 2012 |
Aspirin--from prevention to targeted therapy.
Topics: Aspirin; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Cyclooxyge | 2012 |
Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Cause o | 2013 |
Potential biomarker for aspirin use in colorectal cancer therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers, Tumor; Class I Phosphatidylinositol 3- | 2013 |
Combination aspirin and/or calcium chemoprevention with colonoscopy in colorectal cancer prevention: cost-effectiveness analyses.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium; Cohort Studies; Col | 2013 |
Aspirin, PIK3CA mutation, and colorectal-cancer survival.
Topics: Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Female; Humans; Male; | 2013 |
Aspirin, PIK3CA mutation, and colorectal-cancer survival.
Topics: Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Female; Humans; Male; | 2013 |
Aspirin, PIK3CA mutation, and colorectal-cancer survival.
Topics: Aspirin; Biomarkers, Tumor; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Female; Humans; Male; | 2013 |
Aspirin extends life of some patients with colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma; Class I Phosphatidylinositol 3-Kinases; | 2013 |
Effect of aspirin continuation on blood loss and postoperative morbidity in patients undergoing laparoscopic cholecystectomy or colorectal cancer resection.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cholecystectomy, Laparoscopic; Colorectal Ne | 2013 |
Butyrate and aspirin in combination have an enhanced effect on apoptosis in human colorectal cancer cells.
Topics: Apoptosis; Aspirin; Butyrates; Cell Culture Techniques; Colorectal Neoplasms; Drug Therapy, Combinat | 2002 |
The combination of 1alpha,25(OH2)-vitamin D3, calcium and acetylsalicylic acid affects azoxymethane-induced aberrant crypt foci and colorectal tumours in rats.
Topics: Animals; Aspirin; Azoxymethane; Body Weight; Calcitriol; Calcium; Colorectal Neoplasms; Dose-Respons | 2002 |
[Nonsteroidal anti-inflammatory drugs and the risk of polyposis, colon carcinoma and rectal carcinoma].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Ibupr | 2002 |
Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia.
Topics: Adenoma; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Ca | 2002 |
A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin.
Topics: Aged; Aspirin; Cohort Studies; Colorectal Neoplasms; Denmark; Dose-Response Relationship, Drug; Fema | 2003 |
Aspirin and the prevention of colorectal cancer.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Secondary P | 2003 |
[Non-steroidal anti-inflammatory agents and prevention of colorectal cancer and other types of cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Neoplasms | 2003 |
Advances in reducing colorectal cancer risk. Colorectal cancer is the third most common cancer in women and the second leading cause of cancer death. These statistics belie how preventable this disease really is.
Topics: Adenomatous Polyps; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neopla | 2003 |
Aspirin and the prevention of colorectal cancer.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Colonoscopy; Colorectal Neoplasms; | 2003 |
Aspirin and the prevention of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxyge | 2003 |
Aspirin cuts return of precursor to colorectal cancer.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Humans; Isoenzymes; Treatment Outcome; United States | 2003 |
Will an aspirin a day keep the endoscope away?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; | 2003 |
Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States).
Topics: Adenoma; Adenomatous Polyps; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; As | 2003 |
Aspirin: still learning about the wonder drug.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Colorectal Neopl | 2003 |
Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; As | 2003 |
[Prevention of colorectal cancer: acetylsalicyclic acid and cyclo-oxygenase-2 inhibitors are only partially effective].
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; C | 2003 |
What now for aspirin and cancer prevention?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Pancreatic | 2004 |
A prospective study of aspirin use and the risk for colorectal adenoma.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-R | 2004 |
Aspirin prevention of colorectal cancer: more or less?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Drug Administration | 2004 |
Summaries for patients. Relationships between aspirin dose and colorectal adenomas.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-R | 2004 |
[Chemopreventive agents in colorectal cancer].
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2003 |
Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neoplasms; | 2004 |
Effects of low dose aspirin (81 mg) on proliferating cell nuclear antigen and Amaranthus caudatus labeling in normal-risk and high-risk human subjects for colorectal cancer.
Topics: Adult; Aged; Anticarcinogenic Agents; Aspirin; Cell Division; Colon; Colorectal Neoplasms; Epithelia | 2004 |
Aspirin and colorectal cancer?
Topics: Aspirin; Colorectal Neoplasms; Evidence-Based Medicine; Humans | 2004 |
Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis.
Topics: Adenomatous Polyposis Coli; Apoptosis; Aspirin; beta Catenin; Breast Neoplasms; Cell Nucleus; Colore | 2004 |
The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colorectal Neoplasms; Computer Simulati | 2004 |
Use of aspirin and its effect on adenoma risk.
Topics: Adenoma; Aspirin; Cohort Studies; Colorectal Neoplasms; Female; Humans; Risk Factors; United States | 2004 |
A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma.
Topics: Adenoma; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Case-Control Studies; Colorectal Neopl | 2004 |
Aspirin for persons at higher risk for colorectal neoplasia.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-Respons | 2004 |
Aspirin use and risk for colorectal adenoma.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Risk Factor | 2004 |
[Ulcerative colitis. Maintenance therapy].
Topics: Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-St | 2004 |
[Ulcerative colitis. Cancer prevention].
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy | 2004 |
Colorectal cancer and Coxibs.
Topics: 1,2-Dimethylhydrazine; Animals; Aspirin; Carcinogens; Colorectal Neoplasms; Cyclooxygenase Inhibitor | 2004 |
The effect of aspirin and high fibre diet on colorectal carcinoma: a comparative experimental study.
Topics: Animals; Aspirin; Chi-Square Distribution; Colorectal Neoplasms; Dietary Fiber; Dimethylhydrazines; | 2004 |
Optimizing cardiovascular and chemopreventive benefits of aspirin: what role for the proton-pump inhibitors?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Eso | 2005 |
Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.
Topics: Adenoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonoscopy; | 2005 |
Aspirin-induced nuclear translocation of NFkappaB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency.
Topics: Active Transport, Cell Nucleus; Adaptor Proteins, Signal Transducing; Apoptosis; Aspirin; Base Pair | 2005 |
Anti-inflammatory drugs and malignancy: can an aspirin a day keep cancer at bay?
Topics: Aspirin; Breast Neoplasms; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Female; Humans; Male; Ne | 2005 |
Mesalazine improves replication fidelity in cultured colorectal cells.
Topics: Aspirin; Base Pair Mismatch; Cell Survival; Colorectal Neoplasms; DNA Repair; DNA Replication; Flow | 2005 |
The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neoplasms; | 2005 |
Lifestyle-related risk factors and chemoprevention for colorectal neoplasia: experience from the large-scale NORCCAP screening trial.
Topics: Adenoma; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemoprevention; | 2005 |
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; Dose- | 2005 |
Chemoprevention goes gourmet: different flavors of NO-aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Molecular Structure; | 2005 |
Aspirin scores again.
Topics: Aspirin; Colorectal Neoplasms; Female; Humans; United States | 2005 |
Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium; Calcium, Dietary; Colorectal Neo | 2005 |
Long-term use of aspirin and risk of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Research Design; Ris | 2005 |
[Recommendation with serious adverse effects].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Cyclooxygenase Inhibitors; G | 2006 |
Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Biopsy; California; Color | 2006 |
Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Colonoscopy; Colorectal Neop | 2006 |
[Epidemiology of gastrointestinal bleeding in the elderly].
Topics: Age Factors; Aged; Aged, 80 and over; Angiodysplasia; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2006 |
The association between aspirin use and the incidence of colorectal cancer in women.
Topics: Aged; Aspirin; Chi-Square Distribution; Colorectal Neoplasms; Female; Humans; Incidence; Middle Aged | 2006 |
Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
Topics: Adenoma; Adenomatous Polyposis Coli; Aged; Alanine; Anticarcinogenic Agents; Aspirin; Colorectal Neo | 2006 |
Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cohort S | 2006 |
Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States).
Topics: Adenomatous Polyps; Aspirin; Body Mass Index; Colorectal Neoplasms; Confidence Intervals; Female; Hu | 2006 |
Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer.
Topics: Animals; Apoptosis; Aspirin; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationshi | 2007 |
Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Dis | 2007 |
p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells.
Topics: Apoptosis; Aspirin; Cell Cycle; Cell Nucleolus; Colorectal Neoplasms; Cyclin D1; Cyclin-Dependent Ki | 2007 |
Summaries for patients. Aspirin or nonsteroidal anti-inflammatory drugs for the prevention of colorectal cancer: U.S. Preventive Services Task Force recommendations.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplas | 2007 |
Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement.
Topics: Adenoma; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Colorectal Neoplas | 2007 |
Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Color | 2007 |
More aspirin for less cancer?
Topics: Aspirin; Cohort Studies; Colorectal Neoplasms; Female; Humans; Male; Neoplasms; Randomized Controlle | 2007 |
Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2007 |
Can aspirin prevent colorectal cancer?
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Mal | 2007 |
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Transformation, Neoplastic; Cohort Studies; C | 2007 |
Aspirin and colon cancer--targeting prevention?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Transformation, Neoplastic; Colorectal Neopla | 2007 |
Folate and cancer--timing is everything.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Folic Acid; Humans; | 2007 |
Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cell Proliferation; Co | 2007 |
Chronic proton pump inhibitor therapy and the risk of colorectal cancer.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colore | 2007 |
Can statins pass the aspirin litmus test in cancer?
Topics: Animals; Anticarcinogenic Agents; Aspirin; Clinical Trials as Topic; Colorectal Neoplasms; Humans; H | 2007 |
Aspirin, COX-2, and the risk of colorectal cancer.
Topics: Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibit | 2007 |
Aspirin, COX-2, and the risk of colorectal cancer.
Topics: Aspirin; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Time Factors | 2007 |
Folic acid and prevention of colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Folic Acid; Humans; | 2007 |
Commentary: preventing colorectal cancer with aspirin what next?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Drug Administration Schedule | 2007 |
Commentary: aspirin and cancer prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Drug Administration Schedule | 2007 |
Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Chronic Disease; Colorectal | 2007 |
Commentary: aspirin and colorectal cancer an epidemiological success story.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Drug Utilization; Epidemiolo | 2007 |
Aspirin and nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: weighing the evidence.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Male; Primar | 2007 |
Aspirin dose and duration of use and risk of colorectal cancer in men.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; | 2008 |
Chemoprevention for colorectal cancer: some progress but a long way to go.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Folic Acid; Hematinics; Huma | 2008 |
[ASS in the prophylaxis of colorectal cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Randomized Controlle | 2008 |
Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention.
Topics: Adenoma; Adult; Aged; Anticarcinogenic Agents; Aspirin; Colorectal Neoplasms; Female; Genes, APC; Ge | 2008 |
Aspirin helps prevent recurring colorectal adenomas--folic acid does not.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chemotherapy, Adjuvant; Colo | 2008 |
Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence.
Topics: Adenoma; Adult; Aged; Animals; Aspirin; Calcium Compounds; Colorectal Neoplasms; Dairy Products; Fem | 2008 |
[Administration of acetylsalicylic acid and risk of colorectal adenoma and carcinoma].
Topics: Adenomatous Polyps; Aspirin; Colorectal Neoplasms; Drug Administration Schedule; Follow-Up Studies; | 1995 |
Aspirin and colorectal cancer: the Leisure World cohort revisited.
Topics: Age Factors; Aged; Aspirin; Cohort Studies; Colorectal Neoplasms; Confounding Factors, Epidemiologic | 1995 |
Aspirin and colorectal cancer.
Topics: Aspirin; Colorectal Neoplasms; Humans | 1995 |
Aspirin and colorectal cancer.
Topics: Aspirin; Colorectal Neoplasms; Humans; Time Factors | 1995 |
Aspirin and the risk of colorectal cancer in women.
Topics: Adult; Aspirin; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Middle Aged | 1995 |
Aspirin as prophylaxis against colorectal cancer.
Topics: Arachidonic Acid; Aspirin; Blood Platelets; Colorectal Neoplasms; Female; Humans; Lipoxygenase; Pros | 1995 |
Aspirin: the panacea for colorectal cancer?
Topics: Adult; Aged; Aspirin; Case-Control Studies; Colorectal Neoplasms; Follow-Up Studies; Health Personne | 1995 |
Evaluating risk: a primer for gastroenterologists.
Topics: Adenomatous Polyposis Coli; Aspirin; Colorectal Neoplasms; Duodenal Neoplasms; Humans; Intestinal Ne | 1995 |
Aspirin and the risk of digestive cancers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans | 1995 |
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.
Topics: Adenoma; Adult; Aged; Aspirin; Colonic Polyps; Colorectal Neoplasms; Health Personnel; Humans; Male; | 1994 |
Aspirin in the prevention of colorectal cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; United States | 1994 |
Nonsteroidal antiinflammatory drugs and colorectal cancer. A promising hypothesis but not yet proven.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Health Behavior; Humans; Ran | 1994 |
Aspirin, NSAIDs, and risk reduction of colorectal cancer. The problem is translation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorectal Neoplasms; Humans | 1994 |
Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colorec | 1994 |
Aspirin use and lung, colon, and breast cancer incidence in a prospective study.
Topics: Adult; Aged; Aspirin; Breast Neoplasms; Cohort Studies; Colorectal Neoplasms; Confidence Intervals; | 1994 |
Prospects for preventing colorectal cancer death.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Colorectal Neoplas | 1993 |
Effect of aspirin and NSAIDs on colorectal adenomas. Protective effect may be spurious.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans | 1993 |
Aspirin and the risk of colorectal cancer in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal Neoplasms; Confounding | 1996 |
Aspirin and the risk of colorectal cancer in women.
Topics: Aspirin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Risk | 1996 |
Aspirin and the risk of colorectal cancer in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Risk Factors | 1996 |
Aspirin and the risk of colorectal cancer in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans | 1996 |
Aspirin and the risk of colorectal cancer in women.
Topics: Aspirin; Bias; Colorectal Neoplasms; Female; Humans; Prospective Studies; Retrospective Studies | 1996 |
Aspirin and the risk of colorectal cancer in women.
Topics: Aspirin; Colorectal Neoplasms; Female; Humans | 1996 |
Aspirin and colon cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Colonic Neoplasms; Colorectal | 1996 |
Relationship between colorectal and esophageal cancer.
Topics: Aspirin; Barrett Esophagus; Colorectal Neoplasms; Esophageal Neoplasms; Humans | 1996 |
Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines.
Topics: 3T3 Cells; Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Carcinoma; | 1996 |
G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Cell Li | 1996 |
Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia.
Topics: Adenocarcinoma; Adenoma; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 1996 |
Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Esophageal Neoplasms; Humans | 1996 |
Are aspirin and other non-steroidal anti-inflammatory drugs effective in the prevention and treatment of colorectal cancer?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans | 1996 |
An aspirin a day.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Humans; Platelet Aggregation Inhibitors | 1996 |
Cancer chemoprevention trials.
Topics: Adult; Aspirin; Colorectal Neoplasms; Double-Blind Method; Head and Neck Neoplasms; Humans; Isotreti | 1996 |
Inhibition of prostaglandins may be mechanism by which aspirin protects against certain cancers.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Lung | 1996 |
[Primary prevention of colorectal cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans | 1997 |
A case-control study of dietary intake and other lifestyle risk factors for hyperplastic polyps.
Topics: Adenoma; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; | 1997 |
Aspirin and colorectal cancer.
Topics: Adult; Age Factors; Aged; Aspirin; Case-Control Studies; Colorectal Neoplasms; Female; Geography; Hu | 1997 |
[A 100 years of aspirin: a drug with a future?].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cerebrovascular Di | 1997 |
Deciphering aspirin's many modes of action.
Topics: Alzheimer Disease; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Humans | 1996 |
Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Female; Humans; Mal | 1998 |
[Indications for aspirin on the centennial of its discovery].
Topics: Adult; Aged; Alzheimer Disease; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; A | 1997 |
Aspirin use and p53 expression in colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aspirin; Colorectal Neoplasms; Female; Gene Expression R | 1998 |
From molecular analysis to medical practice: recent studies reveal new therapeutic targets for an old medicine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Ger | 1998 |
Potential population-wide impact of aspirin on colon cancer mortality.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans | 1998 |
[Do aspirin or nonsteroidal anti-inflammatory drugs decrease the risk of colorectal cancer?].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Humans; Risk; Sulin | 1998 |
[Aspirin suppresses microsatellite instability].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Base Pair Mismatch; Colorectal Neoplasm | 1999 |
The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; beta Catenin; Cell Division; Colorectal | 2000 |
Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort | 2000 |
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs.
Topics: Adenoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Colorectal N | 2001 |
The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Catenin; Colorectal Neoplasms; Cyclin D1; Cyc | 2001 |
Colorectal cancer among users of aspirin and non-steroidal antiinflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Cardiovascular Diseases; Cohort | 2001 |
Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorectal Neoplasms; Cost-Benefit An | 2001 |
Summaries for patients. Is aspirin a cost-effective addition to colorectal cancer screening?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorectal Neoplasms; Cost-Benefit An | 2001 |
Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonoscopy; Colorectal Neoplasms; Cost-Bene | 2002 |
Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Cross-Sectional Studies; Cyclooxygena | 2002 |
Diet and colorectal cancer: an investigation of the lectin/galactose hypothesis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Colorectal Neoplasms; Diet; Drug Admi | 2002 |
Aspirin and colonic epithelium.
Topics: Aspirin; Colon; Colorectal Neoplasms; Epithelium; Humans; Male | 1989 |